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Abstract 
The prevalence of overweight and obese individuals has risen dramatically in 
populations around the world over the last 30 years (Popkin et al., 2012) representing 
a rapidly growing burden to public health services (Wang et al., 2011). Reliance on 
lifestyle modification, although initially promising, has proven to be unsuccessful over 
the longer term (Barte et al., 2010) and there are currently a lack of successful 
treatment options.  
Capsaicinoids are a bio-active group of compounds, naturally occurring in the fruit of 
the plant from the genus capsicum. Initial research suggests these compounds may 
have beneficial effects on weight loss outcomes when ingested (Lejeune et al., 2003). 
A systematic review of the available literature on capsaicinoids found evidence that 
ingestion may increase energy expenditure by around 210kJ/day and lipid oxidation 
by around 20%. Ingestion may also reduce energy intake although evidence has been 
conflicting and the size of the effect unclear.  
To further aid understanding, a meta-analysis was undertaken involving intervention 
trials assessing the effects of capsaicinoids on energy intake. Analysis suggested 
capsaicinoid ingestion prior to a meal reduced ad libitum energy intake energy intake 
by 251kJ (60kcal) per meal (95% confidence interval of 337 – 166kJ) p < 0.001. 
Caution should be applied to this result however, due to the small size of the reduction 
and the short term nature of the trials involved. Longer term trials are needed to assess 
potential changes in body composition as a result of capsaicinoid interventions. 
To this end, a six-week placebo control intervention study was conducted to assess 
changes in body fat in 60 Caucasian women. Results of a sensitivity analysis found a 
small, statistically significant decrease in body fat percentage (0.64%, p = 0.022) and 
total body fat (0.67kg, p = 0.007) in the intervention group. However, the robustness 
of these findings are called into question by the results of an interaction analysis which 
of observed no significant difference between placebo control and intervention groups 
over time for these outcomes. The effect was also small and therefore longer term 
supplementation would be required to produce a medically beneficial changes in body 
composition.   
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Chapter 1 – Introduction 
1.1 Background 
Overweight and obese populations represent a rapidly growing financial and health 
threat to many societies (Dietz, 2015). Often described as an epidemic, obesity rates 
began rising in the USA in the 1980s and continues today around the world. In 2008, 
1.5 billion adults (aged 20 and older) were overweight; of these around 500 million 
were obese (WHO, 2011).  
Obesity has been found to decrease health-related quality of life (Fontaine and 
Barofsky, 2001) and overall life expectancy (Peeters et al., 2003). In addition to this, 
obese patients are at an increased risk of coronary heart disease (Colditz et al., 1995, 
Rimm et al., 1995), type 2 diabetes (Colditz et al., 1995), strokes (Rexrode et al., 
1997), hyperlipidaemia (Rabkin et al., 1997), hypertension (Witteman et al., 1989) and 
several cancers (Calle et al., 2003, Calle and Kaaks, 2004). 
The exact costs of obesity to the NHS in the UK are complex to assess, but research 
estimates that the costs were £3.2 billion in 2007 (Allender and Rayner, 2007) and 
have the potential to rise to £5 billion by 2030 (Wang et al., 2011). In the current 
economic climate, with strain on government spending (Swords, 2014), the potential 
costs of treating the co-morbidities of a preventable disorder are prohibitive, with 
research suggesting that the healthcare costs for obese patients are approximately 
30% higher than normal-weight individuals (Pelone et al., 2012). 
Increasing obesity rates reflect a sustained period of positive energy balance for the 
affected population. While it is widely accepted that increasing energy expenditure and 
reducing energy intake form the basis for obesity management, reversing this trend 
has proven very difficult (Gortmaker et al., 2011). Biological, behavioural and 
environmental factors all interact to affect energy balance and body weight regulation 
(Hill, 2006) and reliance on diet and exercise interventions alone have proved 
relatively unsuccessful over the long term, with weight regain a major problem (Wu et 
al., 2009). 
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A number of biological changes occur in the body following weight loss making 
maintenance more difficult and increasing the likelihood of weight regain (MacLean et 
al., 2011). One of the main problems is a reduction in resting metabolic rate following 
weight reduction. As an individual loses weight, their basic energy requirements also 
reduce, as their metabolism slows down. This means further reductions in energy 
intake/increases in energy expenditure are required and it means maintenance of a 
lower body weight is difficult to sustain (Curioni and Lourenco, 2005). In addition to 
this, after weight loss, changes in the circulating levels of several hormones (including 
leptin and ghrelin) involved in the homeostatic regulation of body weight occur 
(Strohacker et al., 2013). These changes encourage weight regain after diet induced 
weight loss and have been observed to persist over a long-term period (one year) 
(Sumithran et al., 2011). There may also be physiological changes in the 
hypothalamus in response to calorie deficiency in some individuals (Sainsbury and 
Zhang, 2010). The hypothalamus is an area of the brain largely responsible for 
signalling hunger and influencing energy intake levels. Changes in this region of the 
brain following weight reduction may make maintaining this loss more problematic 
(Berthoud and Morrison, 2008). 
To counteract this, the pharmaceutical industry has attempted to develop drugs to 
assist weight loss, with limited success. Most of the drugs that have entered the market 
for treating obesity were originally developed to treat psychiatric diseases (Adan et al., 
2008). Targets have included reducing appetite, reducing food absorption (especially 
lipids) and increasing energy expenditure. While drugs have been successful in 
influencing these targets (such as sibutramine, fenfluramine and dexfenfluramine), 
side effects have often proved too severe. A number of drugs have had to be 
withdrawn from the market, particularly because of cardiovascular complications, and 
the options for treatment are currently limited (McGavigan and Murphy, 2012). 
Therefore, the development of safe weight loss aids is of particular interest to doctors, 
health services and individuals looking to lose weight. Researchers have begun 
looking at a number of naturally occurring compounds that may be able to produce 
similar anti-obesity effects, but with less severe side effects. Trials show there may be 
potential to aid people with weight loss for amongst others, caffeine (Boozer et al., 
2002), catechins from green tea (Yang et al., 2012) and capsaicinoids from chilli 
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peppers (Lejeune et al., 2003). However, patent legislation provides little monetary 
incentive for the pharmaceutical industry to develop naturally occurring compounds 
for medical applications. 
This research aims to review and assess current research into the potential weight 
loss effects of capsaicinoids, the group of compounds found in chilli peppers that 
causes their pungent flavour when eaten, and to further investigate these effects by 
carrying out a placebo controlled intervention trial. 
1.2 Aims 
The aims of the research projects are as follows: 
1) To perform a systematic literature search of human intervention trials 
investigating the effects of capsaicinoids on weight management outcomes, 
collate and analyse findings publish the results as a systematic review paper. 
2) Undertake a meta-analysis summarising the results of intervention trials 
measuring the effects of capsaicinoids on energy intake and publish results. 
3) Plan and perform a double-blind, placebo controlled intervention study to 
investigate the effects of capsaicinoids on body fat in human subjects. 
1.3 Structure of the Thesis 
The thesis begins with a literature review (chapter 2) starting with current obesity 
trends, prevalence and a critical appraisal of available treatments. Also featured will 
be an assessment into current research involving capsaicinoids, including structure, 
uses and potential regarding weight loss outcomes, along with current understanding 
of their potential mechanisms of action. Chapter 3 of the thesis presents a meta-
analysis of intervention studies conducted to further understanding regarding 
capsaicinoids’ potential effect on energy intake following ingestion. Chapter 4 details 
an intervention trial undertaken to assess capsaicinoids’ potential effect on fat loss in 
Caucasian women, with the methodology and results presented. Chapter 5 initially 
presents a discussion into the intervention trial, including critical analysis of potential 
issues and then a discussion of the thesis as a whole and what could be done to further 
enhance study in this area.  
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Chapter 2 – Literature Review 
2.1 Introduction 
This chapter will give an overview of current obesity problem, in terms of prevalence, 
past and future trends; the health problems associated with it and the estimated 
financial cost. The review will then explore current treatment practices and finally 
propose evidence for an alternative weight management aid, namely capsaicinoids, a 
naturally occurring group of chemicals found in chillies.  
2.2 Obesity and Weight Management 
The increasing prevalence of overweight and obesity, measured by body mass index 
(BMI), is a worldwide health concern. In a systematic analysis of epidemiological 
studies from 199 countries, 1·46 billion adults worldwide were estimated to be 
overweight in 2008, and of these 502 million were obese (Finucane et al., 2011). The 
effects of consistently high prevalence of obesity on population health are far-reaching; 
societies face being burdened by premature mortality, morbidity associated with many 
chronic disorders, and reduced health-related quality of life (Wang et al., 2011). With 
some researchers  arguing that increasing BMI is a worldwide pandemic (Roth et al., 
2004), that could reverse life-expectancy gains in high-income nations (Olshansky et 
al., 2005).  
2.2.1 Health burden of Obesity 
The rising prevalence of obesity is a worldwide health concern because excess weight 
gain within populations forecasts an increased burden from several diseases. Obesity 
is a major risk factor for cardiovascular disease (CVD) including coronary heart 
disease (CHD), coronary artery disease, stroke, congestive heart failure and atrial 
fibrillation (Guzzardi and Iozzo, 2013). Obesity and overweight are highly prevalent in 
patients with CHD. The prevalence of overweight and obesity in the general U.S. 
population are 66% and 36% respectively (Ogden, 2012), whereas the prevalence 
overweight and obesity rates in patients with CHD entering cardiac rehabilitation are 
more than 80% and 44%, respectively (Audelin et al., 2008). From 1996 to 2006 there 
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was a 33% increase in the prevalence of obesity in individuals with CHD (Audelin et 
al., 2008). 
A significant association between obesity and increased risk for ischemic stroke has 
been documented in both genders and in different ethnic populations (Caucasians, 
African American, Chinese and Japanese) (Yatsuya et al., 2010, Lee et al., 2011, 
Bazzano et al., 2010). Research also suggests the severity of strokes are increased 
with obesity (Osmond et al., 2009). Based on these findings, the American and Stroke 
Associations recommend the treatment of obesity for both primary (Goldstein et al., 
2011) and secondary stroke prevention (Furie et al., 2011). 
While obesity is an independent risk factor for the development of CVD (Wilson et al., 
2002) it also predicts an elevated risk through its association with a cluster of risk 
factors termed the metabolic or insulin resistance syndrome (Grundy et al., 2005). 
These associated risk factors include hypertension, hypertriglyceridemia, low levels of 
high density lipoprotein cholesterol, abdominal obesity, insulin resistance and type 2 
diabetes mellitus (Garg et al., 2014). 
Studies have demonstrated a clear association between obesity and type 2 diabetes 
(Guzzardi and Iozzo, 2013). In a cross-sectional survey of adults with diabetes, the 
lowest prevalence for diabetes was found in individuals with normal weight (BMI <25). 
The prevalence of diabetes increased throughout the range of obesity classes. Nearly 
a quarter of adults with diabetes have poor glycaemic control and nearly half of the 
individuals with diabetes are considered obese (Nguyen et al., 2011b). The prevalence 
of obesity among diabetic individuals is much higher than the reported prevalence of 
obesity in the general adult population. The prevalence of obesity among adults with 
diabetes was found to be 49.1% of a sample of the US population (Nguyen et al., 
2011b), while the prevalence of obesity among the general US population has been 
reported to be 32.2% in adult men and 35.5% in adult women (Flegal et al., 2012). 
Obesity also has a strong influence on cancer mortality, with  epidemiological data 
from the past 25 years pointing to obesity as a cause of approximately 14% of cancer 
deaths in men and up to 20% of cancer deaths in women (Calle et al., 2003). A major 
review of weight and cancer incidence using obesity prevalence data from Europe 
concluded, that obesity was a cause of 11% of colon cancer cases, 9% of 
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postmenopausal breast cancer cases, 39% of endometrial cancer cases, 25% of 
kidney cancer cases, and 37% of oesophageal cancer cases (Vainio et al., 2002). In 
addition, data from the American Cancer Society suggested that overweight and 
obesity were related to increased mortality from liver cancer, pancreatic cancer, non-
Hodgkin's lymphoma, and myeloma (Calle and Kaaks, 2004). The effect of obesity on 
cancer reflects both an increase in incidence and an increase in mortality among those 
diagnosed with cancer (Wolin et al., 2010). 
Excess body weight also contributes to non-fatal but disabling disorders such as 
osteoarthritis (Guh et al., 2009). Moreover, rapidly expanding evidence suggests that 
excess body weight is linked to many additional disorders, including benign prostate 
hypertrophy (Nichols et al., 2011), infertility (Withrow and Alter, 2011), asthma (Wang 
et al., 2008), and sleep apnoea (Sassi, 2010). In addition to this, maternal obesity has 
been linked to an increased risk of congenital anomalies, further contributing to the 
health burden (Stothard et al., 2009). Because in many populations the prevalence of 
obesity is greater at a younger age than in previous generations, present trends in 
obesity project a growth in the percentage of the population living with chronic disease 
(Wang et al., 2011). Some researchers have hypothesised that the continued increase 
in life expectancy achieved by medical and public health advances during the past 
century may be reversed by increasing obesity prevalence (Muennig et al., 2006). 
2.2.2 Financial Burden of Obesity 
The multiple chronic and acute health conditions related with overweight and obesity 
afflicted societies not only by negatively affecting the health-related quality of life of 
their populations but also by incurring considerable financial costs to the individuals 
affected and to society as a whole (Anandacoomarasamy et al., 2009). These costs 
are sustained predominantly from increased the health-care costs and lost economic 
productivity of the individuals involved (Yang and Hall, 2008). The medical costs of 
obesity represent the monetary value of health-care resources required to manage 
obesity-related disorders, including the costs incurred by excess use of ambulatory 
care, hospitalisation, drugs, radiological or laboratory tests, and long term care (Wang 
et al., 2011).  
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In a systematic review of the direct health-care costs of obesity, it was estimated that 
obesity accounted for up to 2.8% of healthcare expenditure; although the authors 
noted that the studies involved were generally very conservative, such that the actual 
amount was likely to be higher (Withrow and Alter, 2011). Analysis from the USA found 
that compared normal-weight individuals, obese patients incur 46% increase in 
inpatient costs, 27% more clinical and outpatient costs, and an 80% increase in 
spending on prescription drugs (Finkelstein et al., 2009).  
In addition to medical costs, economies incur substantial indirect costs from obesity 
as a result of decreased years of disability-free life, increased mortality before 
retirement, early retirement, disability pensions, work absenteeism and reduced 
productivity (Wolfenstetter, 2012). Several studies suggest that the monetary value of 
lost productivity is several times larger than medical costs (Trogdon et al., 2008, 
Finkelstein et al., 2010). Researchers in the USA reported that annual missed 
workdays ranged from 0·5 more days in men who were overweight to 5·9 more days 
in men who were classified as grade III obese (BMI ≥40 kg/m²) than in men of healthy 
weight (Finkelstein et al., 2010).  
Evaluating the costs from the health consequences of obesity is complex; costs are 
affected by a number of factors such as changes in the economy, food system and 
population demographics. Estimation of the cost from lost productivity is especially 
challenging because of the scarcity of data and the assumptions needed for the labour 
market structure (Lehnert et al., 2013). Some researchers argue that inclusion of 
unrelated future costs distorts decision making about resource allocation (Garber and 
Phelps, 1997, Lee, 2008); others advocate the inclusion of unrelated medical costs in 
life-years gained in all economic evaluations of preventive interventions, although they 
acknowledge the practical challenge and scarcity of comprehensive data for doing so 
(Rappange et al., 2008). Regardless, the NHS cannot continue to fund the rising cost 
of treating obesity and its co-morbidities. 
2.2.3 Prevalence and Trends 
Initially observed in high income countries of North America and Western Europe, 
obesity has now become a major contributor to the global burden of disease 
(Olshansky et al., 2005). The worldwide increase in the incidence of obesity and 
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related chronic diseases has been caused by dramatic changes in lifestyles and eating 
habits that promote a positive energy balance and lead to weight gain (Kearney, 2010). 
This has been largely driven by economic development, global trade liberalisation and 
rapid urbanisation of world economies (Hawkes, 2006). Positive energy balance 
occurs when an individual’s caloric intake exceeds their energy expenditure, leading 
to weight gain. Although economic development has led to many benefits such as 
improvements in food security and life quality, it has also lead to an increase in the 
consumption energy dense foods and reductions in physical activity, which has 
triggered the observed increases in overweight and obesity (Fuster and Kelly, 2010). 
The global effect of the obesity epidemic was formally recognised in by the World 
Health Organisation during a special consultation in 1997 (James, 2008). In the past 
15 years a large body of evidence has accumulated documenting the increases in 
prevalence of obesity across the world (Malik et al., 2013). These figures suggest an 
estimated 500 million adults were obese (BMI > 30 kg/m2), which represents 10-14% 
of the world’s population (see figure 2.1). Globally between 1980 and 2008, obesity 
prevalence rose from 4.8% to 9.8% in men and from 7.9% to 13.8% for women 
(Finucane et al., 2011).  
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Figure 2.1 Charts showing in prevalence of obesity among women and men in 1980 
and 2008 from select regions around the world. Adapted from (Finucane et al., 2011). 
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Although figures vary widely across different countries and geographical regions (see 
figure 1.7), in the USA for example in 2009-10, 35.5% of men and 35.8% of women 
were classified as obese (Flegal et al., 2012), in China in 2010 the prevalence of 
obesity (BMI > 28) 11.9% for men and 12.1% for women (Li et al., 2012). As seen from 
figure 1.7, obesity rates are high in developed regions such as North America and 
Europe, but are also high in emerging economic regions such as the Middle East and 
Southern Africa. Low obesity rates are seen in Asia and less the developed economies 
of West and East Africa (Seidell, 2014). 
2.2.3.2 Effect of Income and Socio-economic Status on Obesity Prevalence 
The prevalence of obesity correlates positively with the initial stages of economic 
growth and development in low income countries (Ezzati et al., 2005). Populations 
often undergo rapid nutritional and lifestyle transitions, while having limited access to 
health services and education (Popkin et al., 2012). Research analysing global pat-
terns of nutritional risks in relation to economic development in 100 countries, showed 
that BMI increased rapidly in relation to national income (Ezzati et al., 2005). This is 
of particular concern as over the next three to four decades, global per capita income 
is projected to rise at a rate of >2% per year; and in low income countries, this increase 
is expected to be even more rapid (Kearney, 2010). 
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Figure 2.2 Flow chart representation of the relationship between economic growth and 
obesity (Malik et al., 2013) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Driving this increase are the factors of global trade liberalization, economic growth and 
urbanization; which promote the development of obesity through changes to the 
physical environment and food choice. Movement away from physical labour to 
sedentary activities, creating so called ‘obesogenic’ environments, which affect 
physical activity levels, diet, behaviours and cultural norms (see figure 2.2) (Malik et 
al., 2013). All of these effects combine to create a state of positive energy balance that 
promotes obesity (Popkin et al., 2012). 
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2.2.3.4 Levelling Off in Prevalence Rates 
There is evidence that growth obesity prevalence may be levelling off in some parts of 
the world. A systematic review, including the results from the 52 studies (Rokholm et 
al., 2010), found a clear tendency towards a stabilisation of the obesity levels in 
children and adolescents from Australia, Europe, Russia and the USA and a decrease 
was identified in Japanese children and adolescents. In contrast, strong increases 
were observed in Chinese and Vietnamese children and adolescents. The tendency 
in European adults is, however, more ambiguous, as increases were still reported in 
conscript data from Austria, Denmark and Sweden. (Rokholm et al., 2010). What is 
clear, even with a levelling off of an increase in obesity prevalence, level remain high, 
posing a threat to both global health and global economies (Wang et al., 2011).  
2.2.3.5 Future Trends 
Over the next two decades, the largest proportional increase in the number of adults 
who are overweight or have obesity is expected to occur in low-income and middle-
income countries, where estimates range from increases of 62 – 71% for overweight 
and 205 - 263% for obesity (Kelly et al., 2008). In many of these countries, the increase 
in obesity prevalence has occurred rapidly, as a result of economic development 
(Popkin and Gordon-Larsen, 2004). In many of these emerging economies, people 
who are overweight exist along those who and suffer malnutrition, not only in the same 
communities but even in the same households; this is termed the ‘dual burden 
household’ (Doak et al., 2005). A number of countries therefore, have to manage the 
dual burdens of obesity and related chronic diseases, while still dealing with the 
problems of underweight and under-nutrition (Malik et al., 2013). This creates the 
potential for obesity to create major strain on health services around the world. 
2.2.4 Body Mass Index 
Virtually all measures of obesity prevalence are based on the calculations of 
individual’s body mass index. BMI has a number of advantages: the medical 
profession have been educated in its use and it has made signiﬁcant inroads into the 
general public consciousness (Prentice and Jebb, 2001). It is a relatively simple and 
repeatable measure, with a minimum of equipment needed, (a balance and a 
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stadiometer), meaning it can easily be performed in numerous locations around the 
world (Deurenberg et al., 1991) and the errors in measurement tend to be small (Mei 
et al., 2002). 
However, because the BMI depends upon weight and the square of height, it ignores 
basic scaling laws whereby mass increases to the 3rd power of linear dimensions. 
Hence, larger individuals, even if they had exactly the same body shape and relative 
composition, always have a larger BMI (Taylor and Marchand, 2010). BMI generally 
overestimates adiposity on those with more lean body mass (e.g., athletes) and 
underestimates excess adiposity on those with less lean body mass (Deurenberg et 
al., 2001). Also BMI may not provide an accurate assessment of increased mortality 
risk. A 2005 study showed that overweight people had a similar relative risk of mortality 
as normal weight people as defined by BMI, while underweight and obese people had 
a higher death rate (Flegal et al., 2005). Therefore, the widespread use of BMI is a 
limitation of current obesity research, which may not provide accurate health 
assessment of population groups. 
2.2.5 Current Approaches to Obesity Treatment 
Relatively modest weight loss of 5% to 10% of initial weight has been shown to 
produce significant health benefits (Moyer, 2012). Researchers have found reduced 
cardiovascular disease risk factors such as lower systolic and diastolic blood pressure, 
blood triglycerides and an improved HDL/LDL cholesterol profile (Look AHEAD 
Research Group, 2010); prevention or delay of the development of type 2 diabetes 
(Knowler et al., 2002); and improvements in other obesity related health 
consequences including sleep apnoea (Foster et al., 2009), urinary incontinence 
(Phelan et al., 2012), mobility (Rejeski et al., 2012) and symptoms of depression 
(Rubin et al., 2010). Research from a large (5,145 participants), multi-centre (19 
clinics), long-term trial (13.5 years) found that larger weight losses were associated 
with greater improvements in risk factors. The magnitude of weight loss at was highly 
related to the improvements in blood pressure, glycaemic control, and lipids. There 
also was no evidence that a patient’s weight at baseline affected the amount of 
improvement that occurred with a given percentage change in body weight (except for 
HDL cholesterol) (Wing et al., 2011). 
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To reverse the effects of obesity, people are usually treated by the medical profession 
in a three tier progression. Firstly, people are counselled on evidence-based lifestyle 
approaches that include diet, physical activity and behaviour change therapies. 
Secondly the use of pharmacological agents such Orlistat (sold under the trade names 
Xenical and Alli) have been used as adjuncts to lifestyle modification. Finally, it may 
be appropriate for severally obese individuals who have not been responsive to initial 
treatments to undergo bariatric surgery (Kushner, 2013) 
2.2.5.1 Lifestyle Treatments 
Comprehensive lifestyle modification programs typically provide weekly individual or 
group treatment sessions designed to modify eating and activity habits (Wadden et 
al., 2007). Lifestyle modification, also referred to as behavioural weight control, 
includes 3 primary components: diet, exercise, and behaviour therapy (NHLBI, 2011). 
Interventions tend to be long term with the aim of maintaining behaviour change, in 
larger trials these interventions have lasted for 24 weeks in the Diabetes Prevention 
Program (3200 participants) (Knowler et al., 2002) and six months in the Look AHEAD 
study (5100 participants) (Look AHEAD Research Group, 2003). 
2.2.5.1.1 Diet 
Participants initially follow a calorie restricted diet to induce a medically significant level 
of weight loss is achieved, a different diet may then be followed to maintain losses 
(Wadden et al., 2012). Much research has been carried out into the ideal combination 
of macronutrients to achieve weight loss, however studies show weight loss is 
primarily dependent on reducing total calorie intake, not the proportions of 
carbohydrate, fat, and protein in the diet (Sacks et al., 2009). Incorporating meal 
replacements into the diet is a common strategy (Keogh and Clifton, 2005); meal 
replacements are foods that are designed to take the place of a meal or snack while 
at the same time providing nutrients and good taste within a fixed caloric limit (Wadden 
et al., 2009). For the maintenance diet to achieve long-term weight loss, most obese 
individuals must consciously restrict their energy intake, whether by reducing portion 
sizes, decreasing the energy density of the diet, counting calories (or specific 
macronutrients), or some combination of these approaches (Wadden et al., 2012). 
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2.2.5.1.2 Physical Activity and Exercise 
In addition to reducing caloric intake, participants in weight loss interventions are also 
encouraged to burn more calories. Research has highlighted the distinction between 
physical activity and planned exercise. Whereas physical activity consists of any bodily 
movement that increases energy expenditure, e.g. activities of daily living like walking, 
climbing stairs, gardening, etc., exercise is defined as planned, structured, and 
repetitive bodily movement done to improve or maintain one or more components of 
physical fitness (Armstrong, 2006). Studies have demonstrated that lifestyle activities 
are as effective as structured exercise programs in improving overall fitness and 
maintaining weight loss (Swift et al., 2013). However, physical activity alone is of 
limited benefit in inducing weight loss; most individuals cannot find the time or 
motivation to engage in the high volume of activity required for significant weight loss 
(for example 35 miles of walking a week is required to lose around 0.5 kg/week) 
(Donnelly et al., 2009). Several research investigations have however, shown physical 
activity to be critical for long-term weight management (Catenacci and Wyatt, 2007, 
Tate et al., 2007). 
2.2.5.1.3 Behaviour Therapy 
Behaviour therapy as part of lifestyle modification programs, refers to a set of 
principles and techniques for helping obese individuals modify eating, activity, and 
thinking habits that contribute to their excess weight (Brownell, 2004). This recognizes 
that body weight is affected by factors other than behaviour, including genetic, 
metabolic, and hormonal influences, which likely predispose some persons to obesity 
and set the range of possible weights that a given individual can achieve (Wadden et 
al., 2007).  Key components of behaviour therapy include setting specific goals for 
behaviour change that specify what an individual will do, and when, where, how, and 
for how long he or she will engage in the behaviour (Wadden and Foster, 2000). 
Perhaps the most useful strategy in achieving lifestyle goals is to include self-
monitoring (Burke et al., 2011). Patients are asked to track their food intake, physical 
activity, and weight throughout treatment. The benefits of tracking include having real-
time data on dietary intake as it relates to caloric and other nutritional goals, allows 
reflection and planning of diet, introduces restraint, and provides information to share 
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with the provider; the major drawback however is that many participants find this a 
burden, especially over the longer term (Cadmus-Bertram et al., 2013) 
With intensive lifestyle treatments, a majority of obese participants in clinical trials lose 
7% to 10% of their initial weight after one year (Carvajal et al., 2013). However, results 
from research trials are generally far better than those attained by patients in primary 
care settings. Studies using low-intensity counselling have failed to demonstrate 
clinically meaningful mean weight loss (Wadden et al., 2013). Regardless of initial 
weight loss success, the major problem is often that longer-term weight maintenance 
is difficult, with around 80% of people losing weight failing to maintain this loss over 
multiple years (Wing and Phelan, 2005). For example, figure 2.3 shows this weight 
loss-weight gain cycle of 307 participants over a 2 year period following an intervention 
featuring 20 weekly lifestyle modification sessions, followed by 10 every other week 
interventions (Foster et al., 2010).  
Figure 2.3 Graph showing weight loss and gradual regain over a two year period 
following a 40 week intervention; adapted from (Foster et al., 2010). 
 
With continued lifestyle treatment, weight regain can be minimised but is difficult to 
eliminate entirely, and this features a significant ongoing cost (Ades and Savage, 
2010). The need for constant vigilance to sustain behaviour changes in the face of 
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biologic and environmental pressures to regain weight emphasizes the challenges 
faced by even the most motivated patients who have achieved weight loss. Thus, there 
is a need for adjunctive therapies that can help patients who are not able to lose or 
sustain sufficient weight loss to improve health with lifestyle interventions alone 
(Kushner, 2013). 
2.2.5.2 Pharmacotherapy 
Medications for obesity have traditionally fallen into two major categories: appetite 
suppressants (anorexiants), and gastrointestinal fat blockers. Appetite suppressing 
medications have targeted three monoamine receptor systems in the hypothalamus: 
noradrenergic, dopaminergic and serotonergic (Kushner, 2008). In the 1930s 
amphetamines were first used as anorexiants, but due to their addictive nature were 
replaced with several related compounds, five of which had approval for use in the 
USA by the 1960s (Kushner, 2013). Despite their success in assisting weight loss, 
they have developed a legacy of dubious safety, with a number of drugs removed from 
the marketplace due to safety concerns (Williams, 2010). For example fenfluramine 
was withdrawn from the U.S. market in 1997 after reports of heart valve disease 
(Weissman, 2001) and dexfenfluramine was withdrawn from markets around the world 
following multiple concerns about cardiovascular side effects (Gardin et al., 2000). 
Such withdrawals have left options for pharmacological treatment of obesity limited, 
though the following drugs are approved for use. Orlistat, sold under the brand name 
‘Xenical’ and ‘Alli’, was first approved for use as an anti-obesity drug in 1999 (Ahmad 
and Mahmud, 2010). It is a gastrointestinal lipase inhibitor which, when taken 3 times 
per day during or up to 1 hour after meals, leads to the excretion of approximately 30% 
of ingested fat (Kumar et al., 2013). It is available in prescription (120mg) and over-
the-counter (60mg) strengths. The mean 12-month weight reduction attributable to 
orlistat 120 mg taken 3 times per day is modest: among adults participating in 
behavioural weight control programs and prescribed a lower-fat diet (30% of calories 
from fat) and a multivitamin, participants taking Orlistat lost on average 3.4 kg (3.1% 
of initial weight) more than participants taking placebo (Sjöström et al., 1998). Because 
Orlistat leads to increases in undigested stool triglycerides, it can cause considerable 
gastrointestinal adverse effects, which may result in patients to discontinue therapy 
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(Filippatos et al., 2008). Indeed, despite being approved for indefinite treatment of 
obesity, among those prescribed Orlistat 120 mg clinically, fewer than 10% take it for 
at least 1 year and less than 2% of patients are prescribed the medication for 2 years 
(Hampp et al., 2013). 
Lorcaserin is a serotonergic agent like fenfluramine and dexfenflurame, but with 
improved functional selectivity. It is thought to decrease food intake through the pro-
opiomelanocortin system of neurons (Smith et al., 2010) and has been approved for 
use as a prescription anti-obesity drug in 2012 in the USA (Miller, 2013). In two large 
trials (both over 3000 patients) participants received low-intensity nutritional and 
exercise counselling along with 10mg of lorcaserin. The active intervention decreased 
body weight modestly, by approximately 3.2 kg (3.2% of initial body weight) more than 
placebo after one year (Smith et al., 2010, Fidler et al., 2011). 
Phentermine and topiramate is combination drug that contains a catecholamine 
releaser (phentermine) and an anticonvulsant (topiramate). Weight loss was observed 
as an unintended side effect of topiramate during clinical trials for epilepsy (Ben-
Menachem et al., 2003). The combination drug was developed to reduce adverse 
events incorporating lower doses in a fixed combination formulation which has been 
tested in two large trials (Yanovski and Yanovski, 2014). In the EQUIP trial, with 1267 
participants, those given the top dose had a mean 1-year weight loss of 10.9% vs 
1.6% of initial weight compared to the placebo group (Allison et al., 2012). In the 
CONQUER trial with 2487 participants, one-year mean weight loss was 8.1 kg (7.8%) 
with the recommended dose and 10.2 kg (9.8%) with the top dose vs 1.4 kg (1.2%) 
with placebo (Gadde et al., 2011). It should be noted however, that withdrawal rates 
were high at 40% in the EQUIP trial 31% in the CONQUER trial. 
Although lorcaserin and the phentermine/topiramates combination therapy have been 
approved for use in the USA, both drugs have failed to be approved in Europe. There 
are concerns that despite their success as anti-obesity drugs lorcaserin may increase 
the potential risk of psychiatric disorders (such as depression) and valvulopathy; with 
the phentermine and topiramates combination drug there are concerns about it 
increasing cardiovascular risk  (Woloshin and Schwartz, 2014). Given the history of 
approval and withdrawal of anti-obesity drugs due to long-term safety, researchers 
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have argued it is unclear if these drugs will remain on the market in the USA in the 
future (Wolfe, 2013). The lesson from the withdrawal of previous anti-obesity drugs is 
that uncommon but serious adverse effects may become apparent only when a drug 
is used in larger populations or for longer periods of time than in the preapproval trials 
(Lauer, 2012). Thus, pharmacological treatment options for obesity remain very 
limited, particularly in Europe where only Orlistat is approved and people rarely stick 
to its use long term due to gastro-intestinal side effects. 
2.2.5.3 Bariatric Surgery 
The use of bariatric surgery to treat morbid obesity has increased dramatically over 
the past two decades. An estimated 350,000 bariatric procedures were performed 
globally (63% in US/Canada) in 2008 compared to fewer than 5,000 procedures 
between 1987–1989 (DeMaria et al., 2010). Typically patients have to have failed to 
keep weight off with lifestyle interventions before they become eligible for bariatric 
surgery (NICE, 2006).  
Currently, 90% of procedures are performed laparoscopically; the two most common 
procedures being adjustable gastric banding (42% of procedures), Roux-en-Y gastric 
bypass (40% of procedures) (Buchwald and Oien, 2013) (see table 2.1 for further 
details). Adjustable gastric banding is a simpler, shorter procedure that does not carry 
a long-term risk of malabsorption. It also leads to a lower number of serious 
complications but consistently produces smaller reductions in weight and a higher 
requirement for overall reoperations than Roux-en-Y gastric bypass (Padwal et al., 
2011).  
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Table 2.1 A table describing the most common types of bariatric surgery, adapted from 
(Padwal et al., 2011). 
Procedure Description Illustration 
Adjustable 
gastric 
banding 
A band encircling the proximal 
stomach and connected to a 
subcutaneous port/reservoir is 
inserted. The band remains initially 
deflated and is then progressively 
inflated via the subcutaneous port 
during subsequent postoperative 
outpatient visits to achieve gastric 
restriction and weight loss.  
Roux-en-Y 
gastric 
bypass 
The proximal stomach is separated 
from the distal stomach to form a 
small, restrictive gastric pouch. The 
gastric pouch is connected to mid-
jejunum (thus forming the alimentary 
or roux limb) which has been diverted 
away from the biliopancreatic 
secretions. The length of small 
intestine distal to site at which the roux 
limb and the biliary limb join is termed 
the ‘common limb’ and represents the 
intestinal area where biliopancreatic 
secretions mix with ingested food and 
most absorption occurs. The 
alimentary limb is typically 100 cm in 
length and the biliopancreatic limb 30 
to 50 cm in length.  
 
The clinical benefits of bariatric surgery in achieving weight loss and improving 
metabolic comorbidities have largely been attributed to changes in the physiological 
responses of gut hormones and adipose tissue metabolism (Ionut et al., 2013). 
Metabolic effects resulting from bypassing the foregut include altered responses of 
ghrelin, glucagon-like peptide-1 and peptide YY3–36 (le Roux et al., 2007). Additional 
effects on food intake and body weight control may be attributed to changes in vagal 
nerve signalling; the loss of fat mass, particularly visceral fat, is associated with 
multiple metabolic, adipokine, and inflammatory changes that include improved insulin 
sensitivity, glucose disposal and reduced free fatty acid flux (Laferrère et al., 2011). 
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Mean percent weight loss at 5 years is estimated to be 20% to 25% of initial weight for 
gastric banding (Dixon et al., 2012) and 25% to 30% of initial body weight at 5 years 
for Roux-en-Y gastric bypasses (Vest et al., 2013).  
However, there are risks associated with bariatric surgery and complications are 
frequent. A study of insurance claims of 2522 patients who had undergone bariatric 
surgery showed 22% suffered complications during the initial hospital stay and that 
total rose to 40% in the subsequent six months. Approximately 30% of bariatric surgery 
patients will develop a nutrition-related complication, typically a macronutrient or 
micronutrient deficiency or both, at some point following their operation (Dalcanale et 
al., 2010). Protein-energy malnutrition is one of the most serious nutrition 
complications of bariatric surgery. This complication may be a consequence of 
reduced intake of protein such as red meat, which is poorly tolerated after bariatric 
surgery, or the development of other gastrointestinal problems that result in poor oral 
intake and excessive weight loss (Fujioka et al., 2011). Such side effects have led to 
surgery only being used in the most obese patient (average BMI of those undergoing 
surgery exceeds 45 kg/m2) and considered inappropriate for those of lower BMIs by 
many health professionals and researchers (Consortium, 2009). 
2.3 Potential Role of Bio-active Compounds in Obesity Treatment 
As described previously, the primary method for managing body weight has been a 
three tier approach. Starting with intensive lifestyle interventions, followed by the use 
of medications to either increase energy expenditure or reduce energy intake and 
finally the use of bariatric surgery. Using intensive lifestyle interventions, consisting of 
dietary restriction and physical activity accompanied with behaviour therapy have 
proven to be largely ineffective. Even with long term interventions (around six months), 
once the intervention period finishes compliance with improved lifestyle is poor. The 
result is generally a transient phase of weight loss followed by a return on the trajectory 
towards obesity.   
Anti-obesity drug development programmes have been littered with false starts, 
failures in clinical development, and withdrawals due to adverse effects that were not 
fully appreciated at the time of launch (Rodgers et al., 2012). As a result, current 
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options for treatment are particularly limited, particularly in Europe where only Orlistat 
is available to prescribe and few people stick with taking it over the long term. Once 
established, obesity, like hypertension or dyslipidaemia, requires long term treatment. 
Therefore, medications for obesity treatment must be viewed through the lens of long-
term use when evaluating their safety and efficacy (Yanovski and Yanovski, 2014). 
Most forms of bariatric surgery have a relatively rapid and substantial beneficial effect 
on  weight loss and health markers such as hyperglycaemia (Buchwald et al., 2009). 
It has been argued by some researchers and surgeons therefore, that reservations 
towards surgery should be set aside and that it should be used as a ‘first line’ treatment 
option that can cure obesity (Zimmet and Alberti, 2012). However, the risk of side 
effects with bariatric surgery are substantially higher than all other medical treatments, 
with some researchers suggesting that if it were a medical treatment rather than a 
surgical one, it would by now have been halted by regulatory authorities, and may only 
be appropriate for the most obese patients (Pinkney, 2011).  
Although the increasing prevalence of obesity is associated with an obesogenic 
environment, that encourages over-eating and discourages physical activity, it is now 
recognized that there exist a genetic susceptibilities which also play an important role 
in determining the extent to which an individual resists or is prone to obesity (Blundell 
et al., 2005, Blundell and Cooling, 2000). In addition, it has been established that in 
response to reduced calorific intake and weight loss, there is an accompanying 
decrease in energy expenditure, which is in part due to loss of lean body mass, and in 
part due to an enhanced metabolic efficiency (Major et al., 2007). Such reductions in 
thermogenesis may also persist well beyond the phase of weight loss (Rosenbaum et 
al., 2008) and have been demonstrated in both the resting and non-resting elements 
of energy expenditure (Dulloo et al., 2004). 
These mechanisms may make a significant contribution to weight regain and obesity 
relapse (Rosenbaum et al., 2008). Considering the lack of success of obesity 
treatments, new approaches that could diminish these compensatory mechanisms 
and offset genetic predispositions to obesity and weight regain after weight loss are 
therefore desirable (Hursel and Westerterp-Plantenga, 2010). Due to the lack of 
success of pharmacological agents in providing a clear physiological benefit at an 
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acceptable level of side effects, attention has turned to naturally occurring bio-active 
ingredients. The potential to produce positive effects on thermogenesis, fat oxidation 
and appetite have led to an active search for compounds that could provide such as 
effect without the long-term problems (particularly on cardiovascular risk factors) 
associated with previously developed pharmacological agents (Yuliana et al., 2014). 
One such compound may be capsaicinoids, a compound naturally occurring in chillies 
(Whiting et al., 2012). 
2.4 Chillies 
2.4.1 Origin 
Chillies are the fruits of plants from the genus Capsicum, which are members of the 
night shade family, Solanaceae (Perry et al., 2007). The plants originate from South 
America, with research proposing they evolved in dry, mountainous regions in either 
Bolivia or Peru (Walsh and Hoot, 2001). There are between 23 and 27 wild species, 5 
of which have been domesticated (see table 2.2), and from these 5 species over 2000 
cultivars have been bred (Tewksbury et al., 2006). Chillies available for human 
consumption have a huge range of characteristics with variations in pungency, colour, 
shape, flavour and size. Despite their trait differences however, most chilli cultivars 
commercially grown in the world belong to the species, C. annuum (Bosland, 1992). 
Table 2.2 Domesticated chilli species and common varieties (McGee, 2004) 
Species Commonly Consumed Cultivars 
Capsicum annum Bell pepper, jalapeno, cayenne 
Capsicum chinense Naga, habanero, scotch bonnet 
Capsicum frutescens Tasbasco, peri, Thai peppers 
Capsicum pubescens Rocoto 
Capsicum baccatum Aji 
Chilli has been part of the human diet since at least 7500 BC and archaeological 
evidence indicates they were domesticated more than 6000 years ago in south-
western Ecuador (Perry et al., 2007). They have since become an important food 
source and it is estimated that one quarter of the world’s population consume chillies 
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every day (Cordell and Araujo, 1993). They are also the most widely grown spice 
worldwide, with production and consumption levels 20 times that of black pepper, the 
other major pungent spice (McGee, 2004).They do not however feature prominently 
in the traditional Northern European and North American diet, where consumption 
rates tend to be much lower (Ludy and Mattes, 2011a).  
The main unique feature of the fruit is its pungency or ‘spicy’ sensation when eaten; 
this derives from a group of chemicals unique to the plant – capsaicinoids. They occur 
throughout the fruit, but are concentrated in the placental tissue, which holds up to 
90% of capsaicinoids; lower levels are found in the pericarp and lower still in the seeds 
(which are held in the placental tissue) (Cisneros-Pineda et al., 2007). Evidence 
suggests the plant evolved these molecules as a protection mechanism for seeds 
(Arora et al., 2011). 
2.5 Capsaicinoids 
Unique to chillies, capsaicinoids are the group of chemicals that provide the fruit with 
its most distinctive property – pungency. Although more than 10 different chemicals 
exist, the most prominent forms are capsaicin and dihydrocapsaicin, typically 
accounting for almost 90% of capsaicinoids found in chilli peppers (Meghvansi et al., 
2010). Capsaicin's chemical formula and chemical structure were first determined in 
1919 (Nelson, 1919), and in 1961, similar substances were isolated from chili peppers 
by Japanese chemists who named them capsaicinoids (Kosuge et al., 1961). The 
amount of capsaicinoids produced by chillies can vary widely. Genetics play a major 
role, with Capsicum chinense containing the highest values and are therefore the most 
pungent (the hottest variety is the naga pepper) (Meghvansi et al., 2010). Growing 
conditions also play an important role, such as high temperatures and water 
availability, as does time of harvest (Reilly et al., 2001).  
Research has observed that South American wild chillies are mainly eaten by local 
bird populations, which do not appear to be deterred by the presence of capsaicinoids. 
Local rodents however, are deterred from eating chillies containing capsaicin, both in 
the wild and lab conditions (Tewksbury and Nabhan, 2001). When the rodents 
consume non-pungent chillies, the digestive system damages the seeds, resulting in 
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a zero germination rate. Consuming by the local bird population however, resulted in 
similar rates of germination to that of control seeds planted directly from the fruit 
(Tewksbury and Nabhan, 2001) suggesting capsaicinoids may selectively choose who 
consumes the fruit and therefore who aids seeds dispersal.  
2.5.1 Chemical Structure and Properties 
All capsaicinoids are acid amides, with carbon chains (9-11 atoms in length), 
branched-chain fatty acids and vanillylamine (see table 2.3). The major differences 
between the various capsaicinoid molecules are the length of the aliphatic side chain, 
the presence or absence of a double bond and the branching point (Díaz et al., 2004). 
Most are pungent, but there are also non-pungent capsaicinoids, such as the ω-
hydroxycapsaicin (Ochi et al., 2003). Isolated pure capsaicinoids are crystalline, 
lipophilic, colourless and odourless alkaloids, which are fat, oil and alcohol soluble 
(Reyes-Escogido et al., 2011). Their pungency is very strong; with one part in 100,000 
detectable by tasting (Arora et al., 2011). 
Table 2.3 Structures of most common capsaicinoid compounds (Luo et al., 2011). 
Name Chemical Structure Chemical 
Formula 
Capsaicin 
 
C18H27NO3 
Dihydrocapsaicin 
 
C18H29NO3 
Nordihydrocapsaicin 
 
C17H27NO3 
Homodihydrocapsaicin 
 
C19H31NO3 
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Homocapsaicin  
 
C19H29NO3 
Nonivamide 
 
C17H27NO3 
Capsaicinoids are synthesized naturally in the placenta of chilli fruits from enzymatic 
condensation of vanillylamine and different-sized fatty acid chains which are elongated 
by a fatty acid synthase. This process is regulated by the capsaicin synthase enzyme 
acting specifically on fatty acid chain length, which requires Mg2+, ATP, coenzyme A 
and vanillylamine, the phenolic portion, formed from phenylalanine as a product in the 
phenylpropanoid pathway, while the fatty acid is formed from the amino acids valine 
or leucine (Reyes-Escogido et al., 2011). In vitro synthesis of capsaicinoid molecules 
is also possible. Capsaicinoid production via cell or tissue culture can be augmented 
with the addition of biosynthetic pathway precursors and intermediaries such as 
phenylalanine, ferulic acid and vanillylamine (Ramachandra and Ravishankar, 2002). 
Given the importance of capsaicinoids to the food and pharmacological industries (see 
section 1.2.3), recent research has begun to focus on the genetic factors that influence 
capsaicinoids synthesis (Datta and Jana, 2010, Finger et al., 2010). 
2.5.2 Measuring Capsaicinoid Pungency 
Pungency was first assessed by organoleptic tests, the most famous of which, the 
Scoville heat test, was first introduced by Wilbur Scoville in 1912. The original method 
involved an overnight alcohol extraction from the pepper, then a tasting panel testing 
increasing dilutions of the extract until the pungency was undetectable (Scoville, 
1912). The dilution factor was then assigned to the chilli as ‘Scoville heat units’; the 
more pungent an extract is the more it can be diluted, the higher the score (pure 
capsaicin’s score would be 16 million). The scoring system has been adapted to 
modern chemical analysis and so Scoville heat units are still regularly used to grade 
pepper pungency today (see table 2.4). 
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Table 2.4 Scoville Heat Units (SHU) for variety of peppers (McGee, 2004) 
Pepper Variety Species SHU score 
Naga Capsicum chinense 300,000 - 800,000 
Habanero Capsicum chinense 200,000 - 300,000 
Birds eye Capsicum annuum 100,000 - 125,000 
Tabasco Capsicum frutescens 30,000 - 50,000 
Cayenne Capsicum annuum 30,000 - 50,000 
Chile de Arbol Capsicum annuum 15,000 - 30,000 
Jalapeno Capsicum annuum 7,000 - 25,000 
Ancho Capsicum annuum 2,500 - 3,000 
Bell pepper Capsicum annuum Less than 200 
Organoleptic tests have since been replaced by more modern chemical analysis; the 
most widely used method being high-performance liquid chromatography (HPLC), 
which offers adequate accuracy and precision. The standard analytical method uses 
a 4.6 mm × 250 mm C-18 column with a mobile phase consisting of a mixture of 
acetonitrile, dioxane, water, methanol, and perchloric acid depending on the sample 
concentration, with either absorption UV detection or fluorescence detection used 
depending on sample size (Latimer, 2012). The drawbacks to HPLC method include 
the expense of columns and solvents, analysis time, and production of chemical 
wastes that require proper disposal (Davis et al., 2007). The majority of modern 
published research expresses capsaicin content in mg/g rather than Scoville heat units 
(SHU). 
2.5.3 Current Uses  
Humans have used capsaicinoids for purposes other than food consumption for 
hundreds of years; studies have revealed that chillies (Capsicum solanaceae) were 
incorporated into a number of medicinal preparations by the indigenous Mayan 
inhabitants of Central America (Cichewicz and Thorpe, 1996). 
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In 1878, a burning sensation and hyperaemia was observed when a chilli extract was 
applied to human skin (Toh et al., 1955). Early research with animals revealed a fall in 
blood pressure, increase in salivary and gastric secretion and increased intestinal 
activity after intravenous injections of chilli extracts (DeLille and Ramirez, 1935). 
Understanding the actions of capsaicinoids led to the discovery of its receptor, 
transient receptor potential vanilloid subfamily member 1 (TRPV1 also known as the 
capsaicin receptor) which is central to many of the observed effects capsaicinoids 
have on the human body (see section 2.8.1 for an in depth description of this) (Cioffi, 
2007). Despite research into several different areas of health, capsaicinoids are 
currently only used in medicine for pain relief. 
2.5.3.1 Pain relief 
Pain relief is the most studied medical application of capsaicinoids (Luo et al., 2011). 
What makes capsaicin unique is that the initial excitation of sensory neurons is 
followed by a lasting refractory state, referred to as ‘desensitisation’ (Gerner et al., 
2008). This action is a result of capsaicin’s effect on the transient receptor potential 
cation channel subfamily V member 1 (TRPV1, which occur in cells throughout the 
body), which helps the body detect heat or warmness (Ramsey et al., 2006); capsaicin 
is an agonist of TRPV1 and reduces its heat activation threshold (Knotkova et al., 
2008). Capsaicin activated TRPV1 go into a long refractory state and thus a previously 
excited neuron is resistant to various stimuli ranging from mechanical pressure to 
endogenous and exogenous pain and pro-inflammatory agents (Szallasi and 
Blumberg, 1999).  
2.5.3.2 Cancer 
Evidence has emerged in the last two decades that capsaicinoids may have anti-
cancer properties, and have displayed anti-tumour activity in both in vitro and in vivo 
studies (Sharma et al., 2013). In the cultured cells, capsaicin was able to block breast 
cancer cell migration and kill prostate cancer cells, and dihydrocapsaicin was reported 
to induce the autophagy in human colon cancer cells (Oh et al., 2008, Thoennissen et 
al., 2010, Yang et al., 2010). In the animal models, oral consumption of capsaicin was 
able to decrease the size of breast cancer tumours by 50% in mice, inhibit the 
development of pre-neoplastic breast lesions by up to 80% and direct injection of 
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capsaicin led to 80% reduction in size of the tumours (Thoennissen et al., 2010). 
Research from epidemiological studies however, has suggested that consumers of 
large amounts of chillies were at higher risk of gastric cancer than non-consumers and 
that metabolites of capsaicin (such as the reactive phenoxy radicals) may attack the 
DNA and trigger the mutagenicity and malignant transformation (Báez et al., 2010). 
Therefore, capsaicin has been described as a ‘double edged sword’ with both 
carcinogenic and chemo-preventive properties, and as such has rarely been 
considered to treat cancers in a clinical setting (Luo et al., 2011). 
2.5.3.3 Cardiovascular Effects 
There is evidence that capsaicinoids could have potentially beneficial effects on the 
cardiovascular system (Harada and Okajima, 2009, Peng and Li, 2010) which is rich 
in capsaicin-sensitive sensory nerves (particularly the TRPV1 receptor), and may play 
a role in regulating cardiovascular function through the release of multiple 
neurotransmitters (Zhou et al., 2010). Capsaicin has been shown to inhibit platelet 
aggregation (Adams et al., 2009, Raghavendra and Naidu, 2009), which is a critical 
factor in arterial thrombosis (Chuang et al., 2013). Capsaicinoids also have antioxidant 
properties; in vitro, it has been reported that capsaicin and dihydrocapsaicin were able 
to increase the resistance of LDL to oxidation by delaying the initiation of oxidation 
and/or slowing the rate of oxidation (Ahuja et al., 2006). In vivo, capsaicin treatment 
reduced serum total cholesterol and lipid peroxide level in rats fed on a high fat diet 
(Manjunatha and Srinivasan, 2007), and regular consumption of chilli for 4 weeks 
increased the resistance of serum lipoproteins to oxidation in adult men and women 
(Ahuja and Ball, 2006).  
2.5.3.4 Gastro-Intestinal Effects 
Like the cardiovascular system, the gastrointestinal system is also rich in capsaicin-
sensitive sensory nerves (particularly TRPV1 receptor), which are believed to play an 
important role in the maintenance of gastrointestinal mucosa integrity against injurious 
interventions (Peng and Li, 2010). The gastro-protective effects of capsaicinoids were 
demonstrated in different animal models of gastric mucosal injury, induced by 
hydrochloric acid, ammonia, ethanol, aspirin or indomethacin (Mózsik et al., 2007, 
Szolcsanyi and Bartho, 2001). Additionally, capsaicin has been shown to alter brush 
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border membrane permeability, associated with increased microvilli length and 
perimeter, resulting in an increased absorptive surface of small intestine (Prakash and 
Srinivasan, 2010) and increased mineral absorption in rats (Prakash and Srinivasan, 
2013).  
However, detrimental effects on GI tract on prolonged exposure of high doses of 
capsaicin have been reported. A high dose of capsaicinoids trial led to the exhaust of 
neurotransmitters and the damage of capsaicin-sensitive sensory nerves, which may 
have harmful effects on the gastrointestinal system in rats (Wang et al., 2005). It 
seems, capsaicinoids exert either beneficial or detrimental effects on gastrointestinal 
mucosa depending on the dose and/or duration of treatment (Raybould, 2013).  
Table 2.5 Recent emerging evidence of other physiological actions of capsaicinoids 
Condition Key Finding Reference 
Alzheimer's disease 
 
Capsaicin protected 
against the formation 
of Alzheimer’s lesions 
in rats. 
(Jiang et al., 2013) 
Asthma 
 
Treatment of TRPV1 
channel in mice 
reduced asthma 
symptoms. 
(Rehman et al., 2013) 
Dermatological conditions 
 
21 day capsaicin 
treatment reduced 
symptoms of 
psoriasis vulgaris. 
(Yu, 2011) 
Fibromyalgia 
 
6 weeks of topical 
capsaicin treatment 
significantly reduced 
symptoms. 
(Casanueva et al., 2013) 
Skeletal muscle hypertrophy 
 
Capsaicin mimics 
mechanical load-
induced intracellular 
signalling events 
resulting in muscle 
hypertrophy 
(Ito et al., 2013) 
2.5.4 Toxicity and Adverse Effects 
The dosage at which capsaicinoids are applied is clearly crucial to their use. At high 
does they are a highly irritant substance causing burning or stinging pain to the skin. 
Eye exposure leads to intense tearing, pain, conjunctivitis and blepharospasm. If it is 
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ingested in large quantities it can cause nausea, vomiting, abdominal pain, and 
burning diarrhoea (Hayman and Kam, 2008). The oral toxicity of capsaicin has been 
investigated in mice and rats; with the lethal dose required to kill 50% of the population 
being 118.8 mg/kg for male and 97.4 mg/kg for female mice, and 161.2 mg/kg for male 
and 148.1 mg/kg for female rats. Major toxic symptoms were salivation, erythema of 
skin, staggering gait, bradypnea and cyanosis. Some animals showed tremor, chronic 
convulsion, dyspnoea and lateral or prone position and then died 4 to 26 min after 
dosing. Survivors recovered within 6 hours in mice and 24 hours in rats (Saito and 
Yamamoto, 1996). Other research with dogs suggested pure capsaicin is rapidly 
eliminated, induces transient tachycardia and hypertension, does not alter the duration 
of cardiac action potentials, and causes only very minimal organ toxicities (Chanda et 
al., 2005).  
In studies with human subjects, approximately 54% of patients using capsaicin 
experienced one or more local adverse events (compared to 15% with placebo) 
(Sawynok, 2005). The initial burning side effect of capsaicin cannot be reliably 
prevented with the use of topical local anaesthetics and this is a major limitation in the 
use of capsaicin as a topical therapy (Hayman and Kam, 2008). Another adverse effect 
of capsaicinoids is coughing, which occurred in 8% of patients using 0.075% cream 
whereas none occurred with 0.025% cream. Capsaicin has been extensively used in 
cough testing because it produces a dose-dependent and reproducible cough 
response; with TRPV1 receptors present on sensory airway nerves being crucial to 
the mechanism of the cough reflex (Dicpinigaitis and Alva, 2005). Adverse gastro-
intestinal effects following oral consumption were reported by 11% of participants in a 
trial with 91 participants and a high capsaicin dosage (135mg/day) (Lejeune et al., 
2003), suggesting this is around the upper limit of oral ingestion of capsaicin 
supplements. 
2.6 Capsinoids 
Recently, a number of capsaicin analogues, named capsinoids, have been the focus 
of research. They occur naturally in high levels in a capsicum cultivar named ‘CH-19 
Sweet’, which has low levels of capsaicinoids (Kobata et al., 1998). Capsinoids include 
capsiate, dihydrocapsiate, and nordihydrocapsiate (Kobata et al., 1999); they bear a 
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similar structure (an aliphatic hydroxyl group in vanillyl alcohol with a fatty acid) with 
capsaicinoids, however, the central linkage in both group compounds is different (He 
et al., 2009) (see table 2.5 for structures). They have become of interest to researchers 
as they possess many of the same bio-active properties of capsaicinoids, without the 
same level of pungency. Like capsaicinoids, much of capsinoids’ physiological 
influence come from their agonistic effect on TRPV1 receptors (Iida et al., 2003). 
Table 2.5 Structures and chemical formulas of the most common capsinoids (Luo et 
al., 2011) 
Capsiate OH
O
CH3
O
CH3
CH3
O  
C18H26O4 
Dihydrocapsiate OH
O
CH3
O
CH3
CH3
O  
C18H28O4 
Nordihydrocapsiate OH
O
CH3
O CH3
O CH3  
C17H26O4 
Studies carried out to evaluate the toxicity of capsinoids suggest they are less toxic to 
mammals than capsaicinoids. Research in rats has shown that administration of 
dihydrocapsiate by gavage at a dose of 100 or 300 mg/kg/day for 13 weeks did not 
see any significant changes in clinical signs, body weight, food consumption, water 
intake, ophthalmology, urinalysis, haematology, or blood chemistry (Bernard et al., 
2008, Kodama et al., 2010). 
It has been shown that capsiate, different from capsaicin, is highly lipophilic and easily 
broken down in the normal aqueous conditions, which may account for, at least 
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partially, the non-pungent property and lower toxicity of capsiate (Kawabata et al., 
2006).  In contrast to capsaicin, capsiate did not induce any significant responses 
when applied to the skin surface, eye or oral cavity of mice, suggesting that capsiate 
requires direct access to nerve endings to exhibit its effects (Iida et al., 2003). Other 
research has shown that capsinoids do not stimulate the nociceptors in the mouth of 
humans, meaning upon consumption there is not the same pungent flavour sensation 
(Hursel and Westerterp-Plantenga, 2010). This ability has led to suggestions that 
capsinoids may make a good alternative to capsaicinoids, particularly as some people 
are adverse to the heat sensation in both the mouth and the gastro-intestinal tract, 
especially when consumed in large quantities (Yoneshiro et al., 2012).  
2.7 Capsaicinoids, Capsinoids and Weight Management 
The potential weight management effects of capsaicinoids were first observed in rats 
when capsaicin treatment stimulated epinephrine secretion from the adrenal medulla  
which resulted in a rapid but transient elevation of the respiratory quotient, thus 
showing an increase in energy expenditure (Kawada et al., 1988). Similar effects were 
also observed in human subjects when a 25% increase in the metabolic rate was 
observed after chilli sauce and mustard sauce were added to a meal (Henry and 
Emery, 1986).  
2.7.1 Mechanisms of Action 
Three potential actions of capsaicinoids and capsinoids have been identified that may 
lead to weight loss, weight maintenance or other beneficial health outcomes. Namely 
an increased energy expenditure, increased lipid oxidation and decreased energy 
intake. The potential mechanisms of actions for these effects will be discussed in this 
section. 
2.7.1.1 The Transient Receptor Potential Vanilloid Type 1 Ion Channel 
It was first observed in the 1950s that capsaicin activated a subpopulation of 
nociceptive sensory nerves (Porszasz and Jancso, 1959). The receptor was then 
identified and cloned in 1997 (Caterina et al., 1997) and since then has been renamed 
the transient receptor potential vanilloid type 1 ion channel (TRPV1). Many the known 
actions of capsaicinoids’ and capsinoids’ are mediated by their effects on the TRPV1 
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(Gharat and Szallasi, 2007). Capsaicin contains a vanillyl moiety (Fujiwake et al., 
1980); a chemical structure that  which is believed to cause the activation of the TRPV1 
channel (Mandadi and Roufogalis, 2008).  
Ion channels such as the TRPV1 are located within the plasma membrane of nearly 
all cells and many intracellular organelles. They are often described as narrow, water-
filled tunnels that allow only ions of a certain size or electrical charge to pass through; 
a characteristic known as selective permeability. A typical channel pore is just one or 
two atoms wide at its narrowest point and is selective for specific types of ions, such 
as sodium, potassium or in the case of the TRPV1, predominantly calcium. Ions often 
move through the segments of the channel pore in single file nearly as quickly as the 
ions move through free solution. In many ion channels, passage through the pore is 
governed by a "gate", which may be opened or closed in response to chemical or 
electrical signals, temperature, or mechanical force (Hille, 2001). Activation of TRPV1 
results in increased openness of the ion channel and subsequently increased ion 
movement in and around the channel (Liu et al., 2006).  
TRP channels respond to changes in various physical stimuli such as heat or pressure 
(Nilius and Appendino, 2011). TRPV1 was the first TRP channel shown to respond 
specifically to increased temperatures (Caterina et al., 1997). Interestingly, TRPV1 
seems to be continually active at a low level and hence it is thought it acts as a 
molecular thermometer. It has been proposed therefore, that the main function of 
TRPV1 is to maintain body temperature (Gavva et al., 2007). This putative function 
explains why some TRPV1 agonists such as capsaicinoids can cause a change in 
body temperature, and also why TRPV1 antagonists induce considerable 
hyperthermia in several species (Holzer, 2008). An increase from normal room 
temperature to about 45 °C has been shown to lead to a pronounced increase in the 
intracellular calcium concentration in TRPV1-expressing cells (Caterina et al., 1997). 
TRP channels are widely expressed in excitable and non-excitable cells in both 
vertebrates and invertebrates and appear to represent primary pathways for regulated 
calcium cell entry (O’Neil and Brown, 2003).  
TRPV1 is highly expressed in sensory neurons, including the dorsal root ganglia and 
trigeminal ganglia, with moderate expression in other tissues such as pancreas, brain, 
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liver, bladder, kidney, bowel, and others (Szallasi et al., 2007). When the channel is 
readily activated by vanilloids such as capsaicin, it appears to do so by direct binding 
of the ligand to an intracellular binding site on the channel (Lishko et al., 2007) (see 
figure 2.4). Other TRPV channels have been discovered, such as TRPV2, TRPV3, 
and TRPV4; and they have also been shown to be activated by heat, although it is 
thought they may have a much broader range of functions in addition to thermal 
sensation, including vascular function and inflammation (Baylie and Brayden, 2011, 
De Petrocellis et al., 2012).  
Figure 2.4 The proposed structure of TRPV channels (O’Neil and Brown, 2003) 
 
The channel is proposed to have 6 transmembrane domains (TM1-TM6), a pore loop 
(PL, responsible for channel permeability), a long NH2 terminal and COOH terminal, 
both existing in the cell’s cytoplasm. The NH2 terminal has between 2 and 5 ankyrin 
repeat domains (ARD, commonly occurring protein structures in cells). 
2.7.1.2 Mechanism of Action of Effects on Energy Expenditure 
Capsaicinoids and capsinoids have been observed to cause increases in energy 
expenditure in both human (Lee et al., 2010b, Ludy and Mattes, 2011a) and animal 
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studies (Kawabata et al., 2009). It has been observed in several studies involving 
animal models that capsaicin treatment increased serum catecholamine levels. 
Rats receiving capsaicin injections (intraperitoneally, 6mg/kg) responded in a manner 
similar to that of the metabolism of the catecholamine, epinephrine. Oxygen 
consumption increased upon injection, as did the respiratory quotient, and levels of 
serum glucose and immunoreactive insulin rapidly increased after administration of 
capsaicin. Also, liver glycogen rapidly decreased, in contrast to the serum glucose 
concentration which rapidly increased and the serum-free fatty acid level gradually 
increased. Alterations in energy metabolism which are all similar to those that occur in 
the metabolism of epinephrine (Kawada et al., 1986). This is supported by evidence 
in human trials, where capsaicinoids added to a meal significantly increased plasma 
epinephrine and norepinephrine levels compared with a control condition (Lim et al., 
1997). In another experiment supplementation with propranolol (which inhibits the 
action of catecholamines (Atlas et al., 1974) abolished an increase in energy 
expenditure that was observed when subjects were given a capsaicinoid containing 
meal without propranolol (Yoshioka et al., 1995); thus providing evidence that an 
increase in energy expenditure is caused by the action of catecholamine secretion, as 
a result of capsaicinoid ingestion. These results suggest that the mechanism of action 
of capsaicinoids on the increase of energy metabolism is caused by a direct effect (as 
an agonist) on cells’ catecholamine receptors or by the stimulation catecholamine 
secretion which in turn causes a beta-adrenergic response. 
2.7.1.2.1 Effect of Brown Adipose Tissue 
Evidence has also emerged that brown adipose tissue (BAT) may play an important 
role in capsaicinoid/capsinoid stimulation of energy expenditure. BAT evolved in 
mammals to dissipate large amounts of chemical energy as heat (Seale and Lazar, 
2009). Brown fat cells possess large numbers of mitochondria that contain a unique 
protein called uncoupling protein 1 (UCP1). UCP1 functions to dissipate the proton 
motive force that is normally used to drive the synthesis of cellular ATP (Cannon and 
Nedergaard, 2004). As a consequence of UCP1 action, the energy in the mitochondria 
is released in the form of heat. BAT is a key thermogenic tissue in rodents and other 
small mammals, along with new-born humans that maintain core body temperature in 
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cold weather. The sensation of cold causes sympathetic nerves to release 
catecholamines in BAT that stimulate proliferation and heat production by brown fat 
cells (Lee et al., 2010a). Studies in rodents have also unequivocally demonstrated that 
BAT plays an essential role in energy balance and that its activity profoundly 
influences body weight (Seale et al., 2009). Though BAT persists as a distinct tissue 
in small mammals, the major deposit of BAT in new-born humans (between the 
shoulder blades) regresses shortly after birth (see figure 2.5). Other depots of BAT 
have been known to exist in adult humans for many decades, although levels vary 
greatly between individuals (Nedergaard et al., 2007). Age has been shown to be a 
key factor for BAT levels in humans, with research showing that cold-activated BAT 
was detected in about 55% of individuals in their 20s, but was less than 10% for those 
in their 50s and 60s (Yoneshiro et al., 2011). 
Figure 2.5 Showing the results fluorodeoxyglucose in combination with computed 
tomography analysis of subjects with detectable and non-detectable levels of BAT 
(Saito and Yoneshiro, 2013). 
 
 
 
 
 
Subject with detectable levels of BAT         Subject with non-detectable levels of BAT 
Besides exposure to cold, dietary stimuli can trigger the sympathetic nerve-mediated 
activation of BAT (Young et al., 1982, Nakamura and Morrison, 2007). Capsiate 
administered intragastrically to rats, resulted in a time- and dose-dependent increase 
in integrated BAT sympathetic nerve activity. This increase in sympathetic nerve 
activity was abolished when TRP channels were blocked and was inhibited by the 
removal of the gastrointestinal vagus nerve. The activation of sympathetic nerve 
activity was limited to BAT and did not occur in the heart or pancreas, suggesting BAT 
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may play an important role in stimulating the nervous system to increase energy 
expenditure and aid weight loss (Ono et al., 2011). This provided the first evidence 
that BAT may be playing an important role in increasing energy expenditure. This 
effect was replicated in a human trial (see section 2.7.3 for full details) which showed 
a significant increase in energy expenditure (p < 0.05) following capsinoid ingestion in 
the BAT positive group compared to placebo but a minimal increase in energy 
expenditure in the BAT negative group under the same conditions (Yoneshiro et al., 
2012). Taken together these trials indicated that the presence of BAT may be 
necessary for capsaicinoids and capsinoids to produce an increase in energy 
expenditure. This would explain some of the variation in results seen across 
intervention trials, although further research is required to confirm this. 
Interestingly results from another trial by the same research group suggested that six 
weeks of capsinoid supplementation in human participants (n=10) either increased the 
amount of BAT or increased the functioning of existing BAT, which in turn increases 
energy expenditure following supplementation (Yoneshiro et al., 2013). This may be 
due to recent findings that chronic sympathetic activation produces not only an 
increase in BAT cells but also a remarkable induction of UCP1-positive brown-like 
adipocytes in white adipose tissue (WAT). When this occurs, adipose cells have been 
termed ‘beige or brite’ cells, in mice and rats (Cinti, 2009). While BAT produces heat, 
WAT cells’ primary function is to store lipids. The existence of beige cells suggests 
that despite being structurally different adipose cells may be able to undergo a 
reversible physiological trans-differentiation and take on aspects of the other cell 
type’s functioning (Cinti, 2007).  
A recent trial in which mice received capsaicin supplementation (2mg/kg) for three 
months found alterations in white and brown adipose tissue compared with the control 
group. Capsaicin supplementation increased gene expression associated with 
‘browning’ of WAT (i.e. turning white adipose tissue into brown or ‘beige’ tissue) and 
increases expression of thermogenesis and mitochondrial biogenesis genes in already 
present BAT (Baboota et al., 2014). In addition to this it has been observed that BAT 
activity in humans is markedly increased during winter in individuals who showed 
undetectable activities in summer (Saito et al., 2009). Taken together this data 
suggests that human BAT identified by FDG-CT is largely composed of beige cells 
  
39 
 
and that its activity can be increased in response to appropriate sympathetic 
stimulation. This suggests that capsaicinoids and capsinoids, over time, may increase 
energy expenditure (via BAT) and also increase the amount of BAT (or beige adipose 
tissue) in humans. 
2.7.1.2.2 Overview of Mechanism of Action for Energy Expenditure  
Figure 2.6 A diagram to show the proposed process of increased energy expenditure 
by capsaicinoids and capsinoids, adapted from (Hursel and Westerterp-Plantenga, 
2010). 
Capsaicinoids/Capsinoids 
 
TRPV1 stimulation 
 
Catecholamine Secretion 
 
Beta-adrenoceptors  
 
 
Sympathetic Nervous System 
 
 
UCP Activity 
 
 
Increased Energy Expenditure 
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Capsaicinoids and capsinoids stimulate the TRPV1 receptors in cells, which leads to 
catecholamine secretion from the adrenal medulla (Watanabe et al., 1987). The 
release of catecholamines into the body is detected by cells via their adrenergic 
receptors, many cells possess these receptors, and the binding of a catecholamine to 
the receptor will generally stimulate the sympathetic nervous system. 
This is thought to then lead to an effect on uncoupling proteins (UCPs). Cellular energy 
production takes place across the inner mitochondrial membrane (adenosine 
diphosphate is converted to adenosine triphosphate using a gradient of protons 
produced by the respiratory chain). If protons leak back, abolishing the proton gradient, 
heat is created (a process known as thermogenesis) instead of normal energy usage. 
This disruption of the connection between food breakdown and energy production is 
known as “uncoupling”, and could lead to an increase in energy expenditure (Berger 
et al., 1998).  
Details of human intervention trials investigating the effect of capsaicinoids on energy 
expenditure can be found in table 2.5 below. Six of the 10 trials using capsaicinoids 
and 8 of the 10 trials using capsinoids found a significant increase on energy 
expenditure following an intervention, with figures suggesting an increase between 
41.8kJ – 209.2kJ (10kcal – 50kcal). The majority of trials involved a single dose of the 
intervention so it is not clear from these results if the effects would last over the longer 
term. 
Table 2.5 Intervention trials evaluating the effects of capsaicinoids on energy 
expenditure 
Author Intervention 
Used 
Dosage 
(mg) 
Size (n) Duration Study Type Key Findings 
Henry & 
Emery 1986 
Fresh Chilli Not 
stated 
12 Single 
meal 
Randomise
d control 
Chilli substantially 
increased RMR in all 
subjects 
Yoshioka et 
al 1995 
Dried chilli 
powder  
30 8  Single 
meal 
Randomise
d control 
Increase in energy 
expenditure (EE) for 
30 minutes 
(significance not 
stated).  
Lim et al 
1997 
Dried chilli 
powder 
Not 
Stated 
8 Single 
meal 
Randomise
d control 
Increase in EE of 
10% for 30 minutes 
(not significant) 
Yoshioka et 
al 1998 
Dried chilli 
powder 
30 14 4 meals Randomise
d crossover 
Increase in EE (p < 
0.05) for 180 
minutes. 
Matsumoto 
et al 2000 
Curry sauce 
with chilli 
3 16 Single 
meal 
Randomise
d control 
Significant increase 
seen in lean (p < 
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0.01) but not obese 
group. 
Lejeune et 
al 2003 
Capsaicin 
supplement 
135/day 91 4 months Randomise
d placebo 
controlled 
Significant increase 
in resting EE (p < 
0.005). 
Smeets & 
Westerterp-
Platenga 
2009 
Capsaicinoid 
containing meal 
5 30 Single 
meal 
Randomise
d crossover 
No effect on EE 
detected. 
Ludy & 
Mattes 2011 
Dried chilli 
powder or 
capsule 
Variable 25 6 meals  Randomise
d crossover 
Significant increase 
in EE at higher dose 
(p = 0.013). 
Janssens 
et al 2013 
Dried chilli 
powder 
7.68/day 15 4 x 36 hr 
testing 
periods 
Randomise
d crossover 
Diet induced 
decrease in EE 
attenuated (p=0.02)   
Smeets et 
al 2013 
Capsaicin 
supplement 
2.56 28 36 hr 
testing 
period 
Randomise
d crossover 
Increase in EE when 
consuming a calorie 
restricted diet (p < 
0.05). 
Table 2.6 Intervention trials evaluating the effects of capsinoids on energy expenditure 
Author Intervention 
Used 
Dosage 
(mg) 
Size 
(n) 
Duration Study Type Key Findings 
 Ohnuki et 
al 2001 
CH-19 Sweet 
pepper 
0.03-0.1 
/kg 
11 Single 
meal 
Randomised 
control 
Increases in body 
temperature (p < 
0.01) and oxygen 
consumption (p < 
0.03). 
Kawabata 
et al 2006 
CH-19 Sweet 
pepper 
1/kg 7 2 weeks Randomised 
control 
Decrease in body 
weight (p < 0.05) 
Inoue et al 
2007 
Capsinoid 
supplement 
3 or 10 44 4 weeks Randomised 
placebo 
control 
Dose responsive 
increase in EE 
significant only in 
those with BMI > 24. 
Snitker et al 
2009 
Capsinoid 
supplement 
6 80 12 
weeks 
Randomised 
placebo 
control 
EE 54 kcal/d higher 
in treatment group 
(p = 0.19). 
Galgani & 
Ravussin 
2010 
Dihydrocapsiate 
supplement 
3 & 9 78 4 weeks Randomised 
placebo 
control 
Increased in EE (p = 
0.04), around 50 
kcal/d. 
Galgani et 
al 2010 
Capsinoid 
supplement 
1, 3, 6 & 
12 
13 5 days Randomised 
placebo 
control 
No effect on energy 
expenditure found. 
Josse et al 
2010 
Capsinoid 
supplement 
10 12 Single 
meal 
Randomised 
placebo 
control 
Increases in EE (p < 
0.05). 
Lee et al 
2010 
Dihydrocapsiate 
supplement 
3 & 9 33 4 weeks Randomised 
placebo 
control 
Increase in EE at 
high dosage (p < 
0.05). Dose 
dependant effect 
observed. 
Yoneshiro 
et al 2012 
Capsinoid 
supplement 
9 18 2 days Randomised 
placebo 
control 
Significant increase 
in energy 
expenditure in those 
with Brown Adipose 
Tissue (BAT) 
Yoneshiro 
et al 2013 
Capsinoid 
supplement 
Not 
stated 
10 6 weeks Randomised 
placebo 
control 
Significant increase 
in energy 
expenditure (p < 
0.01), increase in 
BAT activity 
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2.7.1.3 Mechanism of Action of Effects on Lipid Oxidation/Adipose Tissue 
Accumulation 
It has been observed in a number of human intervention trials that capsaicinoid and 
capsinoid supplementation taken over a number of weeks reduces body adiposity 
even if body weight is not reduced (Lejeune et al., 2003, Snitker et al., 2009). In 
addition to this, studies that have monitored expired breathing gases have noticed an 
increase in lipid oxidation after consumption of capsaicinoids (Janssens et al., 2013, 
Lee et al., 2010b).  
Through secretion of adipokines (cell signalling proteins, released by adipose tissue) 
into the blood, adipose tissue plays a central role in development of obesity and 
metabolic disorders such as insulin resistance, diabetes, hyperlipidemia, hypertension 
and cardiovascular disease (Bastard et al., 2006, Palomo et al., 2006). In particular, 
white adipose tissue (WAT) which functions as an energy storage organ through 
formation of triacylglycerol and release of fatty acids into the bloodstream during a 
shortage of energy has a large influence (Trayhurn and Beattie, 2001). As a result of 
over-nutrition, excess WAT builds up and plays a major role in obesity and obesity-
related disorders through dysregulation of normal metabolic functioning (Ouchi et al., 
2011, Galic et al., 2010). Therefore, inhibition of excess WAT can be an efficient 
strategy for prevention of obesity and metabolic disorders (Kusminski and Scherer, 
2012). Several potential mechanisms of action have been detected in research trials 
that may account for the observation that capsaicinoids could be inhibiting the build-
up and function of adipose tissue. 
2.7.1.3.1 Effect of the Sympathetic Nervous System 
Animal studies have shown the sympathetic nervous system (SNS) to have several 
effects on white adipose tissue, including mobilisation of lipid stores. The SNS is the 
principal initiator of lipolysis (Bartness et al., 2001), which involves the hydrolysis of 
triglycerides into glycerol and free fatty acids. Once broken down these free fatty acids 
are released and transported through the blood stream (via lipoproteins) and are 
available for cellular uptake throughout the body (Wakil, 2012). Therefore capsaicinoid 
and capsinoid stimulation of the SNS may account for some of the increased level of 
lipid oxidation observed in human subjects.  
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In addition to initiating lipolysis, stimulation of the sympathetic nervous system has 
been demonstrated to effect adipocyte proliferation (Bartness and Song, 2007). 
Norepinephrine added to white pre-adipocyte cells (in vitro) was found to inhibit their 
normal proliferation. It has also been observed that surgical denervation of WAT 
produces pronounced (approximately 2-fold) increases in fat cell number with little 
change in fat cell size in rats (Cousin et al., 1993). In addition, obesity typically is 
associated with decreases in SNS activity (Bray, 1989), it may be that these two 
characteristics of obesity are related to one another; indeed, it has been hypothesized 
that decreases in SNS activity trigger increased adipocyte proliferation (Bartness et 
al., 2005). So stimulation of the SNS by capsaicinoids and capsinoids may also reduce 
the proliferation of adipose cells. It should however be noted that much of the research 
here has not involved capsaicinoids to stimulate SNS; therefore it is not definitive from 
this research that these capsaicinoids are affecting lipolysis and adipocyte proliferation 
in this way. 
2.7.1.3.2 Effect of TRPV1 Channel 
TRPV1 channels have been detected in pre-adipocytes cells (pre-cursors to 
adipocytes which have not yet fully differentiated) found in both human and mouse 
visceral adipose tissue (Zhang et al., 2007). When researchers induced the process 
of adipogenesis (creation of adipocytes from pre-adipocytes) in vitro, capsaicin dose-
dependently induced calcium influx into the cells and prevented the adipogenesis. In 
the same study the authors carried out in vivo experiments where mice fed a high fat 
diet in the presence of capsaicin exhibited lower body weight and higher TRPV1 
expression compared with mice on a high fat diet alone. In TRPV1 knock-out mice 
there was no significant difference in body weight between mice on a high fat diet with 
or without capsaicin. (Zhang et al., 2007). The results of this trial suggest that capsaicin 
may prevent the formation of adipocytes causing a decrease adipose tissue.  
2.7.1.3.3 Effect on Cellular Enzyme and Protein Expression 
A trial investigating the inhibition of lipid accumulation in adipocytes due to 
capsaicinoids suggests they may affect adipose enzyme expression. Capsaicin 
significantly decreased the amount of intracellular triglycerides and inhibited 
expression of an enzyme that plays a major role in lipid biosynthesis from 
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carbohydrates (glycerol-3-phosphate dehydrogenase) and an enzyme that regulates 
fatty acid storage activity in adipocytes (peroxisome proliferator-activated receptors 
gamma) (Hsu and Yen, 2007). This investigation suggests that capsaicin could reduce 
lipid storage in adipocytes, potentially reducing adipose tissue size. 
Research in rats treated with capsaicin (10 mg/kg) along with a high-fat diet found that 
in comparison with control rats, body weight decreased by 8%. The researchers 
carried out a protein mapping procedure of the rats white adipose tissue, which 
revealed significant alterations to a number of proteins. 10 were significantly up-
regulated and 10 were remarkably down-regulated in rats treated with a capsaicin 
supplemented diet compared to the control rats; most of the identified proteins are 
associated with lipid metabolism and redox regulation (Joo et al., 2010). These results 
suggest that thermogenesis and lipid metabolism related proteins were markedly 
altered in WAT upon supplementation with capsaicin, and demonstrate more of the 
effects that capsaicinoids and capsinoids may be exerting at a cellular level on adipose 
tissue. 
2.7.1.3.4 Effect on Nerve Stimulation 
As capsaicinoids and capsinoids are potent nerve agonists, a number of researchers 
have considered their impact on nerve signals and whether this could affect body fat 
accumulation and distribution. Capsaicin (a dose of 5 mg/kg) administered straight into 
the body cavity was found to desensitise local afferent vagal nerve endings for 
approximately 3 weeks in rats. Following this desensitization, the rats deprived of food 
for 120 h lost significantly more weight than the controls (p < 0.05), suggesting the 
blockade of such nerve signals might enhance loss of body weight upon fasting 
(Garami et al., 2010). The impact of disrupting vagal signalling by surgical restriction 
(SR) or de-sensitisation with capsaicin (DS) on weight gain and fat content was 
assessed in diet-induced obese rats. Rats underwent vagal SR or DS with capsaicin, 
or a sham procedure. Animals were maintained for 11 months on a high-calorie, 
Western style diet; SR rats weighed 19 % less (P = 0.003) and DS rats 7 % less (P = 
0.19) than the control group; SR and DS animals had a 52 % (P < 0.0001) and an 18 
% reduction (P = 0.039) in visceral abdominal fat, respectively. Disrupting vagal 
signalling by SR led to significant reductions in both diet-induced weight gain and 
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visceral abdominal fat deposition; and vagal DS led to more modest, but clinically 
significant reductions in weight and visceral abdominal fat (Stearns et al., 2012).  
Also investigated have been intestinal mucosa afferent nerve terminals which can 
mediate post-prandial changes in intestinal and visceral adipose tissue blood flow 
(Leung, 2008). Capsaicinoids and capsinoids are a potent afferent nerve stimulators 
and functional impairment of these sensory sites has been shown to retard body 
weight gain in rats (Leung et al., 2007), in addition to this intestinal mucosal afferent 
nerve function may be necessary for the physiologic accumulation of fat in visceral 
adipose tissue sites (Leung, 2008). Evidence from these trials suggests capsaicinoids 
impact on nerve cells, particularly along the vagus nerve and the intestinal mucosa 
afferent mechanism, may regulate adipose tissue distribution and prove to be of health 
benefit when ingested orally. 
Details of human intervention trials investigating the effects of capsaicinoids on energy 
expenditure can be found in table 2.8 and the effect of capsinoids in table 2.9 below. 
Four of five capsaicinoid trials and four of six capsinoid trials found a significant 
increase in lipid oxidation following an intervention. Results suggest an increase in 
lipid oxidation of around 20% in the period following a capsaicinoid/capsinoid 
intervention. The majority of the trials involved a single intervention so it is not clear 
from these trials whether the effect would be repeated over the longer term. 
Table 2.8 Intervention trials evaluating the effects of capsaicinoids on lipid oxidation 
Author Intervention 
Used 
Dosage 
(mg/day)  
Size 
(n) 
Duration Study Type Key Findings 
Yoshioka 
et al 1995 
Capsaicin rich 
red pepper  
30 8  Single 
meal 
Randomised 
control 
Decrease in lipid 
oxidation 
(significance not 
stated).  
Yoshioka 
et al 1998 
Capsaicin rich 
red pepper 
30 14 4 meals Randomised 
crossover 
Increase in lipid 
oxidation (p < 0.05) 
for 180 mins. 
Lejeune et 
al 2003 
Capsaicin 
supplement 
135 91 4 months Randomised 
placebo 
controlled 
Lipid oxidation 
increase (p < 0.05), 
No significant effect 
on weight. 
Shin and 
Moritani 
2007 
Capsaicin 
capsule 
150 10 Single 
meal 
Randomised 
crossover 
Increase in lipid 
oxidation (p = 0.05) 
during exercise 
Janssens 
et al 2013 
Dried chilli 
powder 
7.68/day 15 4 x 36 hr 
testing 
periods 
Randomised 
crossover 
Increase in lipid 
oxidation (p = 0.03)   
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Table 2.9 Intervention trials evaluating the effects of capsinoids on lipid oxidation 
Author Intervention 
Used 
Dosage 
(mg) 
Size 
(n) 
Duration Study Type Key Findings 
Inoue et al 
2007 
Capsinoid 
supplement 
3 & 10 44 4 weeks Randomised 
placebo 
control 
Increased lipid 
oxidation (p < 0.05), 
significance only 
reached in group with 
BMI > 25. 
Snitker et 
al 2009 
Capsinoid 
supplement 
6 80 12 weeks Randomised 
placebo 
control 
Abdominal fat 
decreased (p = 0.049). 
Lipid oxidation 
increased (p = 0.06). 
Galgani & 
Ravussin 
2010 
Dihydrocapsiate 
supplement 
3 & 9 78 4 weeks Randomised 
placebo 
control 
No changes in lipid 
oxidation or body fat 
detected. 
Galgani et 
al 2010 
Capsinoid 
supplement 
1, 3, 6 & 12 13 5 days Randomised 
placebo 
control 
No effect on lipid 
oxidation found. 
Josse et al 
2010 
Capsinoid 
supplement 
10 12 Single meal Randomised 
placebo 
control 
Increases lipid 
oxidation, decrease in 
blood free fatty acids 
and glycerol (all p < 
0.05). 
Lee et al 
2010 
Dihydrocapsiate 
supplement 
3 & 9 33 4 weeks Randomised 
placebo 
control 
Increase in fat 
oxidation (p < 0.05). 
2.7.1.4 Effects on Appetite and Energy Intake 
It has been observed in a number of human intervention trials that an effect on appetite 
and energy intake may occur when the diet is supplemented with capsaicinoids 
(Janssens et al., 2014, Ludy and Mattes, 2011a) or capsinoids (Reinbach et al., 2009). 
In addition to this, a meta-analysis (carried out as part of this research, see chapter 3) 
suggested that consuming capsaicinoids prior to a meal could reduce energy intake 
by around 79 kcal (310 kJ) (Whiting et al., 2014). Research suggests supplementation 
may reduce appetite and desire to eat as well as number of calories eaten by reducing 
the actual amount of food eaten or by changing food choice to a preference for lower 
calorie food (increased intake carbohydrate-rich food at the expense of fat-rich foods) 
(Ludy et al., 2012). A number of possible mechanisms of action have been suggested 
for this observation and they will be discussed in this section. 
2.7.1.4.1 Effect of Intestinal Hormones 
In human trials it has been observed that capsaicin could affect energy intake without 
oral stimulation (Westerterp-Plantenga et al., 2005). Therefore it has been 
hypothesised that capsaicinoids and capsinoids may exert an influence on appetite 
via stimulation sites in the intestinal tract; evidence has emerged from a number of 
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trials to support this. In animals, capsaicin has been used to de-sensitise gut neurons 
(especially along the vagal nerve), which has altered the function of a number of 
hormones important to appetite control and gastric emptying, including glucagon-like 
peptide-1(GLP-1) (Ahrén, 2004), ghrelin (Fukuda et al., 2004) and peptide YY (PYY) 
(Fu-Cheng et al., 1997). Research suggests gastric emptying it is a key mediator of 
hunger, satiation and satiety (Janssens et al., 2011). Capsaicin may influence gastric 
motility and was found to significantly increase the gastric emptying rate in a study 
involving 10 human subjects, when given intragastrically (Debreceni et al., 1999) This 
in turn may influence the rate at which hormones such as GLP-1, ghrelin and PYY are 
released,  as the speed at which chyme is released into the intestinal passage is an 
important factor in stimulating cells to release these hormones (Berthoud, 2008). 
GLP-1 is a hormone released by cells distributed throughout the small intestine as a 
result of the presence of nutrients (Sathananthan et al., 2013), it has been shown to 
decrease food intake by increasing satiety signals in the brain (Holst, 2007). Ghrelin, 
also produced by intestinal cells, that is a strong stimulator of appetite (Van Der Lely 
et al., 2004). Ghrelin secretion is stimulated when the stomach is empty, and halted 
when the stomach is stretched (Anderson et al., 2005). It acts on hypothalamic brain 
cells both to increase hunger, and to increase gastric acid secretion and 
gastrointestinal motility to prepare the body for food intake (Schwartz et al., 2000).  
Ghrelin also plays an important role in regulating reward perception in this area of the 
brain through its interaction with dopamine and acetylcholine (Burger and Berner, 
2014). PYY is another intestinal hormone that can have an influence on food intake 
and gastric emptying and is usually secreted alongside GLP-1 (Cox et al., 2010). 
Secretion is mainly stimulated by the presence of food in the digestive tract and higher 
circulating levels result in decreased appetite and energy intake, along with reduced 
gastric motility (Nguyen et al., 2011a).  
Changes in these hormones could have a potentially strong impact on appetite and 
energy intake and all three have been measured following capsaicinoid intake in 30 
human subjects. For 45 minutes after consumption of the capsaicin containing meal 
plasma GLP-1 response was significantly higher compared to the control meal (p < 
0.05) and ghrelin response tended to be lower, although not significantly (p < 0.07); 
PYY responses were not different between the two groups (Smeets and Westerterp-
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Plantenga, 2009). These results suggest a potential mechanism of action for 
capsaicinoids influencing appetite and energy intake (as observed in other trials) by 
affecting the influence of intestinally derived satiety hormones. Possibly this is caused 
by increased gastric motility, thereby increasing the speed of exposure of nutrients to 
hormone releasing cells in the intestinal passage. 
2.7.1.4.2 Effect of the Sympathetic Nervous System 
Capsaicinoids and capsinoid may also be influencing appetite through their action on 
TRPV1 receptors and the resulting stimulation of the sympathetic nervous system 
(SNS). As mentioned earlier, it is generally accepted that capsaicinoids and capsinoids 
stimulate the SNS, causing the release of catecholamines (Hursel and Westerterp-
Plantenga, 2010). Activation of certain adrenoceptors, caused by norepinephrine has 
been shown to decrease food intake (Wellman, 2000), notably beta-receptors (2 and 
3), which research suggests are stimulated as a result of capsaicinoid and capsinoid 
intake. Indeed the release of catecholamines, has been the mechanism of action for 
some appetite suppressant drugs such as Sibutramine (Adan et al., 2008). It is thought 
the release of catecholamines (particularly norepinephrine) has a signalling effect on 
the  hypothalamus, a region of the brain that plays a crucial role in appetite control 
(Suzuki et al., 2010). Therefore the release of catecholamines and sympathetic 
nervous system stimulation is another potential mechanism of action for capsaicinoids 
and capsinoids influencing appetite.  
2.7.1.4.3 Effect on the Brain 
It was found in one investigation into capsaicinoids’ effect on energy intake that 
supplementation reduced calorie intake not by reducing the amount of food eaten, but 
rather by a shift in preference for carbohydrate-rich food over fat-rich food (Westerterp-
Plantenga et al., 2005). Therefore capsaicinoids may be affecting areas of the brain 
involved in food choice and reward through stimulation of neurons in the mouth. This 
is possible as capsaicinoids are a potent stimulator of nociceptors in the mouth, which 
are responsible for detecting temperature and pain (Woolf and Ma, 2007) and would 
likely to have been important in detecting harmful food substances throughout human 
evolution (Julius and Basbaum, 2001). 
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The orbitofrontal cortex is an important area of the brain for the convergence of 
representations of the taste, smell, sight, and mouth feel of food (see figure 2.7), and 
this convergence allows the sensory properties of each food to be represented and 
defined in detail (Rolls, 2004b). This is also the region where a short-term, sensory-
specific control of appetite and eating is implemented (Rolls, 2004a). Capsaicin has 
been shown to be a strong activator of neurons in this part of the brain, via oral 
stimulation in primates (Kadohisa et al., 2004). The orbitofrontal cortex also seems to 
be important in signalling the expected rewards or punishments of a particular action 
(Rolls and Grabenhorst, 2008) and may also go some way to explaining why different 
people experience such different reactions to capsaicinoid exposure. The impact of 
capsaicinoids on the orbitofrontal cortex provides another potential mechanism of 
action of the observed effect of reducing energy intake by affecting food choice. It 
should be noted that research and understanding in this area is still developing and 
much of the research has been with non-human primate brains, opening the possibility 
that effects may be different in humans. 
Figure 2.7 A MRI brain scan showing the location of the orbitofrontal cortex. 
Another area of the brain that plays a critical role in energy balance, affecting energy 
intake and food reward mechanisms, is the hypothalamus (Dietrich and Horvath, 
2013). Located in at the top of the human brain stem (see figure 2.8),  and as well as 
producing hormones, is the site in the brain affected by intestinally released satiety 
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hormones such as GLP-1, ghrelin and PYY (Smith and Thorner, 2012). Studies have 
suggested the presence of TRPV1 channels in different regions of the hypothalamus 
(Menigoz and Boudes, 2011) and that TRPV1 containing neurons are co-expressed 
with multiple neuropeptides with a potential role in satiety (Bishnoi et al., 2011). Recent 
research in mice has found that capsaicin increased expression of TRPV1 genes and 
increased the expression of potentially appetite suppressing genes in the 
hypothalamus compared to control mice (Baboota et al., 2014). Hinting that capsaicin 
may be effecting the hypothalamus to reduce energy intake over time. However, the 
hypothalamus’ impact of energy intake is subject to the control of numerous 
neuropeptides (Zhang et al., 2011) and further research is required to confirm these 
early findings.  
Figure 2.8 A MRI scan showing the location of the hypothalamus in a human brain. 
Details of human intervention trial investigating the effects of capsaicinoids on energy 
intake can be found in table 2.11 below. Four of the 10 trials found a significant 
reduction in energy intake following a capsaicinoid intervention, with another of the 
trials finding a significant effect on circulating intestinal hormones. The majority of trials 
involved a single intervention, so it is not clear from these trials whether any potential 
effect would last over the longer term. 
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Table 2.10 Intervention trials evaluating the effects of capsaicinoids on energy intake 
Author Intervention 
used 
Dose 
(mg) 
Size (n) Duration Study Type Key Finding 
Yoshioka et al 
1999 
Meal with dried 
chilli 
30 13 Single 
Meal 
Randomised 
placebo control 
Non-significant 
reduction in energy 
intake (EI) 
Yoshioka et al 
1999 
Appetiser with 
dried chilli 
18 10 2 Meals Randomised 
placebo control 
Significant reduction in 
EI (p<0.05) 
Yoshioka et al 
2004 
Chilli soup or 
capsules 
0.2, 3 16 Single 
Meal 
Randomised 
double blind 
placebo control 
Non-significant 
reduction in EI 
Westerterp-
Platenga et al 
2005 
Juice with chilli 
or chilli capsules 
2.25 24 4 Days Randomised 
double blind 
placebo control 
crossover 
Significant reduction in 
EI (p<0.05), stronger 
effect with oral 
exposure 
Ahuja et al 
2007 
Preserved chilli 30/day 36 8 weeks Randomised 
controlled 
Crossover 
No effect on EI 
Reinbach et al 
2009 
Chilli capsules 2.5 27 6 meals Randomised 
placebo control 
crossover 
Significant reduction in 
EI during over-feeding 
(p < 0.05) 
Smeets et al 
2009 
Meal with dried 
chilli 
5 30 Single 
meal 
Randomised 
placebo control 
crossover 
Affected 
gastrointestinal 
hormones may reduce 
appetite 
Reinbach et al 
2010 
Appetiser with 
chilli 
0.4 40 Single 
Meal 
Randomised 
placebo control 
crossover 
No effect on EI 
Ludy and 
Mates 2011 
Chilli capsules 3.6 25 6 meals Randomised 
double blind 
placebo control 
crossover 
Significant reduction in 
EI (p<0.05), observed 
only in non-chilli 
eaters 
Janssens et al 
2014 
Chilli capsules 2.56 15 4 x 36 hr 
testing 
periods 
Randomised 
placebo control 
crossover 
Capsaicin tended to 
reduce ad libitum 
energy intake (p=0.07) 
2.7.1.6 Summary of Mechanism of Action for the Effects of Capsaicinoids and 
Capsinoids on Weight Loss and Weight Management 
In conclusion, there are a number of ways in capsaicinoids and capsinoids ingestion 
may be influencing the body in a beneficial way to aid weight loss or maintenance. 
Perhaps the most studied and well-established of these is the pathway through which 
energy expenditure is increased, via stimulation of the TRPV1 receptor and the 
resulting effect on catecholamine release signalling to adrenoceptors, which stimulate 
the SNS and cause uncoupling protein regulation resulting in enhanced energy 
expenditure (through thermogenesis), with BAT potentially playing a crucial role in this 
process. The effect is likely to be relatively small however and it may be that an 
increased in lipid oxidation, resulting in lower adipose tissue levels, is a more 
significant health benefit of ingestion of capsaicinoids and capsinoids. A number of 
potential mechanisms of this were outlined, namely SNS stimulation/catecholamine 
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release, cellular TRPV1 stimulation, an effect on adipose tissue enzymes and protein 
expression and finally neuron stimulation. Less well established has been 
capsaicinoids potential effect on energy intake, which may be reduced following 
ingestion. This may be caused by capsaicinoids affecting intestinally derived satiety 
hormones, influencing certain areas of the brain, SNS stimulation, and increases in 
lipid oxidation. The effect on energy intake are less well established from intervention 
trial and therefore further investigations into these effects may be warranted. 
2.7.2 Biochemistry 
Studies in animals and humans show that topical and oral administration of 
capsaicinoids produce moderate circulating concentrations and high local 
concentrations, depending upon the dose and route of delivery. Using a capsaicin skin 
patch (dose 10mg/kg) with 1–1.5 hours of treatment time in humans, produced peak 
plasma concentrations of 0.5–18 ng/mL in the roughly 30% of patients where 
quantifiable capsaicin levels occurred; capsaicin was cleared in most patients within 
4.5 hours (Babbar et al., 2009). Orally administered capsaicinoids are also efficiently 
(85–95% total dose) absorbed from the gastrointestinal lumen, with minor metabolism 
occurring in the intestine (mainly hydrolysis), but near complete breakdown in the liver 
(Suresh and Srinivasan, 2007). In one study, a 5 g oral dose of chilli (containing 26.6 
mg capsaicin) in 12 humans yielded peak plasma concentrations of capsaicin of 2.5 
ng/mL (Weerapan, 2009), with the author suggesting that the relatively low maximum 
concentration and quick metabolism were the result of extensive metabolic 
breakdown, consistent with prior studies (Donnerer et al., 1990, Kawada et al., 1984). 
Researchers investigating the metabolism of dihydrocapsaicin (a capsaicinoid 
compound), found that within 48 hours of oral administration (20 mg/kg body weight) 
to male adult rats, unchanged dihydrocapsaicin and eight of its metabolites 
(dihydrocapsaicin (8.7% of the total dose), vanillylamine (4.7%), vanillin (9.6%), vanillyl 
alcohol (37.6%) and vanillic acid (19.2%)) were identified in urine as free forms and/or 
their glucuronides. The authors concluded that these results provide strong support 
that capsaicin and its analogues when supplemented to the diet are well absorbed into 
blood (Kawada et al., 1984). In another study, oral capsaicin consumption in rats (30 
mg/kg; approximately five times the average daily intake of capsaicinoids by 
individuals in India, a country with a high average capsaicin intake), demonstrated 
  
53 
 
94% absorption from the intestine with a peak serum concentration of 6.2 µM (Suresh 
and Srinivasan, 2010). In this same study, the authors investigated capsaicin 
concentrations in various organ tissues, finding substantially higher amounts, in the 
liver, kidneys and intestines.  
Researchers have found capsaicinoids are highly responsive to biotransformation by 
P450 enzymes, which are located either in the inner membrane of mitochondria or in 
the endoplasmic reticulum of cells and are found in most tissues in the body. These 
enzymes converted capsaicinoids (capsaicin and nonivamide) into reactive, free 
radical intermediates, which the authors noted may partially explain conflicting reports 
related to the cytotoxic, pro-carcinogenic, and chemo-protective effects of 
capsaicinoids in different cells and organ systems (Reilly et al., 2012). The full 
biological implications of capsaicinoid bio-chemical metabolism remains unknown, 
with future studies needed to evaluate capsaicinoids’ full effects as pharmaceutical, 
cytotoxic and chemo-preventive agents, although the research suggests it is well 
absorbed into the body from oral consumption. 
 
  
54 
 
Chapter 3 - Meta-Analysis of Capsaicinoids Effect on Energy 
Intake 
3.1 Introduction 
Research indicates that capsaicinoids may have a beneficial effect on weight 
management outcomes by reducing energy intake following ingestion. Ten small 
intervention studies have been carried out to investigate this hypothesis. However, 
results have been contradictory, with trials observing a statistically significant effect on 
energy intake in some instances (Westerterp-Plantenga et al., 2005) and no effect in 
others (Smeets and Westerterp-Plantenga, 2009). In order to provide further evidence 
for this hypothesis, a meta-analysis of intervention trials investigating the effect of 
capsaicinoid intake on energy intake was conducted herein. Results showed that 
capsaicinoid intake prior to a meal (in the form of supplement or dried chilli) reduced 
ad libitum energy intake by 251kJ (60kcal) p < 0.001 during the following meal. 
Results, however should be viewed with some caution as analysis indicates there was 
publication bias (p=0.007) The following chapter details the meta-analysis 
methodology, results and discusses how the result furthers our understanding of the 
potential use of capsaicinoids as a weight management aid. 
3.2 Methods 
3.2.1 Identification of Relevant Studies 
Studies were identified by searching Web of Knowledge and PubMed search engines. 
No language restrictions were applied. The initial search was performed on 27th April 
2012 and updated on 27th May 2016. The following search terms were used: 
‘capsaicin’ combined (using Boolean ‘AND’) with ‘energy intake’ and ‘appetite’, in turn. 
Human, randomised, intervention trials, using ‘healthy’ volunteers, compared to 
themselves or to a matched control group were identified and included. ‘Healthy’ 
referred to participants free of disease, but included overweight and obese 
participants. Trials were initially selected based on their abstracts. Full content was 
then reviewed to determine inclusion in the final sample. References lists cited in the 
selected studies were also searched to find additional studies for inclusion. 
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Duplicate manuscripts, studies that did not investigate capsaicinoids’ effect on energy 
intake and studies where the intervention included other bioactive ingredients (such 
as green tea and caffeine) were removed. Studies using multiple bioactive ingredients 
were also removed as it would not be clear how much of the observed effect was due 
to capsaicinoids. The remaining studies investigated the role of capsaicinoids on 
weight management in relation to their effect on energy intake, hunger and satiety 
measures (usually recorded on a 1-10 scale) and intestinal hormone levels.  The most 
frequently used methodology was to measure ad libitum energy intake after 
capsaicinoid intake, therefore this was used in the main analysis. Studies using 
multiple bioactive ingredients were removed as it would not be clear how much of the 
observed effect was due to capsaicinoids. The remaining studies were reviewed to 
establish an appropriate effect size that could be extracted and analysed.  
3.2.2 Data Extraction 
Data extracted from the papers included: participant number, gender, age, BMI and 
ethnicity; study type, dosage, the intervention used and study duration (see tables 3.1 
and 3.2 for further details). The study’s authors and year of publication were also 
recorded. Effect sizes were then extracted for analysis, including mean energy intakes 
(in kJ) for control and intervention groups, along with standard deviations. 
3.2.3 Statistical Analysis  
The combined effect size was calculated using the random effects model and a forest 
plot produced along with the I2 statistic to assess heterogeneity. Sub-group analysis 
was performed assessing differences according to participant ethnicity, age and BMI 
along with study size, dosage, length and type of intervention. Finally, publication bias 
was assessed by calculating Egger’s regression statistic and producing a trim and fill 
plot. All statistical analyses were performed using MIX meta-analysis software version 
2.0 (Bax et al., 2006). 
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3.3 Results 
A total of 41 clinical trials were identified from the database searches. Twenty-eight 
trials were excluded for being duplicates (the same studies found on multiple 
searches) and a further seven were excluded for methodical reasons; five of these did 
not feature investigations examining energy intake and two used intervention featuring 
multiple bio-active ingredients (not just capsaicinoids), leaving a total of 6 trials (see 
figure 3.1). Three more studies were identified from searching the references of the 
trials initially found in the search. Leaving a final total of 9 studies (with 193 
participants) included in the meta-analysis (see table 3.1 for details of study 
participants). 
Figure 3.1 Literature search and inclusion/exclusion of trials 
 
 
 
 
 
 
 
  
Literature Search (n=41) 
Databases: PubMed, Web of Knowledge 
Duplicates Removed (n=28) 
Articles screened for inclusion 
Excluded (n=7) 
No investigation into energy 
intake (n=5) 
Used multiple bioactive chemicals 
in intervention (n=2) 
Included (n=9) 
Studies found from references (n=3) 
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Table 3.1 Key characteristics of participants in the intervention studies 
Trial Gender Ethnicity BMI Age 
Yoshioka et al 
1999(a) 
Female Asian 21.9 26 
Yoshioka et al 
1999(b) 
Male Caucasian 23.7 33 
Yoshioka et al 
2004 
Male Asian 25.6 22 
Westerterp-
Platenga et al 
2005 
Mixed Caucasian 25.0 35 
Ahuja et al 
2007 
Mixed Mixed 26.4 46 
Reinbach et al 
2009 
Mixed Caucasian 22.2 29.6 
Reinbach et al 
2010 
Male and 
Female 
Intervention 
groups 
Caucasian 24.6 22.4 
Ludy and 
Mates 2011 
Mixed Mixed 23.0 22.6 
Janssens et al 
2014 
Mixed Caucasian 23.3 29.7 
There were no issues with adherence to the required diet reported in any of the 
studies. This may be due to their relatively short nature and the fact most of the meals 
were supplied by the researchers and consumed on site, with the exception of one 
study (Ahuja et al., 2007). 
Nine of the eight selected studies followed this design: after randomisation, 
participants would consume a capsaicinoid intervention or placebo, followed by a test 
meal consumed at a research site. The participants would consume food ad libitum 
until full and the remaining food would then be weighed to provide an exact calculation 
of energy intake. The only exception to this (Ahuja et al., 2007), featured 4 weeks of 
chilli supplementation (added to meals by the participant at home) in addition to 
participants’ normal diet, the trial featured a crossover design with 4 weeks of a control 
diet for comparison. Energy intake being assessed with a 4-day weighed food diary 
recorded in the final week of each dietary period. 
Two trials attempted to stimulate periods over and under eating in participants; one 
featured 3 weeks of positive energy balance and 3 weeks of negative energy balance, 
prior to each test meal consumed at a research site (Reinbach et al., 2009). The other 
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trial attempted to simulate these conditions by including high fat or high carbohydrate 
meals as test meals (Yoshioka et al., 1999); with both investigations finding reductions 
in energy intake under both conditions. Another trial measured the effect of the 
hedonistic impact of capsaicinoids by using two different interventions, one capsules 
and one a spicy tomato juice (Westerterp-Plantenga et al., 2005). They observed a 
decrease in energy intakes under both conditions, but a stronger one with oral 
exposure to capsaicinoids. Dosages in the trials ranged from 0.4mg – 33mg and trial 
length varied from a single meal to a four week intervention (see table 3.2 for details).  
Table 3.2 Key characteristics of the intervention trials included in the analysis 
Trial Size 
(n) 
Dose 
(mg) 
Intervention Length Key 
Finding 
Yoshioka et al 
1999(a) 
13 30 Meal with 
dried chilli 
Single 
Meal 
Non-significant 
reduction in EI 
Yoshioka et al 
1999(b) 
10 18 Appetiser 
with dried 
chilli 
2 Meals Significant 
reduction in EI 
(p<0.05) 
Yoshioka et al 
2004 
16 0.2, 3 Chilli soup or 
capsules 
Single 
Meal 
Non-significant 
reduction in EI 
Westerterp-
Platenga et al 
2005 
24 2.25 Juice with 
chilli or chilli 
capsules 
4 Days Significant 
reduction in EI 
(p<0.05), stronger 
effect with oral 
exposure 
Ahuja et al 
2006 
36 33/ 
Day 
Preserved 
chilli 
8 weeks No effect on EI 
Reinbach et al 
2009 
27 2.5 Chilli 
capsules 
6 weeks* Non-significant 
reduction in EI 
Reinbach et al 
2010 
40 0.4 Appetiser 
with chilli 
10 
Meals* 
No effect on EI 
Ludy and 
Mates 2011 
25 3.6 Chilli 
capsules 
6 meals Significant 
reduction in EI 
(p<0.05) in non-
chilli eaters 
Janssens et al 
2014 
15 2.56 Chilli 
capsules 
36 hours Non-significant 
reduction in EI 
EI – energy intake 
The meta-analysis assessed the change in energy intake following the consumption 
of a capsaicinoid intervention compared with a reference value. The combined effect 
size showed that consuming capsaicinoids caused a significant reduction in ad libitum 
energy intake of 251kJ (60kcal) per meal (see figure 3.2, for the forest plot), under the 
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random effects model, with a 95% confidence interval of 337 – 166kJ and p < 0.001. 
The analysis indicated low heterogeneity, I2 = 6.6%. 
Figure 3.2 Forest plot showing the effect size of capsaicinoids v reference for all 
intervention studies.  
 
An effect size of 0 represents no difference between interventions, an effect size < 0 represents a reduction in 
energy intake, >0 represents an increase in energy intake. 
3.3.1 Sub-Group Analysis 
To investigate whether different study and participant characteristics could influence 
the effect size, a number of subgroup analyses were performed. The variables 
analysed were: ethnicity, study size (n), intervention type (food or supplement), study 
length, dosage, average BMI and average participant age. P-values were also 
calculated comparing the ad libitum energy intake of the meal post intervention to the 
ad libitum energy intake of the control meal for each sub-group. Details of the analysis 
Author
Yoshioka et al
Yoshioka et al
Yoshioka et al
Yoshioka et al
Yoshioka et al
Yoshioka et al
Yoshioka et al
Westerterp-Platenga et al
Westerterp-Platenga et al
Ahuja et al
Reinbach et al
Reinbach et al
Reinbach et al
Reinbach et al
Ludy and Mates
Janssens et al
Janssens et al
Synthesis
Year
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1999(b)
1999(b)
2004
2004
2004
2005
2005
2007
2009
2009
2010
2010
2011
2014
2014
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are in table 3.3 below. Results suggest that ethnicity, study size, intervention type, 
study length, age and BMI had no effect on the overall effect size and therefore the 
effect of capsaicinoids on ad libitum energy intake in the present studies. However, 
the size of the dosage may have an impact on the effect of capsaicinoid intervention, 
with a dosage of 2mg or less seemingly having no effect on ad libitum energy intake. 
Table 3.3 Effect sizes and comparative p-values for differing aspects of the 
intervention studies 
Comparison Effect Size p-value 
Ethnicity Asian -244kJ 
Caucasian -281kJ 
0.01 
<0.001 
Study Size ≤20 participants -261kJ 
>20 participants -256kJ 
<0.001 
<0.001 
Intervention Type Food -254kJ 
Supplement -270kJ 
  <0.001 
<0.001 
Study Length Single meal -184kJ 
Multiple meals -318kJ 
0.002 
<0.001 
Dosage ≤2mg 29kJ 
>2mg -300kJ 
0.79 
<0.001 
Age ≤30 -146kJ 
>30 -320kJ 
0.03 
<0.001 
BMI ≤25 -180kJ 
>25 -319kJ 
0.003 
<0.001 
A negative effect size shows a decrease in EI, a positive effect size shows an increase in EI following capsaicin 
ingestion. 
3.3.2 Publication Bias 
To investigate the possibility of publication bias, a trim and fill funnel plot was created 
(see figure 3.3 below). To ensure accurate analysis multiple results from single studies 
were averaged out so that only one effect size from each study was used in the 
analysis. Egger’s regression was calculated as p=0.007, indicating that there was 
publication bias amongst the data found for this analysis. Results from the trim and fill 
plot suggest that publication bias has led to an underestimate of the effect size. 
Inclusion of predicted effect sizes for unpublished analyses, resulted in capsaicinoid 
ingestion causing a decrease in ad libitum energy intake of -356kJ and a 95% 
confidence interval of -447kJ to -265kJ. 
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Figure 3.3 Trim and fill plot detailing change in energy intake following correction for 
potential publication bias 
 
Effect sizes of actual studies shown in blue, generated effect sizes shown in white 
3.4 Discussion 
The results suggest adding capsaicinoids to the diet could have a beneficial effect for 
weight management, by reducing energy intake. However, caution should be applied 
to this result due to the small size of the reduction and the short term nature of the 
trials involved. A calorie imbalance of 2100kJ (500kcal) per day is often suggested as 
ideal for weight loss (Stern et al., 2004), although smaller imbalances can also lead to 
weight loss and improved health outcomes (Hill, 2006). Therefore, a reduction of 
251kJ per meal (95% confidence interval of 337 – 166kJ) repeated three times a day 
may have the potential to lead to beneficial weight loss. Furthermore, evidence of 
publication bias was identified which suggests that the estimate is an underestimate 
and may be 356kJ (95% confidence interval -447kJ to -265kJ.). The I2 statistic was 
low at 6.6%, this suggest that only a small amount of the variance observed between 
the study is due to heterogeneity.  
0.001
0.003
0.005
0.007
0.009
0.011
0.013
-2000 -1500 -1000 -500 0 500 1000 1500 2000
P
re
ci
si
o
n
 (
in
ve
rs
e
 s
ta
n
d
ar
d
 e
rr
o
r)
Change in energy intake (kJ)
0.01 limit
0.05 limit
0.1 limit
Filled synthesis estimate
62 
 
Analysis into publication bias suggested there is likely to be studies among the 
literature investigating capsaicinoids’ effect on energy intake not included in this 
analysis, with Egger’s regression was calculated as p=0.007. The trim and fill plot 
calculated to estimate the potential effect of these missing studies on the combined 
effect size suggests the true effect of capsaicinoids on energy intake may be larger 
than has been calculated in this analysis. 
The results of the sub-groups analysis suggest that the dosage of capsaicinoids used 
is an important factor in producing a reduction in energy intake. The combined effect 
size of the lowest dosage trials (≤2mg of capsaicinoids) showed no reduction in energy 
intake following capsaicinoid ingestion, whereas the combined effect size of those 
trials with a dosage >2mg produced a statistically significant reduction in energy intake 
of 300kJ. Suggesting a dose above 2mg is necessary to produce an effect. It is not 
clear from these studies what the ideal dose of capsaicinoids to reduce energy intake 
would be as there were not enough results from the trials to produce an informative 
dose response curve. Doses varied from 0.4mg (Reinbach et al., 2010) to 33mg 
(Yoshioka et al., 1999).  
All the other sub groups individually analysed, produced a statistically significant 
reduction in energy intake. Suggesting capsaicinoids still produced an effect on energy 
intake regardless of study participant’s ethnicity, age, BMI, whether given in the form 
of supplements or chillies, whether given over a single meal or multiple meals and the 
number of participants in the study. 
It has been suggested that the effects of capsaicinoids may be stronger among Asian 
populations (Hursel and Westerterp-Plantenga, 2010). The suggestion being that due 
to chillies being part of their traditional diet, some genetic adaptation may have 
occurred. The subgroup analysis did not however support this observation, with the 
effect being slightly larger in the Caucasian population (281kJ compared to 244kJ in 
Asian population). Although informative, this result should be viewed with some 
caution, as it involved only a small number of Asian participants (29 Japanese 
participants in 2 trials); therefore it is not possible to conclude that there was a different 
effect among different ethnicities. It should also be noted that the studies only featured 
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Asian and Caucasian participants, so no conclusions can be drawn about 
capsaicinoids effect on energy intake among other ethnicities.  
There was little variance among the average BMIs of the study participants, ranging 
from 21.9 – 26.4kg/m2, therefore it is difficult to draw any conclusions concerning 
whether capsaicinoids may affect energy intake in persons of normal weight range or 
overweight/obese range differently. In addition the majority of the study participants 
were young adults having an average participant age between 22-35 years, with one 
study the exception (Ahuja et al., 2007) having an age range between 22-70. 
Therefore capsaicinoids effect on energy intake among under-18s and older adults is 
not known from the present analysis. 
None of the studies reported issues with compliance of the capsaicinoid intervention, 
this is likely due to the short nature of most of the trials and because a number of the 
studies determined a hedonically acceptable maximum dose prior to the intervention 
(Yoshioka et al., 2004, Westerterp-Plantenga et al., 2005, Ahuja et al., 2007, Ludy and 
Mattes, 2011a). Indeed participants in one trial reported that ingestion of higher 
dosages over a long period would not be possible due to capsaicinoids’ overpowering 
flavour and increases in gastric motility (dosage for this trial was 33mg/day in a 
predominantly Caucasian population) (Ahuja et al., 2007). Compliance issues were 
reported in a 12-week trial, featuring a much higher capsaicinoid dosage (135mg per 
day) and a number of participants were put on half dosages to allow them to continue 
in the trial (Lejeune et al., 2003). 
It may be that rather than decreasing the actual amount of food eaten, capsaicinoid 
intake affected energy intake by changing food choice. Several studies observed a 
preference for carbohydrate-rich rather than fat-rich foods (Yoshioka et al., 1999, 
Yoshioka et al., 2004, Westerterp-Plantenga et al., 2005), which lead to the decrease 
in energy intake, rather than a reduction in the amount of food eaten. Such a change 
in food choice may be made possible by capsaicinoids influencing regions of the brain 
crucial to this process, notably the orbitofrontal cortex (Rolls, 2004b) and the 
hypothalamus (Baboota et al., 2014).  
Several other mechanisms of action have been proposed for how capsaicinoids may 
cause this observed reduction in energy intake. This includes by stimulating the 
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release of a satiety inducing hormone (glucagon-like peptide-1) and reducing levels of 
a hunger promoting hormone (ghrelin) (Smeets and Westerterp-Plantenga, 2009). By 
the stimulation of the sympathetic nervous system, which may lead to a decrease in 
appetite (Wellman, 2000). Finally, capsaicinoids’ may cause an increase in lipid 
oxidation, which is an important signaller for the control of energy intake (Leonhardt 
and Langhans, 2004); see section 2.7.2.3 for a detailed description of these effects. 
Whether a reduction in energy intake would be maintained long term is not clear from 
the studies in this analysis, as most of the trials involved comparison of only two meals 
(one following capsaicinoid ingestion and one control meal). The trial with the longest 
intervention period, lasting 4 weeks, found no difference in energy intake between 
control and intervention groups (Ahuja et al., 2007).  Two studies took into account 
whether participants were regular consumers of spicy foods prior to the trial, however 
results were contrasting. One trial finding a significant reduction in energy intake 
among regular consumers (Westerterp-Plantenga et al., 2005), the other finding a 
significantly reduction in energy intake only in non-regular consumers (Ludy and 
Mattes, 2011a). Also, what is considered regular consumption may vary greatly around 
the world, with average daily chilli consumption levels much higher among Asian 
populations (2.5-8g) than American and European populations (0.05-0.5g) 
(Gonlachanvit, 2010).  
3.5 Summary 
In summary, the analysis suggests there is a possibility capsaicinoids could play a role 
in weight management alongside exercise and other dietary measures. However, 
caution should be applied to this result however, due to the small size of the reduction 
and the short term nature of the trials involved. There was also likely to have been 
some publication bias in the final analysis, meaning that the size of capsaicinoids’ 
effect on ad libitum energy intake may have been under-estimated therefore further 
trial publications should be encouraged. This study, taken together with the published 
literature suggest a dosage of above 2mg of capsaicinoids is needed to produce an 
effect and that a reduction in energy intake may be the result of a preference for 
carbohydrate rich foods over fat rich foods. 
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The extent of the effect on energy intake is relatively small and long term intake is 
likely to be required to produce a beneficial effect. It may also be the case that several 
doses a day are needed to produce a clinically meaningful effect on a person’s weight; 
this may mean that capsaicinoids would need to be taken in the form of a supplement, 
as their strong sensory effect means most people would be unwilling to eat chillies 
with every meal. But combined with capsaicinoids’ effect on energy intake and lipid 
oxidation observed in other research (Ludy et al., 2012, Whiting et al., 2012) there is 
potential for development of a natural weight loss aid, particularly as there currently 
are a lack of pharmaceutical treatment options for obesity.  
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Chapter 4 – Capsaicinoids and Body Fat in Caucasian 
Women: A Randomised Placebo Controlled Trial 
4.1 Introduction 
Previous research has suggested capsaicinoids intake may be associated with body 
composition (Whiting et al., 2012). Intervention trials have shown the acute effects of 
capsaicinoids intakes on increasing energy expenditure (Janssens et al., 2013) 
increasing fat oxidation (Ludy and Mattes, 2011b) and decreasing energy intake . 
However there is a paucity of data on longer-term effects and resulting body 
composition. The aim of the present study was to investigate the effects of 
capsaicinoid intake for six weeks with change in body fat as the primary outcome. 
Secondary outcomes were change in body weight, BMI, waist circumference, waist-
to-hip ratio, BAI, blood glucose and blood cholesterol. 
4.2 Study Design 
We carried out a randomised placebo controlled parallel intervention trial of a 
capsaicinoid supplement for six weeks; with an allocation ratio of one-to-one. A parallel 
study design was used to prevent any potential carry over effect, due to change in 
body fat, biasing the outcome of the observations. 
The study was conducted at Manchester Metropolitan University initially between 
February and May 2014 and then between August 2015 and February 2016. 
Participants for the trial were recruited in three waves via the Manchester Metropolitan 
University email system. After responding to the initial email, participants were then 
asked to complete a screening questionnaire, to assess their eligibility for inclusion in 
the trial (see section 4.4.1 for full details of the recruitment process). Those who met 
the eligibility criteria and consented to take part were invited to the initial measuring 
session. At baseline, 6 anthropometric measurements were taken along with a blood 
sample (see section 4.6 for details of measurements), before participants were 
randomised into the active intervention or placebo control groups. Participants were 
then given a supply of supplements, and asked to take two daily for six weeks. They 
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were also asked to complete a pill diary to assess compliance and a three-day, self-
reported food diary during each week of the trial. 
Further assessment of participants’ anthropometric measurements and blood markers 
occurred at week three and week six, at which point supplementation finished. After a 
further three weeks without supplementation, a final follow-up assessment of 
anthropometric measurements and blood markers occurred (see figure 4.1). Statistical 
analysis was then undertaken to assess the statistical significance of any observed 
changes in the measurements, as a result of the intervention (see section 4.7.2). 
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Figure 4.1 A flow chart outlining process of the trial from recruitment to completion.  
Recruitment 
Assessed for Eligibility  
Screening questionnaire, restrained 
eater questionnaire 
Included Excluded 
Initial Assessment 
Weight, height, waist and hip circumference, Body fat (%), 
total body fat (kg), blood glucose and cholesterol 
Randomisation 
Intervention  
2 capsules, 10 mg daily 
3 Week Assessment  
Weight, height, waist and hip circumference, Body fat (%), 
total body fat (kg), blood glucose and cholesterol 
Statistical Analysis 
Independent-samples t-test 
One-way repeated measures ANOVA 
Placebo 
2 cellulose capsules daily 
Supplementation Finishes  
6 Week Assessment  
Weight, height, waist and hip circumference, Body fat (%), 
total body fat (kg), blood glucose and cholesterol 
9 Week Assessment  
Weight, height, waist and hip circumference, Body fat (%), 
total body fat (kg), blood glucose and cholesterol 
  
Food diary, Supplement compliance diary 
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4.2.1 Ethical Approval and Data Protection 
Ethical approval was sought and granted from the Manchester Metropolitan University 
(Hollings Faculty) ethics committee (granted on 9th October 2013). Initially approval 
was for 30 participants, further approval to increase this number to 60 participants was 
granted in July 2015. The trial was conducted in accordance with the guidelines laid 
down the in the Declaration of Helsinki (World Medical Association, 2013). All 
participant data were kept confidential and in compliance with the Data Protection Act 
1998. Paper records were kept in a locked, fire-proof cabinet and all computer records 
were stored on a password protected laptop. 
4.2.2 Study Population 
4.2.2.1 Recruitment 
Initial interest in the trial was elicited via the email system of Manchester Metropolitan 
University. An advert was placed in a university newsletter (sent via email) to students 
and staff at the university (see appendix 1 for a copy of the email). Participants, who 
expressed an interest in joining the trial, were screened using a questionnaire to 
ensure they met the inclusion-exclusion criteria (see appendix 1 for a copy of 
screening questionnaire).  
4.2.2.2 Inclusion-Exclusion Criteria 
The inclusion-exclusion criteria were developed, based on the criteria used in similar 
capsaicinoid and weight loss trials (Lejeune et al., 2003, Ahuja et al., 2007, Snitker et 
al., 2009, Yang et al., 2012). 
The study included women only to reduce any potential confounding effects due to 
gender differences in fat storage and metabolism. Evidence suggests there are 
pronounced differences in fat oxidation, circulating cholesterol levels, post-prandial fat 
oxidation and fat storage between men and women (Geer and Shen, 2009). 
Participants aged 18-49 years old were selected, as persons under the age of 18 are 
often still in their growing phase (Eveleth and Tanner, 1976) and as such there is a 
possibility they could gain weight during the trial as a result of natural growth. 
Furthermore aging has been associated with changes in energy intake (Roberts, 2000) 
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and a decrease in energy expenditure (Roberts and Rosenberg, 2006) compared to 
earlier in a person’s life. 
Potential participants who were post-menopausal were excluded as research 
suggests there may be changes in the way the body accumulates adipose tissue after 
the menopause as opposed to before (Yannakoulia et al., 2007).  
Potential participants who’s BMI was less than 20kg/m2 were excluded as any fat loss 
in this group could results in the participant becoming underweight and therefore 
placing them at risk of a complication. 
Pregnant women were excluded due to the biological and physiological changes that 
occur during pregnancy.  
Potential participants who were using other supplements and/or medication were 
excluded. An interaction between chillies intake and ACE inhibitor drugs has 
previously been reported (Fugh-Berman, 2000).  
Potential participants who suffered from metabolic or digestive disorders were 
excluded. Capsaicinoids can have a strong effect on the digestive system, which may 
impact a person’s disorder and worsen their symptoms.  
Restrained eaters were excluded from the study as research suggests that restrained 
eaters are prone to over-eating as a result of this restraint (Lowe & Levine, 2005), and 
such over-eating may invalid the observed results of this trial. To assess whether a 
person was a restrained or non-restrained eater a validated questionnaire was used 
(Stunkard and Messick, 1985) (see appendix 1 for a copy of questionnaire). 
4.2.3 Intervention 
The intervention was given in the form of a supplement so the investigation could be 
conducted as a double-blind randomised control trial.  
To determine the minimum dosage at which a biological effect is likely to occur, the 
results from a number of human trials that investigated the effect of capsaicinoids at 
different dosages were evaluated. In trials looking at potential weight loss effects, 
dosages have varied from a single 0.4mg dose (Reinbach et al., 2010) to 135mg/day 
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for 12 weeks (Lejeune et al., 2003). No effect was observed for the 0.4mg dosage; 
however trials giving a dosage of around 2 – 3mg/day have observed an effect 
(Westerterp-Plantenga et al., 2005, Yoshioka et al., 2004, Ludy and Mattes, 2011a, 
Whiting et al., 2014). 
Compliance problems were reported in the highest dosage level trial (135mg/day with 
capsules) although what is acceptable may be influenced by participants’ previous 
exposure and potentially their genetics. Exposure levels in countries with a high intake 
of chillies (such as Mexico, Japan, Korea) have reported intakes 25 - 
200mg/person/day (Scientific Committee on Food, 2001), although intakes tend to be 
much lower among Western Caucasian population (Ludy and Mattes, 2011a). 
Therefore to provide a dosage that is likely to produce a measurable effect on body 
fat, without causing digestive side effects among the study population, a dosage of 
10mg/day was used for the intervention (this was administered as 2 supplements 
containing 5mg of capsaicinoids). 
Capsules were white (to conceal contents) and size 0. Participants were instructed to 
take 2 capsules daily, at separate times and to take them with meals (as capsaicinoids 
are fat soluble molecules). Participants completed a pill diary to monitor compliance. 
4.2.3.1 Placebo 
For this trial cellulose capsules were used for the placebo control and the size and 
colour of the capsules were identical to the intervention (size 0, white colour). 
4.2.4 Outcomes 
The a priori primary outcome was body fat (% and kg) and secondary outcomes were 
weight (kg), BMI (kg/m2), waist circumference (cm), hip-to-waist ratio, BAI, blood 
glucose (mmol/l) and blood cholesterol (mmol/l). All measurements were taken in the 
morning (between 8.30am and 10.30am) in a fasted state, following an overnight fast. 
4.2.4.1 Anthropometric Measurements 
Change in participants’ body fat percentage and total body fat were calculated using 
bio-electrical impedance. Participants were asked not to eat, drink or perform 
strenuous physical activity in the 12 hours prior to arriving for measurements. 
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Participants’ weight was recorded using a Tanita digital body composition scale 
(Tokyo, Japan) in kg to two decimal places. Participants were weighed barefoot, in 
light clothing, on a non-carpeted floor, 200g was subtracted from participants’ weight 
to account for clothing. 
Participant’s height was measured barefoot on a non-carpeted floor using a Seca 
stadiometer (Hamburg, Germany), BMI was calculated as kg/m2. 
Participants’ waist and hip circumference measurements were taken according to the 
World Health Organisation guidelines (WHO, 2008). The position for measuring waist 
circumference was midway between the uppermost border of the iliac crest and the 
lower border of the costal margin (rib cage). The tape was placed around the abdomen 
at the level of this midway point and a reading was taken when the tape was snug but 
did not compress the skin. The participant stood with feet close together, arms at the 
side and wore minimal clothing. Measurements were taken at the end of a normal 
expiration. Each measurement repeated twice. If the measurements were within 1 cm 
of one another, the average was calculated. If the difference between the two 
measurements exceeded 1 cm, the two measurements were repeated. Using the 
same guidelines, hip circumference measurements were taken around the widest part 
of the buttocks. Waist-to-hip ratio was calculated as average waist (cm)/average hip 
(cm). 
Body Adiposity Index is a recently developed measure of adiposity (Bergman et al., 
2011) and is a way of estimating % body fat from height and hip circumference 
measurements; BAI was calculated using the following equation: 
BAI = (Hip circumference / Height1.5) – 18 
4.2.4.2 Blood Measurements 
All blood samples were taken by a trained by a trained phlebotomist, using a finger 
prick blood test, and blood glucose (measured in mmol/litre) and cholesterol levels 
(measured in mmol/litre) were analysed; samples were measured using an Analox 
GM7 analyser and disposed of immediately after analysis of the sample; all needles 
were disposed of in sharps bins. 
  
73 
 
4.2.5 Food Diaries 
The participants were asked to fill out food diaries to ensure there was no difference 
in dietary intake between both intervention and placebo control groups. Participants 
were asked to keep diaries for three days (two weekdays and one weekend day of 
their choosing) of week 1, week 3 and week 6 of the trial. Participants were asked not 
to change their diets whilst being part of the trial. Food diaries were converted into 
nutrient intakes using WISP nutritional analysis software (version 3.0). 
4.2.6 Sample Size 
To perform an a priori sample size calculation, an estimate for the expected effect size 
was obtained using data from a previous study which measured change in body fat 
(kg) over multiple time points due to an intervention using a similar bioactive ingredient 
(green tea catechins) (Yang et al., 2012) (variance of the group means used was 
2.35kg body fat).. An estimate of expected standard deviation was also required, 
however the aforementioned study recruited only participants with a BMI ≥25, so is 
unlikely to be representative of the standard deviations expected in this study. 
Therefore, an estimate of the expected standard deviation was taken from a previous 
intervention study (Ahuja et al., 2007) with similar inclusion-exclusion criteria to the 
present one (standard deviation used was (6.05kg). The calculation was performed 
using G-Power software (Faul et al., 2009), with the significance set to 5% and the 
power set to 90%. The a priori sample size estimation, for a one-way repeated 
measures ANOVA, was for 29 participants in the treatment group. 
4.2.7 Randomisation 
Stratified randomisation was used based on age and baseline BMI. Participants were 
placed into one of the following strata: Age <30 and BMI <26, Age ≥30 and BMI <26, 
Age ≥30 and BMI ≥26, Age <30 and BMI ≥26. A randomisation sequence was created 
for each group using the WinPepi program for epidemiologists (Abramson, 2011). In 
line with recruitment, randomisation was carried out in 3 waves. 
4.2.8 Blinding Procedure 
To ensure the intervention was double blind, randomisation and participant allocation 
to either placebo control or intervention group was carried out by the lead researcher. 
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A technician then placed supplements in unlabelled containers and marked either “A” 
or “B”, depending if they were placebo control or capsaicinoid capsules and the lead 
researcher handed out the supplements to the participants, according to the allocation. 
4.2.9 Statistics 
Means and standard deviations were calculated for all anthropometric measurements 
(body fat (% and kg), weight (kg), height (cm), BMI (kg/m2), waist circumference (cm), 
waist to hip ratio and body adipose index) and blood glucose (mmol/l) and blood 
cholesterol (mmol/l). Data on potential confounders (physical activity, income, alcohol 
intake, smoking and caffeine intake) was collected from participant questionnaires to 
allow comparisons between groups. 
4.2.9.1 Interaction Analysis 
The data for anthropometric and blood measurements was assessed for outliers by a 
visual inspection of the Q-Q plot and the distribution of the data was assessed using 
the Shapiro-Wilk test for normality. If there were no outliers and the data was normally 
distributed, a two-way ANOVA was performed to determine if there was any 
statistically significant interaction between the intervention and placebo control groups 
over time. With a p-value ≤0.05 considered to be statistically significant. If outliers were 
observed or the data was found to be not normally distributed, a non-parametric 
Friedman test was performed as an alternative. Mauchly's test of sphericity was used 
to test the assumption of sphericity, if the assumption was not met, the Greenhouse-
Geisser method was used to correct the result (Greenhouse & Geisser, 1959). 
4.2.9.2 Sensitivity Analysis 
Again, the data for anthropometric and blood measurements was assessed for outliers 
by a visual inspection of the Q-Q plot and the distribution of the data was assessed 
using the Shapiro-Wilk test for normality. If there were no outliers and the data was 
normally distributed, a one-way repeated measures ANOVA was performed to 
determine if there was any statistically significant difference between the means over 
time. With a P value ≤0.05 considered to be statistically significant. If outliers were 
observed, a non-parametric Friedman test was performed as an alternative. If there 
were no outliers but the data was found to be not normally distributed, the repeated 
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measures ANOVA was still carried out, as the test is fairly robust to deviations from 
normality (Lix et al., 1996), Mauchly's test of sphericity was used to test the assumption 
of sphericity, if the assumption was not met, the Greenhouse-Geisser method was 
used to correct the result (Greenhouse and Geisser, 1959). Post-hoc dependent-
samples t-tests were calculated for statistically significant results to identify at which 
measurement point changes occurred, with Bonferroni adjustment used to account for 
multiple t-tests. 
Differences in the % change of mean values were also compared to baseline figures 
for each anthropometric and metabolic outcome and for each measurement (i.e. 
baseline v week 3, baseline v week 6 and baseline v week 9). An independent-samples 
t-test was used to compare the means. Outliers were assessed by a visual inspection 
of the data’s Q-Q plots, the distribution of the data was assessed using the Shapiro-
Wilk test for normality and the homogeneity of variances was assessed using Levene's 
test of equality of variances. If outliers were observed, a non-parametric Mann-
Whitney U test was run as an alternative. If there were no outliers but the data was 
found to be not normally distributed, the independent samples t-test was still carried 
out, as the test is fairly robust to deviations from normality (Myers et al., 2010). If the 
assumption of homogeneity of variances was violated, a modified Welch t test was 
used to calculate p-values. A Bonferroni adjustment was used to correct for multiple t-
tests. 
To assess differences in dietary intake, nutritional data was compared over time using 
a one-way repeated measures ANOVA (using the same assumptions and procedures 
as stated above) and the intervention and placebo control groups were compared 
using an independent-samples t-test (using the same assumptions and procedures as 
stated above).  
4.2.9.3 Intention-to-Treat Analysis 
An intention-to-treat analysis, including all participants who were randomised and 
entered into the trial process was performed for all changes in anthropometric and 
metabolic measurements over time and percent change using the same methodology 
as described above. For participants who dropped out their final measurements (prior 
to withdrawal) were taken forward and used for the remainder of the trial.  
76 
 
All analyses performed using SPSS statistical software (version 22.0) (IBM Corp., 
2013). 
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4.3 Results 
4.3.1 Recruitment and Randomisation 
Following the email advertisement, 95 women expressed an interest in taking part in 
the trial and requested further information. Of these 11 women decided they would not 
be able to commit to the trial due to time commitments or for personal reasons. The 
remaining 84 entered the screening process. Details of exclusions, drop-outs and 
completers are shown in figure 4.2 below. 
Figure 4.2 Recruitment, screening, drop-out and completion of participants. 
 
  
Recruitment 
(n=84) 
Screening 
(n=84) 
Included 
(n=72) 
Completed 
(n=30) 
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(n=72) 
Intervention Group 
(n=36) 
Placebo Group 
(n=36) 
Completed 
(n=30) 
Excluded 
(n=12) 
Significant Change in 
Weight in Last Six Months 
(n=3) 
Restrained Eater (n=7) 
BMI < 20 (n=2) 
Dropped Out 
(n=6) 
Failure to maintain 
supplement routine (n=5) 
Digestive Discomfort (n=1) 
Dropped Out 
(n=6) 
Failure to maintain 
supplement routine (n=6) 
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4.3.2 Drop-out rate, compliance and tolerability 
There was an 83.3% completion rate. Eleven participants dropped-out of the trial after 
failing to maintain the supplement taking regime or for personal reasons, the other 
drop out was a result reported of side effects. This participant reported strong stomach 
cramps after taking the supplements and therefore decided to withdraw from the trial. 
After revealing of blinding, it was shown she was taking the active capsaicinoid 
supplement.  
All completing participants attended all four measuring sessions (baseline, week 3, 
week 6 and week 9) and completed and returned food diaries as requested. 
Supplement taking compliance was monitored via pill diary and all participants 
completed and returned this, reporting a compliance rate of 97% or above. 
4.3.3 Baseline Characteristics 
Participants’ baseline age, anthropometric and metabolic measurements are 
presented in table 4.1 below. The randomisation process resulted in groups with 
largely similar age, anthropometric and metabolic measurements. 
Table 4.1 Baseline age, anthropometric and metabolic measurements for all 
participants, placebo control group and intervention group. 
Measure 
All Participants Placebo Control Intervention 
N 
Mean (±Std. 
Deviation) 
N 
Mean (±Std. 
Deviation) 
N 
Mean (±Std. 
Deviation) 
Age (yrs) 60 30 (±10) 30 29 (±10) 30 31 (±10) 
Height (m) 60 1.65 (±0.07) 30 1.65 (±0.06) 30 1.66 (±0.07) 
Body Fat (%) 60 32.5 (±7.5) 30 31.0 (±6.9) 30 34.1 (±7.9) 
Body Fat (kg) 60 24.7 (±10.8) 30 22.6 (±10.4) 30 26.8 (±11.0) 
Weight (kg) 60 72.95 (±15.57) 30 70.20 (±14.79) 30 75.69 (±16.08) 
BMI (kg/m2) 60 26.5 (±4.7) 30 25.5 (±4.5) 30 27.5 (±4.7) 
Waist (cm) 60 84 (±11) 30 81 (±10) 30 86 (±12) 
Ratio* 60 0.78 (±0.05) 30 0.77 (±0.04) 30 0.80 (±0.06) 
BAI** 60 31.95 (±4.58) 30 31.35 (±4.34) 30 32.56 (±4.80) 
Glucose 
(mmol/l) 
60 4.4 (±0.8) 30 4.4 (±0.8) 30 4.5 (±0.7) 
Cholesterol 
(mmol/l) 
60 3.48 (±0.78) 30 3.40 (±0.76) 30 3.57 (±0.79) 
  
79 
 
*Ratio: waist circumference/hip circumference 
**BAI: (hip circumference/height1.5)-18 
Probable confounders for the trial are presented in table 4.2 below. Results suggest 
the randomisation process resulted largely similar placebo control and intervention 
groups for the confounders assessed. 
Table 4.2 A priori probable confounders at baseline for all participants, placebo control 
group and intervention group. 
Confounder Level 
All 
Participants  
(N) 
Placebo 
Control 
(N) 
Intervention 
(N) 
Physical activity  
at work 
Sedate 16 7 9 
Moderate 29 16 13 
Active 15 7 8 
Physical activity  
outside work 
Sedate 22 10 12 
Moderate 28 15 13 
Active 10 5 5 
Income (£000s) 
0 - 15 27 14 13 
15 - 25 23 12 11 
25 - 50 9 4 5 
50+ 1 0 1 
Alcohol intake  
(units/wk) 
0 - 10 34 18 16 
11 - 20 20 10 10 
21 - 30 5 2 3 
30+ 1 0 1 
Smoking 
Smoker 13 6 7 
Non-smoker 47 24 23 
Caffeine intake  
(caffeinated 
drinks/day) 
0 - 3 30 16 14 
4 - 6 24 11 13 
7+ 6 3 3 
 
4.3.4 Dietary Intake 
The analysis of participants’ nutrient intake per day for the intervention and placebo 
control groups during the trial period are presented in table 4.3 below. There were no 
significant differences in mean nutrient intakes per day during the trial in either 
intervention or placebo control groups. 
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Table 4.3 Nutrient intake (per day) across the trial period for the intervention and 
placebo control groups along with p-values. 
Group Outcome 
Week 1 Week 3 Week 6 
p-value* 
Mean SD Mean SD Mean SD 
Placebo 
Control 
Energy (mJ) 8.21 0.67 7.97 0.41 8.08 0.63 0.266 
Protein (g) 86.1 11.9 83.5 9.4 84.7 11.9 0.426 
Fat (g) 68.7 10.6 66.8 9.9 67.6 9.9 0.292 
Saturated Fat (g) 24.1 4.4 23.4 4.0 23.7 4.4 0.280 
Monounsaturated 
fat (g) 
22.8 3.7 22.1 3.0 22.4 3.5 0.502 
Polyunsaturated 
fat (g) 
10.5 1.4 10.2 1.1 10.3 1.4 0.242 
Carbohydrates 
(g) 
221.3 19.9 215.0 15.9 217.9 21.0 0.683 
Sugars (g) 88.7 13.9 86.1 12.3 87.4 15.1 0.875 
NEMS (g) 42.2 10.6 40.9 9.2 41.5 9.6 0.312# 
Starch (g) 123.5 13.8 120.0 12.1 121.5 13.4 0.189 
Alcohol (g) 9.5 7.8 9.8 8.3 9.7 8.8 0.701# 
Intervention 
Energy (kcal) 1928 116 1941 132 1918 122 0.581 
Energy (mJ) 8.10 0.48 8.15 0.55 8.05 0.51 0.582 
Protein (g) 84.3 10.2 85.0 11.5 84.0 10.8 0.555 
Fat (g) 68.6 13.1 68.9 12.6 68.0 11.8 0.516 
Saturated Fat (g) 27.2 8.9 27.4 8.9 27.0 8.7 0.415 
Monounsaturated 
fat (g) 
24.1 5.2 24.2 5.2 23.9 5.0 0.430 
Polyunsaturated 
fat (g) 
10.3 0.9 10.3 0.9 10.2 0.9 0.572 
Carbohydrates 
(g) 
216.5 14.4 217.8 14.5 215.2 12.7 0.755 
Sugars (g) 86.3 9.3 86.8 9.3 85.7 8.6 0.356 
NMES (g) 42.7 7.5 43.0 7.9 42.5 7.8 0.234# 
Starch (g) 123.1 7.9 123.9 8.1 122.4 7.2 0.851 
Alcohol (g) 9.2 8.5 9.6 8.9 10.0 8.1 0.798# 
*p-values obtained using a one-way repeated measures ANOVA unless indicated otherwise 
#p-values obtained using a non-parametric Friedman test (used due to outlying data)  
A comparison of the mean dietary intakes of the intervention and placebo control 
groups during the trial period is presented in table 4.4 below, with comparative p-
values. Results show there were no significant differences in mean nutrient intakes 
per day during the trial between the intervention and placebo control groups. 
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Table 4.4 Comparison of mean nutrient intakes per day during the trial period in the 
intervention and the placebo groups. 
Outcome 
Placebo Intervention p-
value* 
Mean SD Mean SD 
Energy (MJ) 8.08 0.34 8.10 0.42 .805 
Protein (g) 84.5 9.8 84.4 10.4 .971 
Fat (g) 67.7 9.3 68.5 12.3 .781 
Saturated Fat (g) 23.8 4.0 27.2 8.8 .055 
Monounsaturated fat 
(g) 
22.4 3.2 24.1 5.1 .137 
Polyunsaturated fat 
(g) 
10.4 1.2 10.3 0.8 .750 
Carbohydrates (g) 218 14 217 11 .641 
Sugars (g) 87.4 12.9 86.3 8.5 .696 
NMES (g) 41.6 9.5 42.7 7.6 .595 
Starch (g) 121.7 11.1 123.1 6.3 .544 
Alcohol (g) 9.7 8.8 9.6 9.0 .984 
*p-values obtained using an independent-samples t-test 
4.3.5 Effect of the Intervention 
4.3.5.1 Interaction Analysis 
Results of the anthropometric and metabolic measurements for all outcomes during 
the nine-week trial period are presented in table 4.5 (below). P-values suggest there 
was no significant interaction between the groups over time for any outcome 
measured. 
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Table 4.5 Anthropometric and metabolic measurements at each assessment point during the 9 week trial period for intervention and 
placebo control groups. 
Outcome 
Placebo Control Intervention 
p-value# 
group 
p-value# 
time*group Baseline 
Mean (± Std. 
Deviation) 
Week 3 
Mean (± Std. 
Deviation) 
Week 6 
Mean (± Std. 
Deviation) 
Week 9 
Mean (± Std. 
Deviation) 
Baseline 
Mean (± Std. 
Deviation) 
Week 3 
Mean (± Std. 
Deviation) 
Week 6 
Mean (± Std. 
Deviation) 
Week 9 
Mean (± Std. 
Deviation) 
Body Fat 
(%) 
31.0 (±6.9) 31.3 (±7.1) 31.1 (±7.2) 31.0 (±7.1) 34.1 (±7.9) 34.2 (±7.5) 33.4 (±7.5) 33.6 (±7.6) 0.004 0.996 
Body Fat 
(kg) 
22.6 (±10.4) 22.8 (±10.6) 22.8 (±10.8) 22.7 (±10.9) 26.8 (±11.0) 26.8 (±10.6) 26.1 (±10.5) 26.3 (±10.6) 0.007 0.998 
Weight 
(kg) 
70.20 
(±14.79) 
70.21 
(±14.79) 
70.55 
(±15.03) 
70.55 
(±15.30) 
75.69 
(±16.08) 
75.49 
(±16.17) 
75.29 
(±16.04) 
75.38 
(±16.02) 
0.012 0.999 
BMI 
(kg/m2) 
25.5 (±4.5) 25.5 (±4.5) 25.7 (±4.6) 25.7 (±4.7) 27.5 (±4.7) 27.4 (±4.7) 27.3 (±4.7) 27.4 (±4.7) 0.003 0.998 
Waist (cm) 81 (±10) 81 (±11) 82 (±10) 82 (±10) 86 (±12) 87 (±13) 86 (±13) 87 (±14) 0.001 0.983 
W-H Ratio* 0.77 (±0.04) 0.77 (±0.04) 0.78 (±0.04) 0.77 (±0.04) 0.80 (±0.06) 0.80 (±0.06) 0.79 (±0.06) 0.80 (±0.08) 0.001 0.890 
BAI** 31.35 (±4.34) 31.37 (±4.45) 31.43 (±4.50) 31.58 (±5.35) 32.56 (±4.80) 32.67 (±4.50) 32.60 (±4.60) 32.68 (±4.47) 0.047 1.000 
Glucose 
(mmol/l) 
4.4 (±0.8) 4.3 (±0.6) 4.4 (±0.7) 4.3 (±0.7) 4.5 (±0.7) 4.4 (±0.6) 4.6 (±0.7) 4.4 (±0.7) 0.277 0.939 
Cholesterol 
(mmol/l) 
3.40 (±0.76) 3.36 (±0.78) 3.18 (±0.61) 3.26 (±0.57) 3.57 (±0.79) 3.49 (±0.80) 3.14 (±0.43) 3.30 (±0.59) 0.675 0.925 
*Ratio: waist circumference/hip circumference      
**BAI: (hip circumference/height1.5)-18 
#p-vaules obtained using a two-way ANOVA
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4.3.5.2 Sensitivity Analysis 
Results of the anthropometric and metabolic measurements for all outcomes during 
the nine-week trial period are presented in table 4.6 (below). P-values suggest there 
was significant differences in the intervention group over time for the primary outcome 
of body fat (% and kg) and blood cholesterol. There were no significant differences 
over time for other anthropometric and metabolic measurements. 
Table 4.6 Anthropometric and metabolic measurements at each assessment point 
during the 9 week trial period for intervention and placebo control groups. 
Group Outcome 
Baseline 
Mean (± SD) 
Week 3 
Mean (± SD) 
Week 6 
Mean (± SD) 
Week 9 
Mean (± SD) 
p-value# 
Placebo  
Control 
Body Fat 
(%) 
31.0 (±6.9) 31.3 (±7.1) 31.1 (±7.2) 31.0 (±7.1) 0.468 
Body Fat 
(kg) 
22.6 (±10.4) 22.8 (±10.6) 22.8 (±10.8) 22.7 (±10.9) 0.628 
Weight (kg) 70.20 (±14.79) 70.21 (±14.79) 70.55 (±15.03) 70.55 (±15.30) 0.730 
BMI (kg/m2) 25.5 (±4.5) 25.5 (±4.5) 25.7 (±4.6) 25.7 (±4.7) 0.800 
Waist (cm) 81 (±10) 81 (±11) 82 (±10) 82 (±10) 0.536 
W-H Ratio* 0.77 (±0.04) 0.77 (±0.04) 0.78 (±0.04) 0.77 (±0.04) 0.710 
BAI** 31.35 (±4.34) 31.37 (±4.45) 31.43 (±4.50) 31.58 (±5.35) 0.817 
Glucose 
(mmol/l) 
4.4 (±0.8) 4.3 (±0.6) 4.4 (±0.7) 4.3 (±0.7) 0.480 
Cholesterol 
(mmol/l) 
3.40 (±0.76) 3.36 (±0.78) 3.18 (±0.61) 3.26 (±0.57) 0.114 
Intervention 
Body Fat 
(%) 
34.1a (±7.9) 34.2ab (±7.5) 33.4ac (±7.5) 33.6ac (±7.6) 0.001 
Body Fat 
(kg) 
26.8a (±11.0) 26.8a (±10.6) 26.1b (±10.5) 26.3ab (±10.6) 0.001 
Weight (kg) 75.69 (±16.08) 75.49 (±16.17) 75.29 (±16.04) 75.38 (±16.02) 0.260 
BMI (kg/m2) 27.5 (±4.7) 27.4 (±4.7) 27.3 (±4.7) 27.4 (±4.7) 0.169 
Waist (cm) 86 (±12) 87 (±13) 86 (±13) 87 (±14) 0.445 
W-H Ratio* 0.80 (±0.06) 0.80 (±0.06) 0.79 (±0.06) 0.80 (±0.08) 0.530 
BAI** 32.56 (±4.80) 32.67 (±4.50) 32.60 (±4.60) 32.68 (±4.47) 0.904 
Glucose 
(mmol/l) 
4.5 (±0.7) 4.4 (±0.6) 4.6 (±0.7) 4.4 (±0.7) 0.074 
Cholesterol 
(mmol/l) 
3.57a (±0.79) 3.49a (±0.80) 3.14b (±0.43) 3.30ab (±0.59) 0.005 
*Ratio: waist circumference/hip circumference      
**BAI: (hip circumference/height1.5)-18      
#p-values obtained using a one-way repeated measures ANOVA     
a,b,c depict statistical difference between measurements obtained using a dependent-samples t-test 
(Bonferroni adjusted) 
Graphs for statistically significant findings are presented below. 
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Figure 4.3 Change in body fat (%) during the trial period in the intervention and 
placebo control groups (n=60) with error bars indicating standard deviation. 
 
a,b,c depict statistical difference between measurements obtained using a dependent-samples t-test 
(Bonferroni adjusted) 
Figure 4.4 Change in body fat (kg) during the trial period in the intervention and 
placebo control groups (n=60) with error bars indicating standard deviation. 
 
a,b,c depict statistical difference between measurements obtained using a dependent-samples t-test 
(Bonferroni adjusted) 
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Figure 4.5 Change in blood cholesterol (mmol/l) during the trial period in the 
intervention and placebo control groups (n=60) with error bars indicating standard 
deviation. 
 
a,b,c depict statistical difference between measurements obtained using a dependent-samples t-test 
(Bonferroni adjusted) 
Calculations for % change for all outcomes at week 3, 6 and 9 compared to baseline 
are presented in table 4.7 (below) for both intervention and placebo control groups. 
Results indicate there are no significant difference in percentage change across 
outcomes during the trial period. 
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Table 4.7 Percent change at weeks 3, 6 and 9 compared to baseline for all 
anthropometric and metabolic outcomes for placebo control and intervention groups, 
along with comparative p-values. 
Comparison v baseline 
Group 
p-
value*# 
Placebo Control Intervention 
N Mean SD N Mean SD 
% Fat percentage change week 3 30 1.04 5.03 30 0.85 4.41 0.847 
% Fat percentage change week 6 30 0.01 5.02 30 -1.52 4.48 0.218 
% Fat percentage change week 9 30 -0.09 6.91 30 -1.02 3.62 0.517 
% Fat (kg) change week 3 30 1.06 5.22 30 0.59 4.94 0.720 
% Fat (kg) change week 6 30 0.48 5.23 30 -2.07 4.71 0.053 
% Fat (kg) change week 9 30 0.38 7.84 30 -1.51 4.12 0.247 
% Weight change week 3 30 0.01 1.18 30 -0.29 1.18 0.322 
% Weight change week 6 30 0.47 1.39 30 -0.56 1.41 0.006 
% Weight change week 9 30 0.42 1.75 30 -0.43 1.83 0.071 
% BMI change week 3 30 0.01 1.18 30 -0.42 1.47 0.213 
% BMI change week 6 30 0.47 1.39 30 -0.68 1.78 0.007 
% BMI change week 9 30 0.42 1.75 30 -0.49 2.29 0.089 
% Waist circumference change 
week 3 
30 0.57 4.93 30 0.25 3.81 0.780 
% Waist circumference change 
week 6 
30 1.22 4.75 30 -0.70 5.36 0.146 
% Waist circumference change 
week 9 
30 1.02 5.18 30 0.42 7.32 0.713 
% Waist-Hip ratio change week 3 30 0.50 4.49 30 -0.05 3.46 0.601 
% Waist-Hip ratio change week 6 30 1.09 4.93 30 -0.87 4.21 0.105 
% Waist-Hip ratio change week 9 30 0.71 5.47 30 0.03 5.61 0.637 
% BAI change week 3 30 0.19 4.93 30 0.57 4.37 0.756 
% BAI change week 6 30 0.37 5.42 30 0.34 5.68 0.987 
% BAI change week 9 30 0.66 6.83 30 0.60 4.99 0.967 
% Blood glucose change week 3 30 -0.95 11.35 30 -1.25 13.54 0.926 
% Blood glucose change week 6 30 3.04 16.19 30 4.93 17.45 0.665 
% Blood glucose change week 9 30 0.23 13.55 30 -1.71 14.83 0.600 
% Blood cholesterol change week 3 30 -0.70 10.58 30 -1.77 10.28 0.693 
% Blood cholesterol change week 6 30 -4.27 15.65 30 -9.53 16.68 0.213 
% Blood cholesterol change week 9 30 -1.82 15.81 30 -5.28 17.80 0.429 
#p-values obtained using an independent-samples t-test 
*Statistical significance was set at p≤ 0.002 to account for multiple testing (27 tests) 
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4.3.5.3 Intention-to-Treat Analysis 
The baseline age, anthropometric and metabolic measurements for the intention-to-
treat analysis are presented in table 4.8 below for all participants, placebo control 
and intervention groups. The randomisation process resulted in groups with largely 
similar age, anthropometric and metabolic measurements. 
Table 4.8 Intention-to-treat analysis for anthropometric and metabolic measurements 
at each assessment point during the 9 week trial period for intervention and placebo 
control groups. 
Measure 
All Participants Placebo Control Intervention 
N Mean (±SD) N Mean (±SD) N Mean (±SD) 
Age (yrs) 72 30 (±10) 36 29 (±10) 36 30 (±10) 
Height (m) 72 1.66 (±0.06) 36 1.65 (±0.06) 36 1.66 (±0.07) 
Body Fat (%) 72 32.5 (±7.1) 36 31.6 (±6.6) 36 33.4 (±7.5) 
Body Fat (kg) 72 24.5 (±10.1) 36 23.02 (±9.8) 36 26.0 (±10.3) 
Weight (kg) 72 72.97 (±14.54) 36 70.78 (±13.94) 36 75.17 (±14.97) 
BMI (kg/m2) 72 26.4 (±4.4) 36 25.8 (±4.2) 36 27.1 (±4.7) 
Waist (cm) 72 83 (±11) 36 81 (±10) 36 85 (±11) 
Ratio* 72 0.78 (±0.05) 36 0.77 (±0.04) 36 0.79 (±0.06) 
BAI** 72 31.61 (±4.47) 36 31.23 (±4.25) 36 31.98 (±4.71) 
Glucose 
(mmol/l) 
72 4.4 (±0.7) 36 4.4 (±0.8) 36 4.5 (±0.7) 
Cholesterol 
(mmol/l) 
72 3.44 (±0.69) 36 3.43 (±0.78) 36 3.44 (±0.65) 
*Ratio: waist circumference/hip circumference 
**BAI: (hip circumference/height1.5)-18 
A comparison of baseline age, anthropometric and metabolic measurements for all 
participants who were randomised and all participants who completed the trial is 
presented in table 4.9 below. P-values suggested there was no statistically 
significant difference between all randomised and all completing participants for age, 
anthropometric and metabolic measurements. 
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Table 4.9 Intention-to-treat analysis comparing baseline age, anthropometric and 
metabolic measurements for all randomised participants and all completing 
participants. 
Measure 
All Randomised All Completers 
p-
value# N 
Mean (±Std. 
Deviation) 
N 
Mean (±Std. 
Deviation) 
Age (yrs) 72 30 (±10) 60 30 (±10) 0.872 
Height (m) 72 1.66 (±0.06) 60 1.65 (±0.07) 0.744 
Body Fat (%) 72 32.5 (±7.1) 60 32.5 (±7.5) 0.991 
Body Fat (kg) 72 24.5 (±10.1) 60 24.7 (±10.8) 0.909 
Weight (kg) 72 72.97 (±14.54) 60 72.95 (±15.57) 0.891 
BMI (kg/m2) 72 26.4 (±4.4) 60 26.5 (±4.7) 0.795 
Waist (cm) 72 83 (±11) 60 84 (±11) 0.663 
Ratio* 72 0.78 (±0.05) 60 0.78 (±0.05) 0.970 
BAI** 72 31.61 (±4.47) 60 31.95 (±4.58) 0.922 
Glucose (mmol/l) 72 4.4 (±0.7) 60 4.4 (±0.8) 0.927 
Cholesterol 
(mmol/l) 
72 3.44 (±0.69) 60 3.48 (±0.78) 
0.919 
#p-values calculated using an independent-samples t-test 
*Ratio: waist circumference/hip circumference 
**BAI: (hip circumference/height1.5)-18 
Results of the anthropometric and metabolic measurements for all outcomes, for all 
randomised participants during the trial period are presented in table 4.10 (below). P-
values suggest there was significant differences in the intervention group over time 
for the primary outcome of body fat (% and kg) and blood cholesterol. There were no 
significant differences over time for other anthropometric and metabolic 
measurements. 
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Table 4.10 Intention-to-treat analysis with anthropometric and metabolic 
measurements for all outcomes during the 9 week trial period for placebo control and 
intervention groups (n=36 for all measurements). 
Group Outcome 
Baseline 
Mean (± SD) 
Week 3 
Mean (± SD) 
Week 6 
Mean (± SD) 
Week 9 
Mean (± SD) 
p-value# 
Placebo  
Control 
Body Fat 
(%) 
31.6 (±6.6) 31.8 (±6.8) 31.6 (±6.9) 31.5 (±6.8) 0.462 
Body Fat 
(kg) 
23.02 (±9.8) 23.2 (±10.0) 23.2 (±10.2) 23.1 (±10.3) 0.638 
Weight (kg) 70.78 (±13.94) 70.79 (±13.95) 71.07 (±14.14) 71.07 (±14.38) 0.074 
BMI (kg/m2) 25.8 (±4.2) 25.8 (±4.3) 25.9 (±4.3) 25.9 (±4.4) 0.081 
Waist (cm) 81 (±10) 82 (±10) 82 (±10) 82 (±10) 0.507 
W-H Ratio* 0.77 (±0.04) 0.78 (±0.05) 0.78 (±0.04) 0.78 (±0.05) 0.667 
BAI** 31.23 (±4.25) 31.25 (±4.34) 31.30 (±4.38) 31.42 (±5.12) 0.817 
Glucose 
(mmol/l) 
4.4 (±0.8) 4.3 (±0.6) 4.5 (±0.7) 4.4 (±0.7) 0.480 
Cholesterol 
(mmol/l) 
3.43 (±0.78) 3.40 (±0.76) 3.25 (±0.63) 3.32 (±0.59) 0.115 
Intervention 
Body Fat 
(%) 
33.4a (±7.5) 33.5ab (±7.1) 32.9ac (±7.5) 33.0ac (±7.1) 0.003 
Body Fat 
(kg) 
26.0a (±10.3) 26.0a (±10.0) 25.4b (±9.9) 26.3ab (±10.6) 0.004 
Weight (kg) 75.17 (±14.97) 75.01 (±15.04) 74.84 (±14.93) 74.91 (±14.90) 0.206 
BMI (kg/m2) 27.1 (±4.7) 27.0 (±4.5) 27.0 (±4.4) 26.4 (±5.8) 0.300 
Waist (cm) 85 (±11) 86 (±12) 85 (±12) 86 (±13) 0.444 
W-H Ratio* 0.79 (±0.06) 0.79 (±0.06) 0.79 (±0.06) 0.79 (±0.07) 0.530 
BAI** 31.98 (±4.71) 32.07 (±4.50) 32.01 (±4.55) 32.08 (±4.44) 0.904 
Glucose 
(mmol/l) 
4.5 (±0.7) 4.4 (±0.7) 4.6 (±0.7) 4.4 (±0.7) 0.075 
Cholesterol 
(mmol/l) 
3.44a (±0.65) 3.35a (±0.58) 3.14b (±0.46) 3.27ab (±0.59) 0.007 
*Ratio: waist circumference/hip circumference      
**BAI: (hip circumference/height1.5)-18      
#p-values obtained using a one-way repeated measures ANOVA     
a,b,c depict statistical difference between measurements (Bonferroni adjusted) 
Calculations for % change for all outcomes at week 3, 6 and 9 compared to baseline 
are presented in table 4.11 (below) for all randomised participants, in both 
intervention and placebo control groups, along with comparative p-values. Results 
indicate there are no significant difference in percentage change across outcomes 
during the trial period. 
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Table 4.11 Intention-to-treat analysis for % change at weeks 3, 6 and 9 compared to 
baseline for all anthropometric and metabolic outcomes for placebo control and 
intervention groups, along with comparative p-values. 
Comparison v baseline 
Group 
p-
value*# 
Placebo Control Intervention 
N Mean SD N Mean SD 
% Fat percentage change week 3 36 0.87 4.60 36 0.71 4.02 0.847 
% Fat percentage change week 6 36 -0.06 4.59 36 -1.27 4.12 0.242 
% Fat percentage change week 9 36 -0.07 6.29 36 -0.85 3.32 0.510 
% Fat (kg) change week 3 36 0.89 4.77 36 0.49 4.52 0.720 
% Fat (kg) change week 6 36 0.34 4.80 36 -1.72 4.36 0.061 
% Fat (kg) change week 9 36 0.33 7.13 36 -1.26 3.80 0.244 
% Weight change week 3 36 0.01 1.07 36 -0.24 1.07 0.321 
% Weight change week 6 36 0.39 1.28 36 -0.46 1.30 0.007 
% Weight change week 9 36 0.34 1.60 36 -0.36 1.67 0.071 
% BMI change week 3 36 0.01 1.07 36 -0.35 1.35 0.212 
% BMI change week 6 36 0.39 1.28 36 -0.57 1.64 0.007 
% BMI change week 9 36 0.35 1.60 36 -0.49 1.98 0.192 
% Waist circumference change 
week 3 
36 0.47 4.49 36 0.21 3.46 0.779 
% Waist circumference change 
week 6 
36 1.02 4.32 36 -0.59 4.88 0.145 
% Waist circumference change 
week 9 
36 0.85 4.72 36 0.35 6.66 0.712 
% Waist-Hip ratio change week 3 36 0.42 4.09 36 -0.04 3.15 0.600 
% Waist-Hip ratio change week 6 36 0.90 4.50 36 -0.72 3.85 0.104 
% Waist-Hip ratio change week 9 36 0.59 4.98 36 0.03 5.10 0.636 
% BAI change week 3 36 0.16 4.49 36 0.47 3.98 0.755 
% BAI change week 6 36 0.31 4.93 36 0.29 5.17 0.987 
% BAI change week 9 36 0.55 6.22 36 0.50 4.54 0.967 
% Blood glucose change week 3 36 -0.80 10.33 36 -1.04 12.33 0.926 
% Blood glucose change week 6 36 2.53 14.78 36 4.10 15.99 0.666 
% Blood glucose change week 9 36 0.19 12.33 36 -1.42 13.51 0.599 
% Blood cholesterol change week 
3 
36 -0.58 9.63 36 -1.98 9.78 0.543 
% Blood cholesterol change week 
6 
36 -3.55 14.34 36 -7.11 14.69 0.302 
% Blood cholesterol change week 
9 
36 -1.51 14.40 36 -3.49 15.62 0.579 
#p-values obtained using an independent-samples t-test 
*Statistical significance was set at p≤ 0.002 to account for multiple testing (27 tests) 
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Chapter 5 – Discussion 
5.1 Intervention Trial 
To date, there have been 18 published intervention trials investigating capsaicinoids’ 
effect on weight management outcomes. Despite many trials observing positive 
effects, there is a paucity of data on longer-term effects and resulting body 
composition. The present intervention trial was intended to assess the potential impact 
that capsaicinoids could have on body fat following a six week capsaicinoid 
intervention. Of the published trials, only two of those trials featured multi-week 
interventions. One of which was a weight regain trial (Lejeune et al., 2003) and 
therefore difficult to assess capsaicinoids effect on body fat due to rapid weight loss. 
The other trial’s primary outcome was the effect on metabolic and arterial function and 
featured a crossover design less suited to observing changes in body fat. The present 
trial was therefore the first to assess whether a multi-week capsaicinoid intervention 
could reduce body fat. However, interaction analysis found no significance change 
between the placebo control and intervention groups over time for any of the outcomes 
measured.  
5.1.1 Primary Outcome 
The interaction analysis found no significance change between the placebo control 
and intervention groups over time for body fat percentage (p = 0.996) or total body fat 
(p = 0.998), suggesting the intervention had no effect on these outcomes. There was 
a significant between the groups for both body fat percentage (p = 0.004) and total 
body fat (p = 0.007). This significant difference in adiposity levels between the two 
groups suggests that the randomisation created uneven groups with regard to body 
fat levels. 
However, the sensitivity analysis found that after six weeks of supplementation, the 
capsaicinoid group had a small but statistically significant reduction in mean body fat 
percentage of 0.64% (p = 0.022) and a small but statistically significant decrease in 
mean total body fat of 0.67kg (p = 0.007). There were no significant changes in body 
fat percentage or total body fat in the placebo control group, who remained relatively 
stable throughout the trial; suggesting than the observed change in body composition 
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maybe due to the capsaicinoid intervention. The contrasting results between the 
interaction analysis and the sensitivity analysis however, suggest this finding lacks 
robustness. These contrasting results could be due to a lack of statistical power (that 
the number of participants taking part was too small to observe a significant effect) or 
because there was a difference in adiposity levels between the two groups, which was 
larger than the change in adiposity observed over time. 
A number of previous trials, including both short-term and long-term interventions, 
have found capsaicinoids to increase lipid oxidation (Lejeune et al., 2003, Janssens 
et al., 2013), this is also the case with capsinoid trials (Lee et al., 2010b, Josse et al., 
2010). However, what has not been seen from these trials was whether this increase 
in lipid oxidation would lead to a beneficial change in body composition (i.e. less 
adipose tissue). Previous non-capsaicinoid research has found an association 
between lipid oxidation and the amount of adipose tissue in humans (Schutz et al., 
1992) and it has also been observed in a number of animal studies that capsaicinoid 
ingestion could beneficially alter body composition (Sambaiah and Satyanarayana, 
1982), however, a significant effect has not been observed in humans, prior to the 
present investigation.  
A previous multi-week study monitored change in body fat as a result of a capsaicinoid 
intervention but found no difference in body fat percentage and total body fat between 
the capsaicin and placebo groups (Lejeune et al., 2003). However, that was a weight 
regain study, and had a significantly different methodology which would likely impact 
any observed changes in body fat. Participants lost around 7-8% of body weight (in a 
four-week very low calorie diet) before starting supplementation, and both groups’ 
body fat percentage and total body fat were lower at the end of the trial than they were 
at the start, despite gaining weight during the supplementation period. In addition to 
this, the trial estimated fat free mass and body fat percentage using equations with 
estimates derived from total body water, a technique which has been shown to result 
in less accurate calculations of body fat percentage (Sen et al., 2010). This would be 
a potential problem for short-to-medium length trials as changes in body fat due to 
capsaicinoids are likely to be relatively small. Therefore, it is difficult to assess whether 
the results of the aforementioned trial are directly comparable to this results of the 
present one.  
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Another multi-week capsaicinoid trial (four-week intervention) assessed change in 
body fat and observed no significant effect due to the intervention (Ahuja et al., 2007). 
However, that trial had a cross-over design, with no wash out period whose primary 
outcome was to investigate capsaicinoids’ effect on metabolic and arterial function. A 
cross-over design is unlikely to be conducive to detecting changes in body 
composition, which are slower to occur than metabolic and arterial outcomes and more 
likely to be affected by the impact of the participants’ being under both control and 
intervention conditions. 
Two human trials using capsinoids have investigated whether they could affect body 
composition. A short term trial (two weeks), found capsinoids (again ingested as food) 
found a decrease in body fat percentage (-0.31%), although this was not statistically 
significant (p > 0.05) (Kawabata et al., 2006). This lack of significance may have been 
due to the short intervention period. A longer-term capsinoid trial (intervention lasting 
12-weeks), failed to find a benefit in terms of body fat percentage or body composition, 
with both placebo and intervention groups losing around 1% of body fat during the 
intervention period. However, the capsinoid group did lose significantly higher 
amounts of abdominal fat compared to the placebo group (p = 0.049). Abdominal 
adipose tissue was not recorded in the present study, which used bio-electrical 
impedance to measure adipose tissue, whereas the prior study used dual energy X-
ray absorptiometry, which measures both total and site specific adiposity. It was not 
therefore possible to compare this aspect of the two trials’ results. 
Capsaicinoids may be influencing adipose tissue levels by several different 
mechanisms. Stimulation of TRPV1 receptors, leading to increased activity of the 
sympathetic nervous system, may cause the body to mobilise adipose stores for 
energy usage, leading to an increase in lipid oxidation and an overall reduction in 
adipose tissue (Bartness et al., 2010). Stimulation of TRPV1 channels by 
capsaicinoids may induce calcium influx into cells, which has been demonstrated to 
prevent adipogensis, potentially preventing adipose cells from forming (Zhang et al., 
2007). Capsaicinoids may also be causing this effect by altering the expression of 
adipose cell protein and enzymes and altering adipokine secretion (Joo et al., 2010). 
Finally, capsaicinoids may stimulate and de-sensitive nerve cells leading to changes 
in adipose tissue formation and distribution (Stearns et al., 2012). 
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Also possible is that capsaicinoids may be aiding muscle hypertrophy, leading to lower 
body fat percentages and higher lean mass percentages, with one study finding that 
capsaicin treatment stimulated skeletal muscle hypertrophy in mice (Ito et al., 2013). 
Mechanical load-induced intracellular signalling events are important for subsequent 
skeletal muscle hypertrophy and researchers have found that in the mammalian body, 
muscle hypertrophy required a TRPV1-mediated increase in intracellular calcium 
concentrations. In addition, capsaicin treatment could stimulate the same pathway, 
mimicking the signalling events caused by mechanical loading and causing a 
significant increase in skeletal muscle. 
5.1.2 Secondary Outcomes 
5.1.2.1 Weight  
The results suggest that over a six-week intervention period, capsaicinoid 
supplementation had no statistically significant effect on total body weight. Weight in 
the capsaicinoid group declined slightly after 6 weeks of supplementation (-0.40kg 
from baseline), however this change was not statistically significant, with neither the 
interaction analysis between the two groups over time (p = 0.999) or the sensitivity 
analysis (p = 0.260) finding a significant effect. Such a change in weight is small in the 
context of natural human weight fluctuations. Human body weight can vary due to a 
number of factors including hydration status, food intake, salt intake and menstrual 
cycle (Bunt et al., 1989). Human body weight is known to fluctuate by 2% or more on 
a daily basis (Vivanti et al., 2013), which for the participants in the trial would mean 
daily variations of around 1.5kg. Therefore, it would seem the capsaicinoid intervention 
had minimal effect on body weight following 6 weeks of supplementation.  
It may be that a longer intervention period would be required to observe an effect on 
body weight. Two trials involving capsinoid interventions both found that medium-term 
supplementation (12-weeks) increased energy expenditure by around 50kcal/day 
(Snitker et al., 2009, Galgani and Ravussin, 2010). For this relatively small increase in 
energy expenditure and to aid weight loss would take time. Taking the mean weight 
(72.95kg) and age (29.95) of participants in this trial, a clinically significant weight loss 
(considered to be 5-10% (Douketis et al., 2005)) would be 3.5kg - 7.0kg. Using weight 
loss modelling (Hall and Jordan, 2008), this kind of weight loss would take at least 539 
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days (77 weeks). It may be the case therefore that the trial was not long enough to 
detect changes in body weight. 
Capsaicinoids may also be able to aid reductions in body weight via limiting of energy 
intake. This effect has been observed in intervention trials (Janssens et al., 2014) and 
meta-analysis (Whiting et al., 2014); it may occur through action on intestinal satiety 
hormones (Smeets and Westerterp-Plantenga, 2009), stimulation of the sympathetic 
nervous system (Yoshioka et al., 1999), its effect on the brain, specifically the 
orbitofrontal cortex (Rolls, 2004a) or the hypothalamus (Baboota et al., 2014), or by 
increasing lipid oxidation (Leonhardt and Langhans, 2004). However, like energy 
expenditure, this effect is small; estimates from the meta-analysis suggested a 
decrease in energy expenditure of 251kJ (Whiting et al., 2014). Using weight loss 
modelling, a clinically significant weight loss (5-10%) would take at least 358 days (51 
weeks). Again this is suggestive, that if capsaicinoid supplementation were to lead to 
a beneficial change in body weight, the present trial was too short to detect any effect. 
It is also possible that changes in substrate oxidation due to the intervention may affect 
body weight measurements. Capsaicinoids have been observed to increase lipid 
oxidation and decrease carbohydrate oxidation in both short-term (Janssens et al., 
2013, Shin and Moritani, 2007, Yoshioka et al., 1998) and long-term intervention trials 
(Lejeune et al., 2003). As the body utilises higher levels of adipose stores (i.e. 
increased lipid oxidation), this may result in an increase in body weight, particularly 
over the short-term (Maughan et al., 2007). Carbohydrates are stored in the body as 
glycogen and these stores typically included about 3 or 4 times the weight of glycogen 
in water (Pocock et al., 2013). It is assumed that when these glycogen stores are used, 
the associated water then becomes available to the body and therefore quickly lost; 
thus the body utilising 0.5kg of glycogen for energy usage, would result in a weight 
loss of around 2 – 2.5kg, while utilising of adipose stores would result in a lower 
reduction of body weight (Garrow and Summerbell, 1995). In addition to this, substrate 
utilisation results in high levels of carbon dioxide creation, with lipid oxidation creating 
nearly twice the amount of CO2 as carbohydrate and protein oxidation. As a result lipid 
oxidation actually results in a temporary net gain in body mass as the mass of carbon 
dioxide generated is less than the mass of oxygen consumed (Maughan et al., 2007). 
The overall effect of this is that elevated levels of lipid oxidation, which capsaicinoid 
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supplementation may be causing, could result in slightly higher body weight. Although 
this effect would be small and temporary (particularly as CO2 is expired), potentially 
though it may have had an impact on body weight levels observed in the trial.  
5.1.2.2 BMI 
There was no statistically significant change in BMI in either group throughout the trial.  
Neither the interaction analysis between the two groups over time (p = 0.998) or the 
sensitivity analysis (p = 0.169) finding a significant effect. BMI did decrease in the 
intervention group at week 6 by 0.18kg/m2, compared to baseline (p = 0.480). 
However, the lack of statistical significance and the decrease being very small is 
suggestive that six weeks of capsaicinoid supplementation at this dosage had no effect 
on this measure. This is not surprising as any change in BMI would be related to 
change in body weight. Like for changes in body weight, it is not obvious from the trial 
whether the lack of change in BMI is a result of there being no effect from capsaicinoid 
supplementation or the effect being relatively small and the trial being too short to 
detect it. For an objective assessment of the effects of capsaicinoids on BMI a longer 
term trial would be required. 
5.1.2.3 Waist circumference and waist-to-hip ratio 
There were no significant changes in waist circumference in either group during the 
trial. Neither the interaction analysis between the two groups over time (p = 0.983) or 
the sensitivity analysis (p = 0.445) finding a significant effect. There was also no 
significant change in waist-to-hip circumference in either group, with neither interaction 
analysis between the two groups over time (p = 0.890) or the sensitivity analysis (p = 
0.530) finding a significant effect. Mean waist and hip circumferences in the 
capsaicinoid group fluctuated above and below the baseline value during the trial by 
less than 1cm; with changes not being statistically significant (p > 0.05). In terms of 
the waist-to-hip ratio there were no significant changes in either group during the trial 
period. Suggesting the six week capsaicinoid intervention had no effect on these 
measures. 
Waist circumference is considered to be an indicator of body fat, especially visceral 
adipose tissue (Rankinen et al., 1999). Therefore, it may be expected that a decrease 
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in percentage and total body fat (as observed in this trial) would be reflected in waist 
circumference measurements, however this was not the case. It may be concluded 
that adipose tissue lost was not around the visceral area, or that the waist 
circumference is not a sensitive enough measurement to detect the small decrease in 
body fat (observed via bio-electrical impedance measurements), following six weeks 
of supplementation.  
Waist circumference is a marker prone to variation due to human measurement error 
and natural variation of the human body and therefore less reliable than other 
measurements used in this trial such as weight and body fat (Bigaard et al., 2005, 
Panoulas et al., 2008). In addition to this it is a measurement that is known to vary in 
humans seasonally by several centimetres (Visscher and Seidell, 2004), short term 
variations can also occur due to the respiratory cycle (by between 3 – 8cm) (Pellowe 
et al., 2010), changes due to the menstrual cycle (Kirchengast and Gartner, 2002) and 
due to the effects of food, faeces and ﬂatus (Pellowe et al., 2010), therefore it may not 
be sensitive enough to detect the small changes in adiposity observed. 
Another trial using capsinoid found a reduction in abdominal obesity following 12-
weeks of supplementation (Snitker et al., 2009), so it may be expected that a reduction 
in waist circumference would be observed in this trial. That trial used Dual-energy X-
ray absorptiometry scanning, which is a more sensitive instrument than waist 
circumference to changes in visceral adiposity, and also involved equal amounts of 
both male and female participants, unlike the present trial which involved only women. 
Waist measurement may be a poorer indicator of overall adiposity in women than in 
men (Camhi et al., 2011), with males more likely to store adipose tissue around the 
visceral area than females (Ayonrinde et al., 2011). Thus, any adipose tissue lost in 
the present population group is likely to be less than an all-male or mixed gender 
participant group. Therefore, waist circumference may not be the most reliable 
indicator of adipose tissue levels in the present population group, making it difficult to 
draw conclusions from the observed small changes in waist circumference.  
5.1.2.4 Body Adiposity Index 
There were no statistically significant variations in mean body adiposity index (BAI) 
from baseline value throughout the trial. Observed changes were relatively small and 
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combined with the lack statistical significance with neither the interaction analysis 
between the two groups over time (p = 1.000) or the sensitivity analysis (p = 0.530) 
finding a significant effect. Suggesting the capsaicinoid intervention had little effect on 
this measure of body adiposity. These values reflect the small changes in hip 
circumference observed during the trial, as this measure is based around a calculation 
which uses height and hip circumference. BAI is a relatively recently created measure, 
designed to give an estimation of body adiposity from basic anthropometric 
measurements (Bergman et al., 2011). In this trial mean BAI was consistently close to 
mean percentage body fat (as measured by bio-electrical impedance), being no more 
than 1.5% away at any point in the trial. On an individual basis however, BAI was more 
prone to variations; the highest difference was 8.01% between the two figures (33.89 
for BAI vs 41.9% for body fat percentage). So although a relatively accurate guide on 
a population basis, these individual variations make picking up subtle changes in 
adiposity less reliable using this measure. 
5.1.3 Biochemical analysis 
5.1.3.1 Fasting Blood Cholesterol 
The interaction analysis found no significance change between the placebo control 
and intervention groups over time for fasting blood cholesterol levels (p = 0.925), 
suggesting the intervention had no effect on this outcome. There were however 
statistically significant changes in the intervention group for mean fasting blood 
cholesterol levels observed in the interaction analysis. Mean levels decreased 
0.37mmol/l (from baseline value) at week six (p = 0.006). A similar pattern was also 
observed in the placebo control group, although the differences were smaller and did 
not reach statistical significance (p = 0.114). The contrasting results between the 
interaction analysis and the sensitivity analysis however, suggest this finding lacks 
robustness. These contrasting results could be due to a lack of statistical power, the 
number of participants taking part being too small to observe a significant effect in the 
interaction analysis. 
A number of research studies have investigated the potential of capsaicinoids to affect 
blood cholesterol levels in animal models, however results have been inconclusive 
(Zhang et al., 2013). Capsaicinoids favourably modified the lipoprotein profile in 
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hamsters over a six-week period and rats given capsaicinoid supplementation for 28 
days (Zhang et al., 2013). Another study found a cholesterol lowering effect due to 
capsaicin supplementation in mice fed a high fat diet (Shubha et al., 2011).  
Conversely, another trial reported no effect on cholesterol following capsaicinoid 
supplementation (Srinivasan and Chandrasekhara, 1992). Little research has been 
done into the effect on cholesterol levels in humans, although one trial observed no 
effect following a four-week capsaicinoid supplemented diet (Ahuja et al., 2007).  
The results observed in this trial raise the possibility that capsaicinoids may have a 
cholesterol lowering effect in humans, however further research is required to 
investigate this possibility further. It should be noted that participants in the present 
trial would not be a group considered at risk of cardiovascular related health problems 
due to their cholesterol levels, with all mean and individual participants levels within 
the healthy range of values (Truswell, 2010). Also blood cholesterol levels are prone 
to short-term variations due to a number of factors including genetics and diet, 
specifically the amount of animal fats consumed (Willett, 2013) and are prone to much 
larger variations than anthropometric measurements. For example, in the present trial 
around a 10% reduction was seen in mean blood cholesterol in this trial, whereas a 
10% decrease in body weight would be considered a large variation. 
5.1.3.2 Fasting Blood Glucose 
There were no statistically significant changes in mean fasting blood glucose observed 
throughout the trial observed in either the interaction analysis between the two groups 
over time or the sensitivity analysis. Mean blood glucose fluctuated above and below 
the baseline level in both groups during the nine weeks of the trial and it appears than 
the capsaicinoid intervention had no significant effect on blood glucose during the trial. 
Values for mean blood glucose remained within the normal range for non-diabetics 
throughout the trial (4.0-5.9mmol/litre) (Ceriello et al., 2014), so it appears that six 
weeks of capsaicinoid supplementation had no adverse effects on this measure.  
Research in animal models suggests capsaicinoids can have a significant influence 
on blood glucose and insulin levels. Dietary capsaicin not only improved glucose 
tolerance and increased insulin levels but also lowered daily blood glucose profiles in 
mice (Wang et al., 2012) and capsaicin has been demonstrated to increases glucose 
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uptake in muscle cells, also in mice (Kim et al., 2013). However, another capsaicinoid 
intervention trial in humans which measured changes in blood glucose, found similar 
results to the present study; with no statistically significant difference between control 
and intervention arms of the trial (Ahuja et al., 2007). 
5.1.4 Effect on Appetite and Energy Intake 
It has been observed in several previous research studies that capsaicinoids added to 
the diet my lead to a reduction in energy intake and thereby aiding weight loss 
(Janssens et al., 2014, Ludy and Mattes, 2011a). Although the present study was 
conducted to assess changes in body fat, energy intake was recorded via food 
questionnaires, therefore it is possible to examine if capsaicinoids had any effect. In 
terms of energy intake, both groups had very similar intake levels, which did not 
significantly change over time during the trial period. This contrasts to data from the 
meta-analysis on energy intake, which suggested that capsaicinoid ingestion could 
cause a reduction in energy intake of 251kJ (60kcal) (Whiting et al., 2014); however 
care needs to be taken when drawing conclusions from this data. 
Food diaries are prone to under-reporting and data may be compromised due to recall 
problems or social desirability bias (i.e., misreporting on sensitive or embarrassing 
behaviours to appear more favourable) (Leatherdale and Laxer, 2013), making energy 
intake figures for the present trial prone to bias. The methodology used here was also 
different to other trials investigating this area, which have not relied upon 
questionnaires, but supplied participants with food and measured how much was 
consumed (Westerterp-Plantenga et al., 2005). It may well be the case that food 
diaries are simply not a sensitive enough instrument to detect the small changes in 
energy intake that might potentially have occurred as a result of capsaicinoid ingestion.  
Using Henry energy equations (Henry, 2005) and mean values of age, weight and 
height of each group (at baseline) can give an estimate of the energy requirements 
(assuming seated work and light exercise). Doing so suggests the capsaicinoid group 
should be consuming 2138kcal/day to maintain their current weight and the placebo 
control group 2072kcal/day. Based on reported intakes, the capsaicinoid group would 
have had an energy deficit of 870kJ/day (208kcal/day) and the placebo control group 
a deficit of 586kJ/day (140kcal/day). With such a calorie deficit, particularly for the 
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capsaicinoid group, it would be expected to see a larger reduction in body weight 
during the trial, than was observed. This suggests a potential lack of reliability in the 
reporting of energy intake in the food diaries in this study. Therefore, it makes it difficult 
to draw any conclusion concerning capsaicinoids’ effect on energy intake from the 
results of this investigation. 
5.1.5 Intention-to-treat Analysis 
An intention-to-treat analysis was carried out to assess whether any bias was 
introduced into the trial observations due to participant drop-outs. It would appear from 
analysis however that minimal bias was introduced due to drop-outs. The 
randomisation process resulted in groups with largely similar age, anthropometric and 
metabolic measurements. There were no statistically significant differences when 
comparing the mean baseline age, anthropometric and metabolic measurements of 
all randomised participants verses all completing participants. Together, this suggests 
that at baseline the intervention and placebo control groups were largely similar across 
all measurements and that participant drop out had no impact on this. 
Re-analysing the effect of the intervention including the final measurements of those 
who dropped out had minimal impact on the findings. There was still a statistically 
significance difference over time for the measurements of body fat (%) and body fat 
(kg) and for cholesterol, with no differences observed for any other outcomes. The 
analysis also indicated there are no significant difference in percentage change 
across outcomes during the trial period. These results were similar to the analysis 
that didn’t include participants that dropped-out. Therefore, it’s unlikely that any bias 
was introduced into the results of the trial due to participants dropping out. 
5.1.6 Placebo Control Group 
It was expected that as fat loss is outside of conscious control, there would be no 
evidence of fat loss in the placebo control group. The placebo control group was 
therefore considered a reference group. Placebo effects that have been observed in 
previous research trials are primarily related to subjective and self-appraised 
symptoms (such as pain relief), rather than the causation of permanent physiological 
changes to the body that are measurable (Kaptchuk and Miller, 2015). Statistical 
analysis of the results of the trial was therefore carried out in accordance with this 
102 
 
assumption, by initially using a repeated measures one-way ANOVA to assess change 
in outcomes over time and then analysing the differences in the % change of mean 
values over time. Analysis of the placebo control group found no difference in any of 
the outcomes over time, suggesting the placebo supplement produced no measurable 
effect on the outcomes investigated. 
5.2 Limitations of the Research 
Though informative the present trial has a number of limitations. Results of the 
interaction analysis suggest there were significant differences between the placebo 
control and intervention group among all anthropometric measurements (p < 0.05). 
Therefore, comparison of changes between the two groups over time as a result of the 
intervention are difficult to make. For example, for the primary outcome, the difference 
between the two groups in terms of mean body fat percentage at baseline was 3.1%. 
Body fat percentage changed by no more than 0.7% in either group drawing the trial, 
a much smaller amount than the difference between the two groups. This may explain 
the differences observed by the interaction analysis which found no significant change 
over time and the sensitivity analysis which did find a significant change in the 
intervention group. It appears the randomisation procedure failed to achieve balanced 
placebo control and intervention groups for anthropometric measures. Participants 
were randomised according to age and BMI. It may have been more appropriate to 
randomise the groups via the primary outcome measure of body adiposity.  
For an investigation concerning the effects of changes in body fat the trial was 
relatively short. Changes in body composition take a long time and a particular 
problem for weight loss research is weight regain tends to occur in the years following 
the completion of the intervention (Strohacker et al., 2013). There is some evidence 
the weight loss benefits of capsaicinoids become lessened over time with regular 
consumption (Ludy and Mattes, 2011a), although this effect has not been observed in 
all studies, notably a number investigations in Asian populations who were already 
regular consumer prior to the trials (Yoshioka et al., 1995, Yoshioka et al., 1998, 
Yoshioka et al., 2004). The overall result would have been more informative and 
robust, if it had occurred over a longer period of time. Particularly advantageous would 
information about the effect on body weight, for which a longer trial would be required. 
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This was however, a pilot study with limitations on time and finance and the 
intervention was long enough to observe a statistically significant change in body fat. 
The study utilised a parallel design as opposed to a crossover, where participants 
undergo both placebo control and intervention conditions. Parallel studies have the 
advantage of having a higher statistical power, due to more measurements being 
taken with the same number of participants, therefore are more likely to make accurate 
observations. However, the main drawback is the requirement for a washout period 
where the effects of the intervention leave the body before participants begin the next 
condition. Although a relatively short washout period would be required before 
capsaicinoids would be undetectable in the blood, their potential effect on body 
composition may last much longer. In was determine therefore that due to potential 
changes in body composition and their long lasting effect on the human body, a parallel 
design where participants only undergo one condition would be the most suitable 
design to test the hypothesis. 
The research was carried out in participants who had a BMI of 20 and above, therefore 
it involved both normal weight and overweight participants (BMI ranged from 20.12 – 
41.41kg/m2). As an investigation into capsaicinoids’ potential effects for aiding loss of 
fat, the principal population group that capsaicinoids would be aimed at would be 
overweight persons. Therefore, the result of the trial may would have been more 
informative about capsaicinoids’ effect in this population group had the research 
population only contained overweight participants. Those of a normal weight were 
included in the research to aid recruitment and ensure an adequate number of 
participants were recruited to meet the a priori statistical power calculation. 
The research was only carried out in female participants, therefore it is not clear if 
similar results would be observed in males. Other research trials in this area have used 
female only (Yoshioka et al., 1999), male only (Yoshioka et al., 2004) and mixed 
gender population groups (Janssens et al., 2014) in their investigations and there has 
been no apparent pattern of gender difference. It is likely therefore that the results 
found in the present study would be applicable to both males and females. An all-
female population group was chosen to limit potential confounders in the observations 
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made as a result of the intervention, but leaves open the possibility that the effect may 
be different in differing genders. 
With an all-female population group, effects of the menstrual cycle on the observed 
measurements need to be considered. Prior research has found that the menstrual 
cycle can have an impact on energy intake and potentially the weight of participants 
during intervention trials (Buffenstein et al., 1995). Typical menstrual cycles are round 
28 days (Singh et al., 2008), therefore during the six-week intervention period, 
participants may have been through different stages of their menstrual cycles and this 
may have had an impact on food intake, potentially this may have introduced some 
bias into the trial. The robustness of the observations may have been improved having 
an eight-week intervention, ensuring the majority of participants passed through two 
complete cycles and minimising any potential impact on the results. 
The research was only carried out in Caucasian participants, therefore it is not obvious 
from this trial whether the result could be repeated in other population groups. Habitual 
dietary intake of capsaicinoids varies greatly around the world, with a large difference 
between Caucasian and Asian populations (López-Carrillo et al., 2003). Whether 
habitual intake may have an effect on capsaicinoids’ action is unclear, although there 
is some evidence of genetic adaptations among Asian populations to green tea (Hursel 
and Westerterp-Plantenga, 2010), another food commonly consumed in Asia, but less 
so amongst Caucasians, therefore it is a possibility. This population group was chosen 
to limit potential confounders in the observations made as a result of the intervention, 
but leaves open the possibility that the effect may be different in differing ethnic groups. 
There was a reliance on self-reporting for some aspects of the study; notably historical 
recall, especially changes in weight, reporting of restrained eating tendencies (using 
the three factor eating questionnaire) and during the trial, in particularly food and 
supplement diaries. Although not ideal, historical screening for changes in weight and 
eating habits, using questionnaires, does provide a way to assess these measures in 
a simple and time efficient manner; it does however leave open the possibility of 
recruitment of participants who may not be suitable.  
Participants were not included in the trial if their weight had fluctuated more than 3kg 
in the past six months. However, as it was self-reported it assumes that participants 
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are regularly monitoring their weight prior to commencement of the trial, which may 
not be the case for everyone. Indeed, only three of the 84 participants who entered 
the screening process reported a change in weight of more than 3kg in the past six 
months. An improvement to the study design would have been to have a lead-in period 
in which to measure participants’ weight several weeks before commencement of the 
intervention and excluding those with a large change at baseline; although this would 
make the trial longer and costlier to run. In terms of actual fluctuations during the trial, 
as a group the participant population did remain relatively weight stable throughout the 
trial; with the mean of both placebo control and intervention groups not fluctuating by 
more than 0.4kg, suggesting the study population was relatively weight stable. 
Adherence of supplement taking was also self-reported, using supplement diaries, 
which were chosen as a simple and cost effective way of monitoring. It is possible to 
use more accurate measure such as pill bottles with digital lids, that record whenever 
they are opened (Dang, 2012), unfortunately these were beyond the budget for the 
trial. Another method to monitor compliance would be to monitor blood or urine levels 
of capsaicinoids. Research capsaicinoids have a short life in the blood stream, before 
being broken down (Weerapan, 2009) so it is not clear if this would be easy to detect. 
Research from animals has found capsaicinoids detectable in urine (Kawada et al., 
1984), so this may potentially be an improved methodology. 
Self-reported adherence of supplement taking was high at over 97%; this is much 
higher than has been reported in a review of compliance rates for prescription 
medicine involving 76 healthcare studies, which observed rates of 51% - 79% (Schmitz 
et al., 2005), with forgetfulness is generally sited as the major cause of failure to 
comply (Vervloet et al., 2012). A high compliance rate is crucial for any trial to 
successfully assess an intervention and a weakness of the present study is reliance 
on participant self-reporting. 
Self-reporting was also used to monitor food intake during the trial; via 3-day food 
diaries, recorded weekly. The use of self-reported food diaries in other research trials 
have been shown to have a degree of unreliability, particularly under-reporting of 
energy intake (Ambrosini et al., 2009); accuracy may be compromised due to recall 
problems or social desirability bias (i.e., misreporting on sensitive or embarrassing 
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behaviours to appear more favourable) (Leatherdale and Laxer, 2013). Therefore, the 
accuracy of reporting of food intake in the present study is uncertain. Self-recorded 
food diaries were also not accurate enough to test the potential effects of capsaicinoids 
on energy intake. Although changes in energy intake have been observed in several 
trials due to capsaicinoid interventions, the changes are too small to be reliably 
observed via food diaries, so this could not be assessed during this intervention. 
In order to accurately test the effects of the intervention, participants were asked to 
maintain their current diet and exercise regime during the trial. Assuming participants 
were weight stable prior to commencement of the intervention and that they did not 
change either their dietary or exercise habits, any changes observed changes in body 
composition could be attributed to the intervention. Unfortunately, there was no cost 
effective way for this variable to be controlled for during the present trial. Other 
research studies, similar to the present one, have tried to control for energy intake by 
supplying participants with food throughout the trial (Yang et al., 2012). While this 
would certainly have produced a more reliable way of controlling energy intake, it was 
unfortunately outside the scope of the finances for this investigation. A weakness of 
this research therefore, is reliance on participants’ complying with the request to 
maintain their normal diet and exercise regime. 
Although it is common for dietary trials to ask participants to maintain their normal diet 
during a research trial, it’s possible that these instructions may have impacted the 
energy intake figures for the trial. Participants potentially may have followed their 
regular eating habits to comply with the instructions rather than following their hunger. 
Therefore, the potential energy intake reducing effect of capsaicinoids may have been 
negated. The instructions to maintain a normal diet were however chosen as the act 
of keeping a food diary can have a significant impact on dietary intake by itself 
(Neuhouser et al., 2008) and may have introduced bias into the results of the trial if 
the instruction to maintain normal dietary habits was not given. 
The trial used bio-electrical impedance as the main measure of changes in 
participants’ body composition during the trial. However, the accuracy of bio-electrical 
impedance has been questioned in some studies due to its reliance on population-
specific equations to calculate body composition (Böhm and Heitmann, 2013); this is 
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thought to most likely to problematic in obese persons, whose body fat distribution 
may vary significantly from norms (Pimentel et al., 2010). Therefore, it could be argued 
that use of a more reliable method of measuring body composition would have 
produced a more accurate result in the present study; especially as observed changes 
in body composition were small. In addition, use of dual energy X-ray absorptiometry 
would also have provided information concerning distribution of body fat. Bio-electrical 
impedance was chosen as it is relatively quick and non-invasive compared to other 
ways of measuring (such as air displacement plethysmography or dual energy X-ray 
absorptiometry), which may have helped improve participant recruitment and 
retention. Facilities for the use of this method were also readily available at the 
university’s physiology laboratory.  
A methodological improvement that may have aided the accuracy of the 
measurements would have been to asked participants to urinate prior to 
measurements, to ensure a more consistent level of water in the body during the 
measurements. Hydration levels can affect bio-electrical impedance readings (Sun et 
al., 2005) and therefore may have impacted upon observations from the trial. 
Measurements were taken first thing in the morning after an overnight food and liquid 
fast, but asking participants to urinate prior to the measurements may have aided 
accuracy. 
During the trial a number of different anthropometric measurements were recorded (in 
the case of weight, hip and waist circumference and body fat level) and calculated (in 
the case of BMI, BAI and hip/waist ratio). Although measurements of participants’ body 
fat percentage and total body fat showed a statistically significant change, this was not 
reflected in the other anthropometric measurements. If this was the case it would have 
added more weight to the hypothesis that capsaicinoid supplementation can cause a 
beneficial change in body composition. It could be argued therefore that this is 
increases the probability that the observed change was due to chance, rather than the 
intervention. However, the observed change in body adiposity was small and the other 
the other anthropometric measures may not have been sensitive enough to detect this 
change. Waist and hip measurements are reliant on human measuring consistency 
and subject to relatively large natural fluctuations (Bosy-Westphal et al., 2010) and the 
calculated indicators, BAI and hip/waist ratio, are also reliant on these measures. 
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Overall the results of the trail suggest capsaicinoids interventions could have the 
potential to aid weight management outcomes. Results from this research study 
suggest that supplementation with capsaicinoids may produce a small decrease in 
body fat when ingested for six weeks. This decrease is probably too small to provide 
any immediate health benefit and supplementation would need to continue for longer 
periods and to be done in conjunction with diet and exercise interventions. 
5.3 Thesis Discussion 
5.3.1 Introduction 
This research project was intended to assess the potential impact that capsaicinoids 
could have on weight management outcomes. Specifically, to perform a systematic 
literature search of human intervention trials investigating the effects on weight 
management outcomes and to collate and analyse findings into a review paper. 
Following this it was found there was conflicting data as to capsaicinoids effect on 
energy intake and a meta-analysis summarising the results of intervention trials in this 
area was undertaken. In addition, despite there being numerous short-term 
intervention trials with promising results, there had also been a lack of longer-term 
intervention trials investigating capsaicinoids potential effect on body composition. 
Therefore, a double-blind, placebo controlled intervention study to investigate the 
effects of capsaicinoids on body fat was undertaken. This section will review the main 
findings of the thesis, what conclusions can be drawn from this research and 
recommendations for future research will also be discussed. Findings will also be 
critically examined in light of previous research around this subject. 
5.3.2 Current Obesity Treatments 
There is currently a lack of viable options for the treatment of obesity. Intensive lifestyle 
interventions, consisting of dietary restriction and physical activity/exercise 
accompanied with behaviour therapy have proven to be largely ineffective (Mann et 
al., 2007). Even with longer term interventions (six months and over), once the 
intervention period finishes compliance with improved lifestyle is poor. The result is 
generally a transient phase of weight loss followed by a return on the trajectory towards 
obesity (Kushner, 2013). Anti-obesity drug development programmes have been 
littered with false starts, failures in clinical development, and withdrawals due to 
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adverse effects that were not fully appreciated at the time of launch (Rodgers et al., 
2012). As a result current options for treatment are particularly limited, particularly in 
Europe where only Orlistat is available to prescribe and few people stick with taking it 
over the long term. Most forms of bariatric surgery have a relatively rapid and 
substantial beneficial effect on  weight loss and health markers such as 
hyperglycaemia (Buchwald et al., 2009). However, the risk of side effects with bariatric 
surgery are substantially higher than all other medical treatments, with some 
researchers suggesting that if it were a medical treatment rather than a surgical one, 
it would by now have been halted by regulatory authorities, probably subject to 
appropriate controlled trials (Pinkney, 2011). The majority of surgeries are also carried 
out on severely obese patients (BMI > 45) and it is not clear that the same benefits 
experienced by this population would occur in those with less severe obesity (Pinkney, 
2011).  
There is therefore, currently a lack of successful obesity treatments. New approaches 
to aid weight and fat loss and prevent weight regain are therefore desirable. Due to 
the lack of success of pharmacological agents in providing a clear physiological benefit 
at an acceptable level of side effects, there is potential for naturally occurring bio-active 
ingredients that can produce positive effects on thermogenesis, fat oxidation and 
appetite to aid this process. Such compounds may be able to provide such an effect 
without the long-term problems (particularly on cardiovascular risk factors) associated 
with previously developed pharmacological agents (Yuliana et al., 2014). One such 
compound may be capsaicinoids, a compound naturally occurring in chillies (Whiting 
et al., 2012). 
5.3.3 Capsaicinoids 
Intervention trials evaluating the effects of capsaicinoids and their sister compounds 
capsinoids on weight loss outcomes suggest there may be an effect on 3 areas: 
increased energy expenditure, increased lipid oxidation and decreased energy intake. 
The results suggest that the effects are relatively modest, with figures of an increase 
in energy expenditure of around 50 kcal/day (Snitker et al., 2009, Galgani and 
Ravussin, 2010) and increase in lipid oxidation of around 20% (Lejeune et al., 2003) 
and a decrease in energy intake. Caution is however, required in interpreting these 
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results due to a number of reasons. Firstly, the majority of the research studies have 
been small scale intervention trials, with a low number of participants. This increases 
the likelihood of type 1 errors (finding an effect when there is not one) and type 2 errors 
(failing to find an effect when there is one) and are a major drawback of this area of 
research, with even the largest intervention trial having only 91 participants. 
There are a number of ways in capsaicinoids and capsinoids may be providing a 
beneficial effect to weight loss management outcomes. Perhaps the most studied and 
well-established of these is the pathway through which energy expenditure is 
increased, via stimulation of the TRPV1 receptor and the resulting effect on 
catecholamine release signalling to adrenoceptors, which stimulate the SNS and 
cause uncoupling protein regulation resulting in enhanced energy expenditure 
(through thermogenesis), with BAT potentially playing a crucial role in this process. 
Research suggests capsaicinoids may also increase fat oxidation, with a number of 
potential mechanisms of this were outlined, namely SNS stimulation/catecholamine 
release, cellular TRPV1 stimulation, an effect on adipose tissue enzymes and protein 
expression and finally neuron stimulation. Less well established has been 
capsaicinoids potential effect on energy intake, which may be reduced following 
ingestion. This may be caused by capsaicinoids affecting intestinally derived satiety 
hormones, influencing certain areas of the brain, SNS stimulation, and increases in 
lipid oxidation. The effect on energy intake are less well established from intervention 
trial and therefore further investigation into these effects is warranted. To assess this 
further a meta-analysis into these effects was carried out. 
5.3.4 Meta-Analysis into Capsaicinoids Effect on Energy Intake 
The literature search carried out for the purposes of the meta-analysis suggest there 
has been 10 intervention trials carried out over the last 16 years investigating the 
effects of capsaicinoids on energy intake. However, results have been contradictory, 
with some trials observing a statistically significant effect (Westerterp-Plantenga et al., 
2005) and others no effect (Smeets and Westerterp-Plantenga, 2009). In order to 
provide further evidence for the hypothesis that capsaicinoids may affect energy 
intake, a meta-analysis of intervention trials was undertaken. 
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Results from the meta-analysis into the effects of capsaicinoids on energy intake 
suggest there is a possibility they could play a role in weight management alongside 
exercise and other dietary measures. The combined effect size showed that 
consuming capsaicinoids caused a significant reduction in ad libitum energy intake of 
251kJ (60kcal) per meal (see figure 3.2, for the forest plot), under the random effects 
model, with a 95% confidence interval of 337 – 166kJ and p < 0.001. The analysis 
indicated low heterogeneity, I2 = 6.6%. Results, however should be viewed with some 
caution as analysis indicates there was publication bias (p=0.007). 
The results also suggest a dosage of a least 2mg of capsaicinoids is needed to 
produce an effect and that a reduction in energy intake may be the result of a 
preference for carbohydrate rich foods over fat rich foods. If the calculated reduction 
in energy intake (309.9kJ) was repeated on daily basis, weight loss modelling (Hall 
and Jordan, 2008) predicts the observed weight loss would be 5.3kg. After this the 
body’s reduced calorie demands would result in weight maintenance (calculation 
based on sedentary male, 40 years of age, weighing 100kg). However, it should be 
noted such weight loss would take several years to achieve. The extent of the effect 
on energy intake is relatively small and therefore long term intake is likely to be 
required to produce a beneficial effect on weight management outcomes. Combined 
with capsaicinoids’ effect on energy intake and lipid oxidation observed in other 
research (Ludy et al., 2012, Whiting et al., 2012) it maybe that capsaicinoids could 
produce a beneficial effect on body composition, especially body fat with a longer-term 
intervention. However, there had prior to this thesis been a lack of multi-week 
capsaicinoid interventions to investigate this hypothesis. To investigate the potential 
of capsaicinoids on body fat and other weight management outcomes further, an 
intervention trial was carried out. 
5.3.5 Intervention Trial: Capsaicinoids and Body Fat in Caucasian Women 
Reducing body fat mass is usually a key aim of diet and physical activity changes 
individuals undertake to as part of weight loss programs, although few capsaicinoid 
trials have assessed the potential effects. To the knowledge of the author, only two 
trials have assessed changes in body composition following a multi-week intervention 
with capsaicinoids (Lejeune et al., 2003, Ahuja et al., 2007). Change in body fat was 
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not the primary outcome in either study however and the research methodology of 
both trials means assessing change in body fat is difficult (see section 6.1.2 for more 
details). There have been around 30 trials, based around single dose interventions 
that have investigated the effects of capsaicinoids and capsinoids on energy 
expenditure, lipid oxidation and appetite. While findings from these trials are 
informative, to assess changes in body fat, longer-term trials are required. The present 
intervention trial was undertaken to test the hypothesis that capsaicinoids’ effect 
energy expenditure, lipid oxidation and appetite could lead to a significant change in 
body fat with longer-term intervention. 
Results from this research study suggest that supplementation with capsaicinoids may 
produce a small effect on body composition when ingested for six weeks, participants’ 
body fat percentage and total body fat decreased by 0.64% and 0.67kg respectively. 
However, the robustness of this finding is called into question by the result of the 
interaction analysis which found no significant difference between the two groups over 
time for body adiposity. This decrease is also probably too small to provide any 
immediate health benefit. Therefore, supplementation would need to continue for a 
longer period and be done in conjunction with diet and exercise interventions. Typical 
targets for a health benefit from weight loss intervention are a reduction of 5-10% 
(Moyer, 2012), although there are no generally accepted targets for reductions in 
adipose tissue. There was no evidence of a statistically significant effect on body 
weight, following the supplementation period; however, excess adipose tissue 
storage, particularly for an extended period of time is a major health issue and 
reduction in levels could provide a powerful health benefit without weight reduction 
(Virtue and Vidal-Puig, 2010).  
Reduction in white adipose tissue could provide a substantial health benefit to 
individuals, particularly those suffering from obesity. During recent years, research has 
found adipose tissue is an active endocrine organ that secretes more than 600 
bioactive factors (Lehr et al., 2012). Of particular importance are adipokines (cell 
signalling proteins) play an important role in the regulation of appetite and satiety 
control, fat distribution and energy expenditure (Van Gaal et al., 2006). Altered 
adipokine secretion due to elevated adipose tissue levels has been associated with 
increased metabolic and cardiovascular obesity-related disorders (Blüher, 2013). 
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Reduction in adipose tissue levels should therefore be a key aim of obesity treatment 
and results from this trial suggest capsaicinoid supplementation may provide a benefit 
to individuals in aiding adipose tissue reduction.  
Whether capsaicinoids can be of benefit in terms of actual body weight reduction is 
unclear from this research. There is some debate as to whether the types energy 
imbalance that capsaicinoids have been observed to cause (50-75kcal/day), could 
lead to long-term weight loss. It has been argued that the general increase in body 
weight observed in the United States over the past 3–4 decades, may have been 
triggered by a persistent positive energy imbalance of as little as 50 kcal/day (Hill, 
2006). However, others have argued that 50kcal/day is just within the range of natural 
metabolic variability and would have minimal effect on weight loss over the long-term 
(Butte and Ellis, 2003). What is clear is that this trial was not long enough to definitively 
answer if capsaicinoid supplementation could lead to weight loss, and that a longer 
term trial of 1-2 years would be necessary to answer this question. 
Also observed was a statistically significant reduction in mean fasting blood cholesterol 
levels of around 10%. Results of capsaicin interventions in animal models have been 
mixed (Zhang et al., 2013) and the one trial measuring effects of capsaicinoids in 
humans observed no effect following a four-week intervention diet (Ahuja et al., 2007). 
However the results observed in this trial raise the possibility that capsaicinoids may 
have a cholesterol lowering effect in humans, which is potentially of benefit to 
cardiovascular health (Goldstein and Brown, 2015), however further research is 
required to investigate this possibility further.  
5.4 Conclusions 
As stated in detail in section 2.5, obesity is a worldwide problem that threatens both 
the health of many individuals and the finances of many health services and 
economies (Wang et al., 2011). Levels may have peaked in certain developed 
economies, but are still growing in many parts of the world (Swinburn et al., 2011). As 
mentioned previously, treatment options are currently limited and either relatively 
unsuccessful (lifestyle modifications) or have serious side effects that may outweigh 
any benefit (pharmaceutical treatments and bariatric surgery). There is a strong need 
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for new treatment alternatives to be developed to work alongside current options and 
several bio-active compounds have shown initial promise in this area. However their 
development into potential weight loss and weight maintenance aids is unattractive for 
pharmaceutical companies; as natural occurring compounds they are not patentable 
and therefore they are not commercially viable for development and testing. The aim 
of this work therefore, was to look in detail at the potential for capsaicinoids to be used 
in this manner (see table 7.1 for the main aims and the resulting outcomes of the 
research project). 
The present thesis found that a six-week capsaicinoid intervention could cause a 
significant reduction in body fat. However, the robustness of this finding was called 
into question by the results of the interaction analysis, which failed to find a significant 
difference between the placebo control and intervention groups over time. In addition, 
the reduction was small, and unlikely to be of significant clinical benefit for an 
individual’s health. There was no evidence of a decrease in body weight following a 
six-week capsaicinoid intervention. For capsaicinoids to be of benefit in a real world 
setting, therefore a longer-term intervention period would be required, as effects are 
small and would need to slowly accumulate. 
Capsaicinoid may also be have the potential to be of assistance in maintaining weight 
losses; long-term regain is a major issue for current obesity treatments. It has been 
established that in response to reduced calorific intake and weight loss, there is an 
accompanying decrease in energy expenditure, which is in part due to loss of lean 
body mass, and in part due to an enhanced metabolic efficiency (Major et al., 2007). 
Such reductions in thermogenesis may also persist well beyond the phase of weight 
loss (Rosenbaum et al., 2008) may make a significant contribution to weight regain 
and obesity relapse (Rosenbaum et al., 2008). Capsaicinoids potential to cause small 
increases in energy expenditure and fat oxidation, along with small decreases in 
energy intake may make them a suitable to aid the prevention of weight regain in 
individuals following calorie induced weight loss. 
It is also likely that for meaningful weight management benefits, these compounds will 
need to be consumed as a supplement, rather than as a food, so individuals could 
adhere to the long-term intake required. Capsaicinoids have a pungent sensation 
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when eaten that many people find unpleasant and would stop them from regular 
consumption, which is likely to limit adherence to necessary ingestion rates. Therefore, 
supplementation may present the most realistic option for the long-term intake 
required to see a clinically significant benefit. Capsaicinoids, at the level used in this 
research, appear to be safe and were well tolerated, with minimal side effects for most 
participants. Suggesting they have the potential to be suitable for long-term 
supplementation, although further research is required. Capsinoids do not have the 
same pungency in the mouth and gastro-intestinal tract and may be of benefit to those 
who find consumption of capsaicinoids problematic. Overall there is promise in this 
area of research that capsaicinoids and capsinoids, may be a benefit for those looking 
to lose weight and to those looking to maintain losses already achieved.  
Table 5.1 The main aims and outcomes of the research project 
Aim Date 
Performed 
Key Findings Outcome 
Systematic literature 
search of human 
intervention trials 
investigating the effects 
of capsaicinoids and 
capsinoids on weight 
management outcomes 
Initially: 
07.10.2011  
Updated: 
14.10.2011 
20 intervention trials into 
capsaicinoids and 
capsinoids effect on 
weight management 
outcomes in humans 
carried out since 1995 
n/a 
Collate and analyse 
findings of literature 
search and review their 
outcomes 
07.2011 – 
12.2011 
50kcal/day increase in 
energy intake, a 20% 
increase in lipid oxidation 
and a decrease in energy 
intake. 
Publication 
in Journal 
“Appetite” 
(see 
appendix 3) 
Undertake a meta-
analysis of the results of 
intervention trials 
measuring the effects of 
capsaicinoids on energy 
intake 
01.2012 – 
06.2013 
A reduction in ad-libitum 
energy intake of 309.9kJ 
(74.0kcal) per meal, 95% 
confidence interval of 
481.5 – 138.3kJ (115.0 – 
33.0kcal) and p < 0.001 
Publication 
in Journal 
“Appetite” 
(see 
appendix 3) 
Undertake a double-blind, 
placebo controlled 
intervention trial to 
investigate the effects of 
capsaicinoids on body 
weight and composition 
in human subjects 
02.2014-
02.2016 
A reduction in body fat 
percentage of 0.64% (p = 
0.022) and in total body 
fat of 0.67kg (p = 0.007) 
after six weeks of 
capsaicinoids 
supplementation. No 
significant change in body 
weight observed. 
Awaiting 
submission 
to journal 
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5.5 Recommendations for Further Work Based on this Research 
There are a number of considerations to account for in the planning of future research 
in this area. Particularly informative in terms of the effect of capsaicinoids and 
capsinoids would be a long-term supplementation trial, lasting six months or longer. 
The nature of weight loss research necessitates long time periods of intervention as 
changes take time and there is a need for effects to be continued for the long term if 
interventions are to be effective. Also, despite much research in this area, observing 
changes in energy expenditure, lipid oxidation, energy intake and changes in body 
composition, no investigation has observed capsaicinoids or capsinoids aiding 
reductions in body weight. Any potential effect on weight loss appears to be small and 
trials have not been of sufficient length to conclude either affirmatively or negatively to 
this hypothesis. 
It may be that if capsaicinoids or capsinoids were to be of benefit their effect would be 
best used in combination with other bio-active ingredients. Studies have investigated 
the effects of a number of other bio-active food compounds that may be of benefit to 
weight loss; in particular there are bodies of evidence for the effects of caffeine (Hursel 
and Westerterp-Plantenga, 2010) and catechins found in green tea (Phung et al., 
2010). Bio-active ingredients have also been beneficially combined with other food 
ingredients such as inulin (Yang et al., 2012) and protein (Smeets et al., 2013). In 
addition to this, synergistic effects are sometimes observed when ingredients are 
combined and investigated (Shen et al., 2010, Zemel et al., 2004), which may occur 
in this instance. Generally, research involving multiple ingredient weight loss 
supplements including capsaicinoids or capsinoid has found a stronger effect than 
alone, however it is not clear if these ingredients are working synergistically. If a long-
term trial weight loss trial was conducted in this area, with the financial investment that 
it would entail, it may be the best use of resources to investigate a multi-ingredient 
supplement. 
The effect of capsaicinoids and capsinoids of differing ethnicities is also of interest. 
There are conflicting reports that there may be differing effects in differing ethnicities 
due to genetic adaptations that may have occurred over time (Hursel and Westerterp-
Plantenga, 2010, Whiting et al., 2014). This is also a potential issue because of very 
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variable habitable dietary consumption rates of capsaicinoids in differing countries, 
ethnic groups and even within populations (Mattes, 2012). In addition to this, 
participants used for research trials have been either predominately Asian or 
Caucasian, meaning there is a particular lack of investigations in black populations. 
This may be an issue to be addressed in future research and should certainly be a 
consideration in planning. 
There is evidence to suggest capsinoids may have a re-modelling effect on adipose 
tissue, turning stores of potentially harmful white adipose tissue into more beneficial 
brown or ‘beige’ adipose tissue (Yoneshiro et al., 2013). The functioning of adipose 
tissue is a relatively new area of research, with much still to be learnt. However initial 
investigations reveal some promise that harmful tissue can be altered in a beneficial 
way for health without major reductions in weight or body fat (Sun et al., 2011). 
Capsaicinoids and capsinoids may be compounds that can aid this process, and this 
promises to be an interesting area for future obesity research. 
Also of potential interest would whether capsaicinoids and capsinoids can be of benefit 
when used with other lifestyle modifications to aid weight loss and/or maintenance. 
Changes to diet and physical activity combined with behaviour therapy typically 
produces weight loss in the region of 5-7% when applied for a relatively long period of 
time (e.g. six months) (Unick et al., 2011); however, as stated previously, weight regain 
is often an issue in this area (Strohacker et al., 2013). It would therefore be informative 
for the use of capsaicinoids and capsinoids in a non-research setting whether they can 
provide benefit by increasing initial body weight reductions and aiding maintenance of 
new weight level over the longer-term. 
Following the observation that six weeks of capsaicinoid supplementation reduced 
fasting blood cholesterol, further research in this area is warranted. Previous research 
in animal models has observed mixed results (Zhang et al., 2013, Srinivasan and 
Chandrasekhara, 1992) an no statistically significant was observed in the only 
previous invention trial in humans (Ahuja et al., 2007). Of particular interest would be 
an investigation into capsaicinoids potential effect in those with elevated blood 
cholesterol and at increased risk of cardiovascular related health issues, as all 
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participants in this research had levels considered within the healthy range of values 
(Truswell, 2010).  
Finally, in capsaicinoid and capsinoid weight loss trials, numerous differing dosages 
have been used; ranging from 0.4mg to 135mg/day (Lejeune et al., 2003, Reinbach et 
al., 2010). This is a large variation and is of concern particularly for the use of 
capsaicinoids, as they have a strong pungency and dosages that are too high may 
cause reductions in compliance. Meta-analysis work suggest effects occur and 
medium to high dosage levels (Ludy et al., 2012, Whiting et al., 2014), however while 
informative, this is far from conclusive. Choosing the correct dosage level is of vital 
importance and more research into the effects at different quantities would aid this. 
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Information Sheet 
Study Title: The effects of Chilli Capsaicinoids on Weight Loss Markers in Females 
Introduction 
Research suggests capsaicinoids (found in chillies) may help people who are trying to lose 
weight and we wish to see the effects on people’s body composition when they consume 
capsaicinoids over a period of time. You are being invited to take part in this study, but 
before you agree it’s important you understand what it will involve for you.  
What exactly will be happen if I take part in the study?   
Pre-study screening questionnaire – After reading this form if you are interested in 
taking part you will ask you to complete a questionnaire. Participants for this study 
must be female, aged 18-45 years, without any medical conditions that can affect body 
weight, metabolism or digestion; pre-menopausal and not pregnant. 
Consent – If you meet the inclusion criteria and would like to take part you must 
complete a consent form; however, you are free to withdraw at any time. 
Which group? – To compare the results of our study some people will take a 
capsaicinoid supplement and some will take a placebo supplement (containing no 
active ingredients). To make sure the groups are the same you will be put into a group 
by chance (randomly). This will be a double blind trial so neither you nor the 
researchers will know which group you are in. 
Measurements and blood samples – For this trial we will need to take a number of 
your measurements; this will include you’re: Height, Weight, Waist and hip 
circumference, percentage body fat and a blood sample (done with a finger prick). 
These measurements and blood samples will be taken at the start, after 3 and 6 weeks 
of daily supplementation then one last time 3 weeks later.  
Location - We would need you to come to Manchester Metropolitan University’s 
physiology lab in the Hollings building (room C.G.29) on the All Saints campus on at 
the beginning of the study, after three weeks, six weeks and after eight weeks, so we 
could perform these measurements. 
Supplements – You will be given six weeks’ worth of supplements at the start of the 
trial; you will need to take two supplements a day. 
Food and compliance diaries – You will be asked record what food and drinks you 
have consumed for three days of each week of the trial and complete a diary confirm 
you took the supplement each day. 
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What risks will I face in this study? 
Capsaicinoids are a natural substance and in previous use of them in research the 
only reported side-effects was mild discomfort of the digestive system, although this 
only occurred at a higher dosage than the one being used in this trial.  
Do I have to change my diet for the study? 
We would like to maintain your normal diet and exercise habits throughout the study. 
How can I benefit if I take part in this study?  How could others benefit? 
Benefits may include losing weight or body fat; however, we cannot promise that you will 
experience any benefits from participating in this study. We hope the information learned 
from this study will benefit others in the future. 
If I wish to stop taking part in this study, what should I do?  
You are free to leave the study at any time. If you are thinking of leaving the study, 
please contact Stephen Whiting (stephenjohnwhiting@gmail.com).  
If I join this study, will it cost me anything?  
You do not have to pay anything to be in this study. However, taking part in this study 
may lead to added costs for you such as travel expenses to the University.   
How will my privacy be protected? 
We take your confidentiality very seriously; your personal information will not be made 
public or shared with anyone and will be kept in accordance with the 1998 Data 
Protection Act. We are hoping to publish the results of the trial in a scientific journal, 
however all results will be published anonymously. 
Who can I contact about this study? 
If you have any questions or concerns before, during or after the study please contact 
Stephen Whiting at stephenjohnwhiting@gmail.com. 
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Consent Form 
Please answer yes/no 
Have you read the information sheet? 
Do you understand what the project is about?  
Have you asked all the questions you need too?  
Have all your questions been answered?  
Are you aware you will need to take a supplement every day?  
Are you aware that 4 blood samples will be taken and analysed?  
Are you aware a number of body measurements will be taken?  
Are you aware you will be asked to complete a weekly food diary? 
Are you aware you will be asked to complete a supplement diary? 
Can you confirm you are not pregnant?  
Do you understand that it is OK to stop taking part at any time? 
Are you willing to take part? 
 
Name of participant        Date    Signature 
 
Name of researcher        Date    Signature 
ID No: 
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Screening Questionnaire 
Part 1 
Name  
 
Age  
 
Please state your ethnicity  
(please circle or delete as 
appropriate) 
White                                   Mixed Race 
Asian/Asian British              Black/Black 
British 
Arab/Middle Eastern            Other 
 
How would you describe your 
activity level at work? 
(please circle or delete) 
Active                                    Moderately 
active  
Moderately sedentary                       
Sedentary 
 
How would you describe your 
activity level outside of work? 
(please circle or delete) 
Active                                    Moderately 
active  
Moderately sedentary                       
Sedentary 
 
Please state your income level £0 - £15,000  
ID No: 
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(please circle or delete as 
appropriate) 
£15,000 - £25,000  
£25,000 - £50,000 
£50,000 - £100,000 
£100,000+ 
 
Please state your occupation  
 
Please indicate your alcohol intake 
level.  
(please circle or delete ) 
1 pint of beer is 2 units  
1 large glass of wine is 3 units  
1 measure of spirits is 1 unit  
0-10 units per week  
10-15 units per week 
15-21 units per week 
21-29 units per week 
30+ units per week 
 
 
How many of the following drinks 
do you drink a day? 
(please state a number) 
Tea:  
Coffee: 
Caffeinated soft drinks (such as coke): 
Energy drinks (such as Red Bull): 
 
Are you a smoker?  
(please circle or delete) 
          Yes                                   No 
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Can you confirm you are not 
pregnant or planning to start a 
pregnancy during the course of the 
trial? 
(please circle or delete) 
I not pregnant and have no plans to start a 
pregnancy 
 
I am pregnant or plan to start a pregnancy in 
the next 8 weeks 
 
Can you confirm you have not yet 
started the menopause? 
(please circle or delete) 
           Not started                 Have started 
 
Do you follow a special diet or have 
any specific dietary requirements; 
such as vegetarian or vegan 
(if yes please state) 
           Yes                            No 
 
Have you lost of gained a large 
amount of weight in the last 6 
months? 
(If yes, please give details) 
           Yes                            No 
 
Do you regularly take any 
supplements?  
(if yes please list) 
           Yes                            No 
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Do you take any medication that 
may affect your weight such as 
Corticosteroids or Paxil? 
(if yes please list) 
           Yes                            No 
 
Do you suffer from any medical 
conditions that can affect your body 
weight, metabolism or digestion; 
such as Crohn’s or coeliac 
disease? 
           Yes                            No 
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Part 2 
Please answer these questions by circling Y or N or delete as 
appropriate 
I usually eat too much at social occasions, like parties and 
picnics 
Y N 
Dieting is so hard for me because I just get too hungry Y N 
I deliberately take small helpings as a means of controlling my 
weight 
Y N 
Sometimes things just taste so good that I keep on eating even 
when I am no longer hungry 
Y N 
When I feel anxious, I find myself eating Y N 
Life is too short to worry about dieting Y N 
I often feel so hungry that I just have to eat something Y N 
It is not difficult for me to leave something on my plate Y N 
When I am with someone who is overeating, I usually overeat 
too 
Y N 
While on a diet, if I eat food that is not allowed, I consciously 
eat less for a period of time to make up for it 
Y N 
When I feel unhappy, I often overeat Y N 
I enjoy eating too much to spoil it by counting calories or 
watching my weight 
Y N 
My weight has hardly changed at all in the last ten years Y N 
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I am always hungry so it is hard for me to stop eating before I 
finish the food on my plate 
Y N 
When I feel lonely, I console myself by eating Y N 
I eat anything I want, any time I want Y N 
I count calories as a conscious means of controlling my weight Y N 
I do not eat some foods because they make me fat Y N 
I am always hungry enough to eat at any time Y N 
While on a diet, if I eat a food that is not allowed, I often then 
splurge and - eat other high calorie foods 
Y N 
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Food Diary 
Please record all the food and drinks you have consumed for 3 days (2 
weekdays and one weekend day), in the space that follows. Please 
include as much detail as possible, including: 
1. Approximate time of eating or drinking  
2. Quantity or amount eaten e.g. 6 tablespoons, 1 cup, 1 thick slice, etc.  
3. Type of food, e.g. orange juice, chocolate, chicken breast 
4. Any brands names of products used, e.g. Philadelphia cream cheese, 
Kellogg’s cornflakes cereal etc. 
5. Addition of ingredients during preparation and cooking, e.g. sugar / oil  
6. Any sub-recipes, e.g. for a sandwich may include 2 slices Warburton’s 
medium sliced white bread (buttered), 50g of mature cheddar cheese, 2 
slices wafer thin ham, 3 slices of tomato 
7. Details of all drinks consumed 
8. Please fill in the date at the top of each day you record. 
9. We only need to know what you actually ate. You should not feel 
embarrassed about any food, as there are no "good" or "bad" foods. No 
one eats just the right foods all the time. 
Over the page is an example day has been filled in for you to see. 
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Day 1 – Date: 06.03.2014     ID No: 024 
Time Details of food and 
drink 
Quantity eaten or 
description of size 
8.30am Toast – Hovis white bread 
Margarine 
Robinsons raspberry jam 
White coffee, 1 sugar 
2 thick slices 
Thinly spread 
Thickly spread 
1 mug 
11am Danish pastry – apple flavour 
Tea with milk, 1 sugar 
1 medium 
1.30pm Ham and cheese sandwich: 
30g cheddar cheese, 2 slices 
wafer thin ham, 2 slices Hovis 
white bread (margarine) 
White coffee, 1 sugar 
1 sandwich 
 
 
 
1 mug 
4pm Kit-kat 
Tea with milk 1 sugar 
1 two finger 
1 mug 
7pm Spaghetti Bolognaise, with 
onion, carrot and beef mince 
Orange squash 
1 medium portion 
 
1 medium glass 
9.30pm 
 
 
 
 
Tea with milk, 1 sugar 1 mug 
10pm Kelloggs crunchy nut cornflakes 
Semi-skimmed milk 
1 large bowl 
Any other notes 
e.g. today was representative 
of a typical day, I was unwell 
today etc. 
This was a typical weekday  
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Day 1 – Date:  
Time Details of food and 
drink 
Quantity eaten or 
description of size 
   
   
   
   
   
 
 
 
  
   
Any other notes 
e.g. today was representative 
of a typical day, I was unwell 
today etc. 
  
ID No: 
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 Day 2 – Date:        
Time Details of food and 
drink 
Quantity eaten or 
description of size 
   
   
   
   
   
 
 
 
  
   
Any other notes 
e.g. today was representative 
of a typical day, I was unwell 
today etc. 
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Day 3 – Date:        
Time Details of food and 
drink 
Quantity eaten or 
description of size 
   
   
   
   
   
 
 
 
  
   
Any other notes 
e.g. today was representative 
of a typical day, I was unwell 
today etc. 
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Pill Diary 
1 
Supplement 1 
 
Supplement 2 
2 
Supplement 1 
 
Supplement 2 
3 
Supplement 1 
 
Supplement 2 
4 
Supplement 1 
 
Supplement 2 
5 
Supplement 1 
 
Supplement 2 
6 
Supplement 1 
 
Supplement 2 
7 
Supplement 1 
 
Supplement 2 
8 
Supplement 1 
 
Supplement 2 
9 
Supplement 1 
 
Supplement 2 
10 
Supplement 1 
 
Supplement 2 
11 
Supplement 1 
 
Supplement 2 
12 
Supplement 1 
 
Supplement 2 
13 
Supplement 1 
 
Supplement 2 
14 
Supplement 1 
 
Supplement 2 
15 
Supplement 1 
 
Supplement 2 
16 
Supplement 1 
 
Supplement 2 
17 
Supplement 1 
 
Supplement 2 
18 
Supplement 1 
 
Supplement 2 
19 
Supplement 1 
 
Supplement 2 
20 
Supplement 1 
 
Supplement 2 
21 
Supplement 1 
 
Supplement 2 
22 
Supplement 1 
 
Supplement 2 
23 
Supplement 1 
 
Supplement 2 
24 
Supplement 1 
 
Supplement 2 
25 
Supplement 1 
 
Supplement 2 
 
ID No: Start Date: 
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26 
Supplement 1 
Supplement 2 
27 
Supplement 1 
Supplement 2 
28 
Supplement 1 
Supplement 2 
29 
Supplement 1 
Supplement 2 
30 
Supplement 1 
Supplement 2 
31 
Supplement 1 
Supplement 2 
32 
Supplement 1 
Supplement 2 
33 
Supplement 1 
Supplement 2 
34 
Supplement 1 
Supplement 2 
35 
Supplement 1 
Supplement 2 
36 
Supplement 1 
Supplement 2 
37 
Supplement 1 
Supplement 2 
38 
Supplement 1 
Supplement 2 
39 
Supplement 1 
Supplement 2 
40 
Supplement 1 
Supplement 2 
41 
Supplement 1 
Supplement 2 
42 
Supplement 1 
Supplement 2 
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Appendix 2 – Process of Ethical Approval 
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Application Number________________ Date Received____________________  
Application for Ethical Approval  
Introduction  
All university activity must be reviewed for ethical approval. In particular, all 
undergraduate, postgraduate and staff research work, projects and taught 
programmes must obtain approval from the Academic Ethics committee.  
Application Procedure  
The form should be completed legibly (preferably typed) and, so far as possible, in a 
way which would enable a layperson to understand the aims and methods of the 
research. Every relevant section should be completed. Applicants should also include 
a copy of any proposed advert, information sheet, consent form and, if relevant, any 
questionnaire being used. The Principal Investigator should sign the application form. 
Supporting documents, together with one copy of the full protocol should be sent to 
the Faculty/Campus Research Group Officer.  
Your application will require external ethical approval by an NHS Research Ethics 
Committee if your research involves staff, patients or premises of the NHS (see 
guidance notes)  
Work with children and vulnerable adults  
You will be required to have an Enhanced CRB Disclosure, if your work involves 
children or vulnerable adults.  
The Academic Ethics Committee will respond as soon as possible, and where 
appropriate, will operate a process of expedited review.  
Applications that require approval by an NHS Research Ethics Committee or a 
Criminal Disclosure will take longer.  
1. Details of Applicants  
1.1. Name of applicant (Principal Investigator): Stephen Whiting 
 
Telephone Number: 07834705020  
Email address: 06437832@stu.mmu.ac.uk  
Status: Postgraduate Researcher Postgraduate Student (Taught or Research)  
Staff Department/School/Other Unit: Department of Food and Tourism Management 
Programme of study (if applicable): n/a 
Name of supervisor/Line manager: Kritika Mahadevan 
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1.2. Co-Workers and their role in the project: (e.g. students, external collaborators, 
etc.)  
Name: Emma Derbyshire  
2. Details of the Project  
2.1. Title: Effects of chilli capsaicinoids on the body composition of overweight 
females. 
 2.2. Description of the Project: (please outline the background and the purpose of the 
research project, 250 words max): See end of application   
2.3. Describe what type of study this is (e.g. qualitative or quantitative; also indicate 
how the data will be collected and analysed). See end of application 
2.4. Are you going to use a questionnaire?  
YES (Please attach a copy)  
2.5. Start Date / Duration of project: February, lasting 9 weeks  
2.6. Location of where the project and data collection will take place: MMU All Saints 
campus 
2.7. Nature/Source of funding:  MMU 
2.8. Are there any regulatory requirements?  
NO  
3. Details of Participants  
3.1. How many? 30 This sample size is based on a similar type of trial (Beneficial 
effects of catechin-rich green tea and inulin on the body composition of overweight 
adults; Yang et al Brit J Nutr (2012) 107, 749–754). 
3.2. Age: 18 - 50 
3.3. Sex: Female 
3.4. How will they be recruited? Email, copy attached 
3.5. Status of participants: (e.g. students, public, colleagues, children, hospital 
patients, prisoners, including young offenders, participants with mental illness or 
learning difficulties.)  Students and university employees 
3.6. Inclusion and exclusion from the project: see end of application 
3.7. Payment to volunteers: (indicate any sums to be paid to volunteers). No payments 
3.8. Study information: A copy of the information sheet is attached. 
Have you provided a study information sheet for the participants?  
YES (Please attach a copy)  
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3.9. Consent:  
(A written consent form for the study participants MUST be provided in all cases,  
unless the research is a questionnaire.)  
Have you produced a written consent form for the participants to sign for your records?  
YES (Please attach a copy)  
4. Risks and Hazards  
4.1. Are there any risks to the researcher and/or participants?  
(Give details of the procedures and processes to be undertaken, e.g., if the researcher 
is a lone-worker.) See end of application 
4.2. State precautions to minimise the risks and possible adverse events: See end of 
application 
4.3. What discomfort (physical or psychological) danger or interference with normal 
activities might be suffered by the researcher and/or participant(s)? State precautions 
which will be taken to minimise them: n/a 
5. Ethical Issues  
5.1. Please describe any ethical issues raised and how you intend to address these: 
See end of document 
6. Safeguards/Procedural Compliance  
6.1. Confidentiality:  
6.1.1. Indicate what steps will be taken to safeguard the confidentiality of participant 
records. If the data is to be computerised, it will be necessary to ensure compliance 
with the requirements of the Data Protection Act 1998.  
6.1.2. If you are intending to make any kind of audio or visual recordings of the 
participants, please answer the following questions: n/a  
6.1.2.1. How long will the recordings be retained and how will they be stored? n/a 
6.1.2.2. How will they be destroyed at the end of the project? n/a 
6.1.2.3. What further use, if any, do you intend to make of the recordings? n/a 
6.2. The Human Tissue Act  
The Human Tissue Act came into force in November 2004, and requires appropriate 
consent for, and regulates the removal, storage and use of all human tissue.  
 
6.2.1. Does your project involve taking tissue samples, e.g., blood, urine, hair etc., 
from human subjects?  
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NO  
6.2.2. Will this be discarded when the project is terminated?  
N/A 
6.3. Insurance  
The University holds insurance policies in place to cover claims for negligence arising 
from the conduct of the University's normal business, which includes research carried 
out by staff and by undergraduate and postgraduate students as part of their course. 
This does not extend to clinical negligence.  
In addition, the University has provision to award indemnity and/or compensation in 
the event of claims for non-negligent harm. This is on the condition that the project is 
accepted by the insurers prior to the commencement of the research project and 
approval has been granted for the project from a suitable ethics committee.  
Research which is applicable to non-negligent harm cover involves humans and 
physical intervention which could give rise to a physical injury or illness which is 
outside the participants’ day to day activities. This includes strenuous exercise, 
ingestion of substances, injection of substances, topical application of any substances, 
insertion of instruments, blood/tissue sampling of participants and scanning of 
participants.  
The following types of research are not covered automatically for non-negligent harm 
if they are classed as the activities above and they involve:  
Anything that assists with and /or alters the process of contraception, or investigating 
or participating in methods of contraception  
Anything involving genetic engineering other than research in which the medical 
purpose is treating or diagnosing disease  
Where the substance under investigation has been designed and /or manufactured by 
MMU  
Pregnant women  
Drug trials  
Research involving children under sixteen years of age Professional sports persons 
and or elite athletes.  
Overseas research  
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Will the proposed project result in you undertaking any research that includes any of 
the 8 points above or would not be considered as normal University business? If so, 
please detail below: No 
6.4. Notification of Adverse Events (e.g., negative reaction, counsellor, etc.): (Indicate 
precautions taken to avoid adverse reactions.)  
Please state the processes/procedures in place to respond to possible adverse 
reactions.  
n/a  
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2.2 Description of the Project 
Capsaicinoids (the ‘spicy’ chemicals found in chillies) have been proposed to have an 
anti-obesity effect (Whiting et al., 2012). Current rates of overweight and obesity are 
rising, in 2009, 1.5 billion adults (20 and older) were overweight; of these around 500 
million were obese (World Health 2012). This has led to numerous health problems; 
obesity, especially visceral obesity carries a strong risk of metabolic diseases and 
related cardio-vascular disease.  
Lifestyle modifications are important but reliance on diet and exercise interventions 
alone have proved relatively unsuccessful, particularly in the long term (Wu et al 2009). 
The use of bioactive ingredients in conjunction with weight loss programmes may help 
to further stimulate weight loss and lead to improvements in body composition profile 
(Belza et al 2007). Potentially helping people lose weight and maintain those gains. 
While studies have looked at the anti-cancer (Yang et al 2010), anti-inflammatory 
(Choi et al 2011) and antioxidant (Henning et al 2011) effects of capsaicinoids, few 
have presented investigated potential weight loss benefits. The aim of this study will 
be to investigate whether capsaicinoid supplements affects body weight and fat mass 
in obese and overweight females. 
2.3 Type of Study 
The trail will be a quantitative study. A number of anthropometric measurements to be 
taken: height, body weight, waist circumference, hip circumference and body fat ratio 
(to be measured using bio-electrical impedance). The measurements will be recorded 
at baseline, week three, week six and week eight. 
Blood samples (finger prick) will be collected at baseline, third, sixth and eighth week 
of the experiment; with blood glucose and blood lipid levels to be measured.  
3.6 Inclusion Criteria 
 Females 
 Aged 20-50 years 
 BMI ≥20kg/m2. 
Exclusion criteria  
 Use of medication and supplements 
 Postmenopausal women 
 Metabolic diseases 
 Digestive diseases 
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 Pregnant females 
4.1  Risks and Hazards 
The intervention has been used in a number of trials before without and major side 
effects; the only reported problems have been some intestinal discomfort when a high 
dosage has been used. 
The taking of blood. 
4.2  Precautions 
We plan to use a lower dosage so that this problem is minimised. 
Blood will be taken via a finger prick by trained phlebotomist Mark Kelly 
5.1 Ethical Issues 
The trial will be conducted according to the guidelines laid down in the Declaration of 
Helsinki. 
All procedures are to be approved by the MMU Ethics Committee.  
Written consent will be obtained from all subjects, after they have read through the 
information sheet and had the opportunity to ask a researcher any questions they may 
have. 
6.1.1 Confidentiality 
All computerised records will comply with the requirements of the Data Protection Act 
1998. 
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Study Protocol 
Effects of chilli capsaicinoids on the body composition of overweight females. 
Rationale 
Capsaicinoids/capsinoids have been proposed to have an anti-obesity effect 
(Whiting et al., 2012). Rates of overweight and obesity are rising, in 2009, 1.5 billion 
adults (20 and older) were overweight; of these around 500 million were obese 
(World Health 2012) (WHO, 2011) (WHO, 2011) (WHO, 2011) (WHO, 2011) (WHO, 
2011) (WHO, 2011) (WHO, 2011) (WHO, 2011) (WHO, 2011) (WHO, 2011) (WHO, 
2011) (WHO, 2011) (WHO, 2011) (WHO, 2011) (WHO, 2011) (WHO, 2011) (WHO, 
2011) (WHO, 2011) (WHO, 2011) (WHO, 2011) (WHO, 2011) (WHO, 2011c) (WHO, 
2011b) (WHO, 2011b) (WHO, 2011b) (WHO, 2011c) (WHO, 2011c). This has led to 
numerous health problems; obesity, especially visceral obesity carries a strong risk 
of metabolic diseases and related CVD. Lifestyle modifications are important but 
reliance on diet and exercise interventions alone have proved relatively unsuccessful 
(Wu et al 2009). The use of bioactive ingredients in conjunction with weight loss 
programmes may help to further stimulate weight loss and lead to improvements in 
body composition profile (Belza et al 2007). While studies have looked at the anti-
cancer (Yang et al 2010), anti-inflammatory (Choi et al 2011) and antioxidant 
(Henning et al 2011) effects of capsaicinoids, few have presented investigated 
potential weight loss benefits. 
Aim: To investigate whether a capsaicinoid supplement affects body weight and fat 
mass in obese and overweight females. 
Proposed methods 
Subjects 
 Aim for 60 females, aged 20-45 years 
 BMI ≥20kg/m2. 
 Subjects to be recruited by announcement at MMU 
Exclusion criteria:  
 Use of medication and supplements 
 Postmenopausal women 
 Metabolic diseases 
 Digestive diseases 
Before the experiment is conducted, the content, purpose and possible study risks 
will be explained to all subjects and written, informed consent obtained. 
Study design 
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 To be conducted according to the guidelines laid down in the Declaration of 
Helsinki. 
 All procedures to be approved by the MMU Ethics Committee. 
 Written consent to be obtained from all subjects. 
 Subjects to be assigned to either a control (n=30) or experimental group (n=30) 
 The intervention will be for 6-weeks, plus another assessment at week 8. 
 Compliance of supplements to be monitored/logged with a pre-established 
protocol. 
 The consumption of other food and beverages containing 
capsaicinoids/capsinoids to be prohibited. 
 Subjects to be advised to maintain their diet and physical activity levels. 
 Subjects will record their dietary intakes for 3 days at baseline, 6 weeks and 9 
weeks. 
Anthropometric measurements 
Height, body weight, waist circumference and hip circumference are to be measured 
at baseline, third, sixth and eighth week. 
Body fat ratio is to be measured using bioelectrical impedance analysis method 
(using ‘BodyStat 4000’). 
Outcomes: Body weight (kg), BMI changes, changes in fat mass (kg), changes in 
body mass (kg), changes in waist circumference (cm), changes in hip circumference 
(cm). 
Blood sampling and analysis 
Blood samples (finger prick) are to be collected at baseline, sixth and eighth week of 
the trial. Blood glucose to be measured using ‘Analox GM7 analyser’ and blood lipid 
levels to be measured using ‘CardioChek-PA’ . 
Safety and tolerability 
Any symptoms reported?  
Note: the intervention lasts for six weeks.  
Participants to return week 9, to establish whether body weight/fat mass and 
biochemical parameters return back to normal (should increase back up in theory). 
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Confirmation of Ethical Amendments 
Ethical approval was granted on 9th October 2013, since then the following amendments 
have been made to the trial: 
 Placebo supplements to be filled by Stephen Whiting at MMU. 
 Participants asked to make an extra visit to the university mid-way through the trial 
(to repeat the same measurements as other visits). 
 Participants asked to complete a pill diary to confirm they have taken 2 supplements 
a day. 
 Screening questionnaire created to assess eligibility for the trial and collect some 
basic participant data. 
I can confirm I am supportive of these changes: 
 
Stephen Whiting (Researcher) 
 
 
Kritika Mahadevan (Supervisor) 
 
 
Emma Derbyshire (Supervisor) 
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Appendix 3 – Publications 
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Systematic Review 
 
  
183 
 
Meta-Analysis Presentation (Nutrition Society Summer Conference) 
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Meta-Analysis Paper 
 
